(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 March 2004 (04.03.2004)

PCT

(10) International Publication Number
WO 2004/018660 A2

(51) International Patent Classification⁷: C12N 9/00

(21) International Application Number: PCT/EP2003/009145

(22) International Filing Date: 15 August 2003 (15.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

02102168.8	19 August 2002 (19.08.2002)	EP
02102169.6	19 August 2002 (19.08.2002)	EP
02102170.4	19 August 2002 (19.08.2002)	EP
02102171.2	19 August 2002 (19.08.2002)	EP
02102172.0	19 August 2002 (19.08.2002)	EP
02102173.8	19 August 2002 (19.08.2002)	EP
02102174.6	19 August 2002 (19.08.2002)	EP
02102176.1	19 August 2002 (19.08.2002)	EP
02102178.7	19 August 2002 (19.08.2002)	EP
02102179.5	19 August 2002 (19.08.2002)	EP
02102181.1	19 August 2002 (19.08.2002)	EP
02102183.7	19 August 2002 (19.08.2002)	EP

(71) Applicant (*for all designated States except US*): DSM IP ASSETS B.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): ALBANG, Richard [DE/DE]; Lochhamer Str. 11, 82152 Martinsried (DE). FOLKERS, Ulrike [DE/DE]; Treffauer Strasse 54, 81373 München (DE). FRITZ, Andreas [DE/DE]; Lochhamer Strasse 11, 82152 MARTINSRIED (DE). GERHARD, Beatrix [DE/DE]; Albrecht-Schweitzer 3, 85521 Ottobrunn (DE). HEINRICH, Oliver [DE/DE]; Lochhamer Str. 11, 82152 Martinsried (DE). ILGENFRITZ, Hilmar [DE/DE]; Lochhamer Strasse 11, 82152 Martinsried (DE). MAIER, Dieter [DE/DE]; Lochhamer Str. 11, 82152 Martinsried (DE). SPREAFICO, Fabio [DE/DE]; Lochhamer Str. 11, 82152 Martinsried (DE). WAGNER, Christian [DE/DE]; Lochhamer Str. 11, 82152 Martinsried (DE). BOER, DE, Lex [NL/NL]; Middenweg 61, NL-2291 HV WATERINGEN (NL). MEIMA, Roelf, Bernhard [NL/NL]; Hoefslag 28, NL-3471 AH Kamerik (NL).

(74) Agents: MATULEWICZ, Emil, Rudolf, Antonius et al.; DSM Intellectual Property, Delft Office (600-0240), P.O. Box 1, NL-2600 MA Delft (NL).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL LIPASES AND USES THEREOF

(57) Abstract: The invention relates to a newly identified polynucleotide sequence comprising a gene that encodes a novel lipolytic enzyme from *Aspergillus niger*. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel lipolytic enzyme as well as the amino acid sequence of the full-length functional protein and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein a lipolytic enzyme according to the invention is genetically modified to enhance its activity and/or level of expression.

WO 2004/018660 A2

NOVEL LIPASES AND USES THEREOF

Field of the invention

The invention relates to newly identified polynucleotide sequence comprising a gene that encodes a novel lipolytic enzyme from *Aspergillus niger*. The invention features the full length nucleotide sequence of the novel gene, the cDNA sequence comprising the full length coding sequence of the novel lipolytic enzyme as well as the amino acid sequence of the full-length lipolytic enzyme and functional equivalents thereof. The invention also relates to methods of using these enzymes in industrial processes and methods of diagnosing fungal infections. Also included in the invention are cells transformed with a polynucleotide according to the invention and cells wherein a lipolytic enzyme according to the invention is genetically modified to enhance its activity and/or level of expression.

Background of the invention

Baked products such as bread are prepared from a dough which is usually made from the basic ingredients (wheat) flour, water and optionally salt. Depending on the baked products, other ingredients added may be sugars, flavours etceteras. For leavened products, primarily baker's yeast is used next to chemical leavening systems such as a combination of an acid (generating compound) and bicarbonate.

In order to improve the handling properties of the dough and/or the final properties of the baked products there is a continuous effort to develop processing aids with improving properties. Processing aids are defined herein as compounds that improve the handling properties of the dough and/or the final properties of the baked products. Dough properties that may be improved comprise machineability, gas retaining capability, reduced stickiness, elasticity, extensibility, moldability etcetera. Properties of the baked products that may be improved comprise loaf volume, crust crispiness, crumb texture and softness, flavour relative staleness and shelf life. These dough and/or baked product improving processing aids can be divided into two groups: chemical additives and enzymes (also referred to as baking enzymes).

Yeast, enzymes and chemical additives are generally added separately to the dough. Yeast may be added as a liquid suspension, in a compressed form or as

active dry (ADY) or instant dry yeast (IDY). The difference between these yeast formulations is the water- and yeast dry matter content. Liquid yeast has a yeast dry matter content of less than 25% (w/v). Cream yeast is a particular form of liquid yeast and has a dry matter content between 17 and 23% (w/v). Compressed yeast has a yeast dry matter content between 25-35% (w/v) while the dry yeast formulations have a yeast dry matter content between 92-98% (w/v).

Enzymes may be added in a dry, e.g. granulated form or in liquid form. The chemical additives are in most cases added in powder form. Also, processing aid compositions which are tailored to specific baking applications, may be composed of a dedicated mixture of chemical additives and enzyme.

The preparation of a dough from the ingredients and processing aids described above is well known in the art and comprises mixing of said ingredients and processing aids and one or more moulding and fermentation steps.

The preparation of baked products from such doughs is also well known in the art and may comprise molding and shaping and further fermentation of the dough followed by baking at required temperatures and baking times.

Chemical additives with improving properties comprise oxidising agents such as ascorbic acid, bromate and azodicarbonate, reducing agents such as L-cysteine and glutathione, emulsifiers acting as dough conditioners such as diacetyl tartaric esters of mono/diglycerides (DATEM), sodium stearoyl lactylate (SSL) or calcium stearoyl lactylate (CSL), or acting as crumb softeners such as glycerol monostearate (GMS) etceteras, fatty materials such as triglycerides (fat) or lecithin and others.

As a result of a consumer-driven need to replace the chemical additives by more natural products, several baking enzymes have been developed with dough and/or baked product improving properties and which are used in all possible combinations depending on the specific baking application conditions. Suitable enzymes include starch degrading enzymes, arabinoxylan- and other hemicellulose degrading enzymes, cellulose degrading enzymes, oxidizing enzymes, fatty material splitting enzymes, protein degrading, modifying or crosslinking enzymes.

Starch degrading enzymes are for instance endo-acting enzymes such as alpha-amylase, maltogenic amylase, pullulanase or other debranching enzymes and exo-acting enzymes that cleave off glucose (amyloglucosidase), maltose (beta-amylase), maltotriose, maltotetraose and higher oligosaccharides.

Arabinoxylan- and other hemicellulose degrading enzymes are for instance xylanases, pentosanases, hemicellulase, arabinofuranosidase, glucanase and others.

Cellulose degrading enzymes are for instance cellulase, cellobiohydrolase and beta-glucosidase.

Oxidizing enzymes are for instance glucose oxidase, hexose oxidase, pyranose oxidase, sulfhydryl oxidase, lipoxygenase, laccase, polyphenol oxidases and others.

Fatty material splitting enzymes are for instance lipolytic enzymes such as triacylglycerol lipases, phospholipases (such as A_1, A_2, B, C and D) and galactolipases.

Protein degrading, modifying or crosslinking enzymes are for instance endo-acting proteases (serine proteases, metalloproteases, aspartyl proteases, thiol proteases), exo-acting peptidases that cleave off one amino acid, or dipeptide, tripeptide etceteras from the N-terminal (aminopeptidases) or C-terminal (carboxypeptidases) ends of the polypeptide chain, asparagines or glutamine deamidating enzymes such as deamidase and peptidoglutaminase or crosslinking enzymes such as transglutaminase.

Baking enzymes may conviently be produced in microorganisms. Microbial baking enzymes are available from a variety of sources; Bacillus spec. are a common source of bacterial enzymes, whereas fungal enzymes are commonly produced in Aspergillus spec.

Baking enzymes may be used in a manifold of baked goods. The term "baked goods" is herein defined as to comprise bread products such as tin bread, loaves of bread, French bread as well as rolls, cakes, pies, muffins, yeast raised and cake doughnuts and the like.

In the above processes, it is advantageous to use baking enzymes that are obtained by recombinant DNA techniques. Such recombinant enzymes have a number of advantages over their traditionally purified counterparts. Recombinant enzymes may be produced at a low cost price, high yield, free from contaminating agents like bacteria or viruses but also free from bacterial toxins or contaminating other enzyme activities.

Object of the invention

It is an object of the invention to provide novel polynucleotides encoding novel lipolytic enzymes with improved properties. A further object is to provide naturally and recombinantly produced lipolytic enzymes as well as recombinant strains producing these. Also fusion polypeptides are part of the invention as well as methods of making

and using the polynucleotides and polypeptides according to the invention.

It is also an object of the invention to provide novel lipolytic enzymes, which solve at least one of the above-mentioned problems or to provide novel lipolytic enzymes, which have one or more improved properties if used in dough and/or baked products, selected from the group of increased strength of the dough, increased elasticity of the dough, increased stability of the dough, reduced stickiness of the dough, improved extensibility of the dough, improved machineability of the dough, increased volume of the baked product, improved crumb structure of the baked product, improved softness of the baked product, improved flavour of the baked product, improved anti-staling of the baked product, improved colour of the baked product, improved crust of the baked product or which have a broad substrate specificity.

Summary of the invention

The invention provides for novel polynucleotides encoding novel lipolytic enzymes. More in particular, the invention provides for polynucleotides having a nucleotide sequence that hybridises preferably under highly stringent conditions to a sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38. Consequently, the invention provides nucleic acids that are more than 40% such as about 60%, preferably 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% homologous to the sequences selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38.

In a more preferred embodiment the invention provides for such an isolated polynucleotide obtainable from a filamentous fungus, in particular *Aspergillus niger* is preferred.

In one embodiment, the invention provides for an isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

In a further preferred embodiment, the invention provides an isolated polynucleotide encoding at least one functional domain of a polypeptide selected from

the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

In a preferred embodiment the invention provides a lipolytic enzyme gene selected from the group consisting of SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34 and 37. In another aspect the invention provides a polynucleotide, preferably a cDNA encoding an *Aspergillus niger* lipolytic enzyme whose amino acid sequence is selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or variants or fragments of that polypeptide. In a preferred embodiment the cDNA has a sequence selected from the group consisting of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35 and 38 or functional equivalents thereof.

In an even further preferred embodiment, the invention provides for a polynucleotide comprising the coding sequence of the polynucleotides according to the invention, preferred is the polynucleotide sequence selected from the group consisting of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 23, 26, 29, 32, 35 and 38.

The invention also relates to vectors comprising a polynucleotide sequence according to the invention and primers, probes and fragments that may be used to amplify or detect the DNA according to the invention.

In a further preferred embodiment, a vector is provided wherein the polynucleotide sequence according to the invention is functionally linked with regulatory sequences suitable for expression of the encoded amino acid sequence in a suitable host cell, such as *Aspergillus niger* or *Aspergillus oryzae*. The invention also provides methods for preparing polynucleotides and vectors according to the invention.

The invention also relates to recombinantly produced host cells that contain heterologous or homologous polynucleotides according to the invention.

In another embodiment, the invention provides recombinant host cells wherein the expression of a lipolytic enzyme according to the invention is significantly increased or wherein the activity of the lipolytic enzyme is increased.

In another embodiment the invention provides for a recombinantly produced host cell that contains heterologous or homologous polynucleotide according to the invention and wherein the cell is capable of producing a functional lipolytic enzyme according to the invention, preferably a cell capable of over-expressing the lipolytic enzyme according to the invention, for example an *Aspergillus* strain comprising an increased copy number of a gene or cDNA according to the invention.

In yet another aspect of the invention, a purified polypeptide is provided. The polypeptides according to the invention include the polypeptides encoded by the polynucleotides according to the invention. Especially preferred is a polypeptide selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

Accordingly, in one aspect the present invention provides a lipolytic enzyme composition containing as an active ingredient an enzyme selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

In another aspect, the invention provides a method of making baked goods wherein there is incorporated into the dough used for making the baked goods one or more enzymes selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

Fusion proteins comprising a polypeptide according to the invention are also within the scope of the invention. The invention also provides methods of making the polypeptides according to the invention.

The invention also relates to the use of the lipolytic enzyme according to the invention in any industrial process as described herein.

Detailed description of the invention

A lipolytic enzyme is defined herein as an enzyme exhibiting at least one and preferably two or three or four or more of the following lipolytic activities: triacylglycerol lipase, phospholipase A_1, phospholipase A_2, phospholipase B, phospholipase C, phospholipase D, lysophospholipase and galactolipase.

Polynucleotides

The present invention provides polynucleotides encoding lipolytic enzymes having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof. The sequences of the seven genes encoding the lipolytic enzymes NBE028, NBE029, NBE030, NBE031, NBE032, NBE033, NBE034, NBE036, NBE038, NBE039, NBE043, NBE045 and NBE042 respectively were determined by sequencing genomic clones

obtained from *Aspergillus niger*. The invention provides polynucleotide sequences comprising the genes encoding the lipolytic enzymes NBE028, NBE029, NBE030, NBE031, NBE032, NBE033, NBE034, NBE036, NBE038, NBE039, NBE043, NBE045 and NBE042 as well as their complete cDNA sequences and their coding sequences (Table 1). Accordingly, the invention relates to isolated polynucleotides comprising the nucleotide sequences selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 or functional equivalents thereof.

Table 1.

lipolytic enzyme	Sequence (SEQ ID NO)		
NBE xxx	genomic	cDNA	amino acid
NBE028	1	2	3
NBE029	4	5	6
NBE030	7	8	9
NBE031	10	11	12
NBE032	13	14	15
NBE033	16	17	18
NBE034	19	20	21
NBE036	22	23	24
NBE038	25	26	27
NBE039	28	29	30
NBE043	31	32	33
NBE045	34	35	36
NBE042	37	38	39

More in particular, the invention relates to an isolated polynucleotide hybridisable under stringent conditions, preferably under highly stringent conditions, to a polynucleotide selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38. Advantageously, such polynucleotides may be obtained from filamentous fungi, in particular from *Aspergillus niger*. More specifically, the invention relates to an isolated polynucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4,

5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38.

The invention also relates to an isolated polynucleotide encoding at least one functional domain of a polypeptide having an amino acid sequences selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules which may be isolated from chromosomal DNA, which include an open reading frame encoding a protein, e.g. an *Aspergillus niger* lipolytic enzyme. A gene may include coding sequences, non-coding sequences, introns and regulatory sequences. Moreover, a gene refers to an isolated nucleic acid molecule as defined herein.

A nucleic acid molecule of the present invention, such as a nucleic acid molecule having the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 or a functional equivalent thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, using all or portion of the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 as a hybridization probe, nucleic acid molecules according to the invention can be isolated using standard hybridization and cloning techniques (e. g., as described in Sambrook, J.,. Fritsh, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual.2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 can be isolated by the polymerase chain reaction (PCR) using synthetic oligonucleotide primers designed based upon the sequence information contained in the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38.

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis.

Furthermore, oligonucleotides corresponding to or hybridisable to nucleotide sequences according to the invention can be prepared by standard synthetic techniques, e. g., using an automated DNA synthesizer.

In one preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 2. The sequence of SEQ ID NO: 2 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 1. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE028 polypeptide as shown in SEQ ID NO: 3.

In a second preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 5. The sequence of SEQ ID NO: 5 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 4. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE029 polypeptide as shown in SEQ ID NO: 6.

In a third preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 8. The sequence of SEQ ID NO: 8 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 7. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE030 polypeptide as shown in SEQ ID NO: 9.

In a fourth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 11. The sequence of SEQ ID NO: 11 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 10. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE031 polypeptide as shown in SEQ ID NO: 12.

In a fifth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 14. The sequence of SEQ ID NO: 14 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 13. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE032 polypeptide as shown in SEQ ID NO: 15.

In a sixth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 17. The sequence of SEQ ID NO: 17 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 16. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE033 polypeptide as shown in SEQ ID NO: 18.

In a seventh preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 20. The sequence of SEQ ID NO: 20 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 19. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 21.

In a eight preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 23. The sequence of SEQ ID NO: 23 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 22. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 24.

In a nineth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 26. The sequence of SEQ ID NO: 26 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 25. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 27.

In a tenth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 29. The sequence of SEQ ID NO: 29 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 28. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 30.

In a eleventh preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 32. The sequence of SEQ ID NO: 32 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 31. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 33.

In a twelvth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 35. The sequence of SEQ ID NO: 35 corresponds to the coding region of the *Aspergillus niger* gene provided in SEQ ID NO: 34 This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 36.

In a thirteenth preferred embodiment, an isolated nucleic acid molecule of the invention comprises the nucleotide sequence shown in SEQ ID NO: 38. The sequence of SEQ ID NO: 38 corresponds to the coding region of the *Aspergillus niger* gene

provided in SEQ ID NO: 37. This cDNA comprises the sequence encoding the *Aspergillus niger* NBE034 polypeptide as shown in SEQ ID NO: 39.

In another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule which is a complement of the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 or a functional equivalent of these nucleotide sequences. A nucleic acid molecule, which is complementary to another nucleotide sequence, is one that is sufficiently complementary to the other nucleotide sequence such that it can hybridize to the other nucleotide sequence thereby forming a stable duplex.

One aspect of the invention pertains to isolated nucleic acid molecules that encode a polypeptide of the invention or a functional equivalent thereof such as a biologically active fragment or domain, as well as nucleic acid molecules sufficient for use as hybridisation probes to identify nucleic acid molecules encoding a polypeptide of the invention and fragments of such nucleic acid molecules suitable for use as PCR primers for the amplification or mutation of nucleic acid molecules. An "isolated polynucleotide" or "isolated nucleic acid" is a DNA or RNA that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding (e.g., promotor) sequences that are immediately contiguous to the coding sequence. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA or a genomic DNA fragment produced by PCR or restriction endonuclease treatment) independent of other sequences. It also includes a recombinant DNA that is part of a hybrid gene encoding an additional polypeptide that is substantially free of cellular material, viral material, or culture medium (when produced by recombinant DNA techniques), or chemical precursors or other chemicals (when chemically synthesized). Moreover, an "isolated nucleic acid fragment" is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.

As used herein, the terms "polynucleotide" or "nucleic acid molecule" are

intended to include DNA molecules (e.g., cDNA or genomic DNA) and RNA molecules (e.g., mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. The nucleic acid may be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acids that have altered base-pairing abilities or increased resistance to nucleases.

Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to a nucleic acid molecule according to the invention. Also included within the scope of the invention are the complement strands of the nucleic acid molecules described herein.

Sequencing errors

The sequence information as provided herein should not be so narrowly construed as to require inclusion of erroneously identified bases. The specific sequences disclosed herein can be readily used to isolate the complete gene from filamentous fungi, in particular *Aspergillus niger* which in turn can easily be subjected to further sequence analyses thereby identifying sequencing errors.

Unless otherwise indicated, all nucleotide sequences determined by sequencing a DNA molecule herein were determined using an automated DNA sequencer and all amino acid sequences of polypeptides encoded by DNA molecules determined herein were predicted by translation of a DNA sequence determined as above. Therefore, as is known in the art for any DNA sequence determined by this automated approach, any nucleotide sequence determined herein may contain some errors. Nucleotide sequences determined by automation are typically at least about 90% identical, more typically at least about 95% to at least about 99.9% identical to the actual nucleotide sequence of the sequenced DNA molecule. The actual sequence can be more precisely determined by other approaches including manual DNA sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in a determined nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the predicted amino acid sequence encoded by a determined nucleotide sequence will be completely different from the amino acid

sequence actually encoded by the sequenced DNA molecule, beginning at the point of such an insertion or deletion.

The person skilled in the art is capable of identifying such erroneously identified bases and knows how to correct for such errors.

Nucleic acid fragments, probes and primers

A nucleic acid molecule according to the invention may comprise only a portion or a fragment of the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38, for example a fragment which can be used as a probe or primer or a fragment encoding a portion of protein according to the invention. The nucleotide sequence determined from the cloning of the lipolytic enzyme gene and cDNA allows for the generation of probes and primers designed for use in identifying and/or cloning other lipolytic enzyme family members, as well as lipolytic enzyme homologues from other species. The probe/primer typically comprises substantially purified oligonucleotide which typically comprises a region of nucleotide sequence that hybridizes preferably under highly stringent conditions to at least about 12 or 15, preferably about 18 or 20, preferably about 22 or 25, more preferably about 30, 35, 40, 45, 50, 55, 60, 65, or 75 or more consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 or of a functional equivalent thereof.

Probes based on the nucleotide sequences provided herein can be used to detect transcripts or genomic sequences encoding the same or homologous proteins for instance in other organisms. In preferred embodiments, the probe further comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor. Such probes can also be used as part of a diagnostic test kit for identifying cells that express a lipolytic enzyme protein.

Identity & homology

The terms "homology" or "percent identity" are used interchangeably herein. For the purpose of this invention, it is defined here that in order to determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the

sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions/total number of positions (i.e. overlapping positions) x 100). Preferably, the two sequences are the same length.

The skilled person will be aware of the fact that several different computer programmes are available to determine the homology between two sequences. For instance, a comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. (48): 444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at http://www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. The skilled person will appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms.

In yet another embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity two amino acid or nucleotide sequence is determined using the algorithm of E. Meyers and W. Miller (CABIOS, 4:11-17 (1989) which has been incorporated into the ALIGN program (version 2.0) (available at http://vega.igh.cnrs.fr/bin/align-guess.cgi) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for

example, identify other family members or related sequences. Such searches can be performed using the BLASTN and BLASTX programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide searches can be performed with the BLASTN program, score = 100, word length = 12 to obtain nucleotide sequences homologous to PLP03 nucleic acid molecules of the invention. BLAST protein searches can be performed with the BLASTX program, score = 50, word length = 3 to obtain amino acid sequences homologous to PLP03 protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17):3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., BLASTX and BLASTN) can be used. See http://www.ncbi.nlm.nih.gov.

Hybridisation

As used herein, the term "hybridizing" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 50%, at least about 60%, at least about 70%, more preferably at least about 80%, even more preferably at least about 85% to 90%, more preferably at least 95% homologous to each other typically remain hybridized to each other.

A preferred, non-limiting example of such hybridization conditions are hybridization in 6x sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 1x SSC, 0.1 % SDS at 50°C, preferably at 55°C, preferably at 60°C and even more preferably at 65°C.

Highly stringent conditions include, for example, hybridizing at 68°C in 5x SSC/5x Denhardt's solution / 1.0% SDS and washing in 0.2x SSC/0.1% SDS at room temperature. Alternatively, washing may be performed at 42°C.

The skilled artisan will know which conditions to apply for stringent and highly stringent hybridisation conditions. Additional guidance regarding such conditions is readily available in the art, for example, in Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, N.Y.; and Ausubel et al. (eds.), 1995, Current Protocols in Molecular Biology, (John Wiley & Sons, N.Y.).

Of course, a polynucleotide which hybridizes only to a poly A sequence (such

as the 3' terminal poly(A) tract of mRNAs), or to a complementary stretch of T (or U) resides, would not be included in a polynucleotide of the invention used to specifically hybridize to a portion of a nucleic acid of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

Obtaining full length DNA from other organisms

In a typical approach, cDNA libraries constructed from other organisms, e.g. filamentous fungi, in particular from the species *Aspergillus* can be screened.

For example, *Aspergillus* strains can be screened for homologous polynucleotides by Northern blot analysis. Upon detection of transcripts homologous to polynucleotides according to the invention, cDNA libraries can be constructed from RNA isolated from the appropriate strain, utilizing standard techniques well known to those of skill in the art. Alternatively, a total genomic DNA library can be screened using a probe hybridisable to a polynucleotide according to the invention.

Homologous gene sequences can be isolated, for example, by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of nucleotide sequences as taught herein.

The template for the reaction can be cDNA obtained by reverse transcription of mRNA prepared from strains known or suspected to express a polynucleotide according to the invention. The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequences of a new PLP03 nucleic acid sequence, or a functional equivalent thereof.

The PCR fragment can then be used to isolate a full length cDNA clone by a variety of known methods. For example, the amplified fragment can be labeled and used to screen a bacteriophage or cosmid cDNA library. Alternatively, the labeled fragment can be used to screen a genomic library.

PCR technology can also be used to isolate full-length cDNA sequences from other organisms. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source. A reverse transcription reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis.

The resulting RNA/DNA hybrid can then be "tailed" (e.g., with guanines) using a

standard terminal transferase reaction, the hybrid can be digested with RNase H, and second strand synthesis can then be primed (e.g., with a poly-C primer). Thus, cDNA sequences upstream of the amplified fragment can easily be isolated. For a review of useful cloning strategies, see e.g.,Sambrook et al., supra; and Ausubel et al., supra.

Vectors

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a protein according to the invention or a functional equivalent thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. The terms "plasmid" and "vector" can be used interchangeably herein as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operatively linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for

expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signal). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive or inducible expression of a nucleotide sequence in many types of host cells and those which direct expression of the nucleotide sequence only in a certain host cell (e.g. tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, encoded by nucleic acids as described herein (e.g. lipolytic enzymes, mutant lipolytic enzymes, fragments thereof, variants or functional equivalents thereof, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of lipolytic enzymes in prokaryotic or eukaryotic cells. For example, a protein according to the invention can be expressed in bacterial cells such as *E. coli* and *Bacillus species*, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression vectors useful in the present invention include chromosomal-, episomal- and virus-derived vectors e.g., vectors derived from bacterial plasmids, bacteriophage, yeast episome, yeast chromosomal elements, viruses such as baculoviruses, papova viruses, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids.

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* lac, trp and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. The skilled person

will know other suitable promoters. In a specific embodiment, promoters are preferred that are capable of directing a high expression level of lipolytic enzymes in filamentous fungi. Such promoters are known in the art. The expression constructs may contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will include a translation initiating AUG at the beginning and a termination codon appropriately positioned at the end of the polypeptide to be translated.

Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-percipitation, DEAE-dextran-mediated transfection, transduction, infection, lipofection, cationic lipidmediated transfection or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual, 2nd,ed. Cold Spring Harbor Laboratory,* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Davis et al., *Basic Methods in Molecular Biology* (1986) and other laboratory manuals.

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methatrexate. A nucleic acid encoding a selectable marker is preferably introduced into a host cell on the same vector as that encoding a protein according to the invention or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g. cells that have incorporated the selectable marker gene will survive, while the other cells die).

Expression of proteins in prokaryotes is often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, e.g. to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to

increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety after purification of the fusion protein. Such enzymes, and their cognate recognation sequences, include Factor Xa, thrombin and enterokinase.

As indicated, the expression vectors will preferably contain selectable markers. Such markers include dihydrofolate reductase or neomycin resistance for eukarotic cell culture and tetracyline or ampicilling resistance for culturing in *E. coli* and other bacteria. Representative examples of appropriate host include bacterial cells, such as *E. coli*, *Streptomyces* and *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS and Bowes melanoma; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria are pQE70, pQE60 and PQE-9, available from Qiagen; pBS vectors, Phagescript vectors, Bluescript vectors, pNH8A, pNH16A, pNH18A, pNH46A, available from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia. Among preferred eukaryotic vectors are PWLNEO, pSV2CAT, pOG44, pZT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Other suitable vectors will be readily apparent to the skilled artisan.

Known bacterial promoters for use in the present invention include *E. coli* lacI and lacZ promoters, the T3 and T7 promoters, the gpt promoter, the lambda PR, PL promoters and the trp promoter, the HSV thymidine kinase promoter, the early and late SV40 promoters, the promoters of retroviral LTRs, such as those of the Rous sarcoma virus ("RSV"), and metallothionein promoters, such as the mouse metallothionein-I promoter.

Inserting an enhancer sequence into the vector may increase transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act to increase transcriptional activity of a promoter in a given host cell-type. Examples of enhancers include the SV40 enhancer, which is located on the late side of the replication origin at bp 100 to 270, the cytomegalovirus early promoter enhancer, the polyoma

enhancer on the late side of the replication origin, and adenovirus enhancers.

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signal may be incorporated into the expressed polypeptide. The signals may be endogenous to the polypeptide or they may be heterologous signals.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification.

Polypeptides according to the invention

The invention provides an isolated polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39, an amino acid sequence obtainable by expressing the polynucleotide selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 in an appropriate host. Also, a peptide or polypeptide comprising a functional equivalent of the above polypeptides is comprised within the present invention. The above polypeptides are collectively comprised in the term "polypeptides according to the invention"

The terms "peptide" and "oligopeptide" are considered synonymous (as is commonly recognized) and each term can be used interchangeably as the context requires to indicate a chain of at least two amino acids coupled by peptidyl linkages. The word "polypeptide" is used herein for chains containing more than seven amino acid residues. All oligopeptide and polypeptide formulas or sequences herein are written from left to right and in the direction from amino terminus to carboxy terminus. The one-letter code of amino acids used herein is commonly known in the art and can be found in Sambrook, et al. (*Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor Laboratory*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989)

By "isolated" polypeptide or protein is intended a polypeptide or protein removed from its native environment. For example, recombinantly produced

polypeptides and proteins expressed in host cells are considered isolated for the purpose of the invention as are native or recombinant polypeptides which have been substantially purified by any suitable technique such as, for example, the single-step purification method disclosed in Smith and Johnson, Gene 67:31-40 (1988).

The lipolytic enzyme according to the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant, insect and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes.

A lipolytic enzyme according to the invention may be advantageously used in baking processes. The amount of enzyme to be added to the dough is determined empirically. It may depend on the quality of the flour used, the degree of improvement which is required, the kind of bread or baked goods, the method of preparing the dough, the proportion of other ingredients etcetera.

Protein fragments

The invention also features biologically active fragments of the polypeptides according to the invention.

Biologically active fragments of a polypeptide of the invention include polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the lipolytic enzyme (e.g., the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and

39), which include fewer amino acids than the full length protein, and exhibit at least one biological activity of the corresponding full-length protein. Typically, biologically active fragments comprise a domain or motif with at least one activity of the corresponding full length protein.

A biologically active fragment of a protein of the invention can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the biological activities of the native form of a polypeptide of the invention.

The invention also features nucleic acid fragments which encode the above biologically active fragments of the lipolytic enzyme protein.

Fusion proteins

The proteins of the present invention or functional equivalents thereof, e.g., biologically active portions thereof, can be operatively linked to a non-lipolytic enzyme polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. As used herein, a lipolytic enzyme "chimeric protein" or "fusion protein" comprises a lipolytic enzyme polypeptide operatively linked to a non-lipolytic enzyme polypeptide. A "lipolytic enzyme polypeptide" refers to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39, whereas a "non-lipolytic enzyme polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the lipolytic enzyme, e.g., a protein which is different from the lipolytic enzyme and which is derived from the same or a different organism. Within a lipolytic enzyme fusion protein the lipolytic enzyme polypeptide can correspond to all or a portion of a lipolytic enzyme protein. In a preferred embodiment, a lipolytic enzyme fusion protein comprises at least one biologically active fragment of a lipolytic enzyme protein. In another preferred embodiment, a lipolytic enzyme fusion protein comprises at least two biologically active portions of a lipolytic enzyme protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the lipolytic enzyme polypeptide and the non-lipolytic enzyme polypeptide are fused in-frame to each other. The non-lipolytic enzyme polypeptide can be fused to the N-terminus or C-terminus of the lipolytic enzyme

polypeptide.

For example, in one embodiment, the fusion protein is a GST-lipolytic enzyme fusion protein in which the lipolytic enzyme sequence is fused to the C-terminus of the GST sequence. Such fusion proteins can facilitate the purification of recombinant lipolytic enzyme(s). In another embodiment, the fusion protein is a lipolytic enzyme protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian and Yeast host cells), expression and/or secretion of lipolytic enzyme can be increased through use of a heterologous signal sequence.

In another example, the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (*Current Protocols in Molecular Biology*, Ausubel et al., eds., John Wiley & Sons, 1992). Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, California). In yet another example, useful prokaryotic heterologous signal sequences include the phoA secretory signal (Sambrook et al., *supra*) and the protein A secretory signal (Pharmacia Biotech; Piscataway, New Jersey).

A signal sequence can be used to facilitate secretion and isolation of a protein or polypeptide of the invention. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain. Thus, for instance, the sequence encoding the polypeptide may be fused to a marker sequence, such as a sequence encoding a peptide, which facilitates purification of the fused polypeptide. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in *Gentz et al, Proc. Natl. Acad. Sci. USA 86*:821-824 (1989), for instance, hexa-histidine provides for convenient

purificaton of the fusion protein. The HA tag is another peptide useful for purification which corresponds to an epitope derived of influenza hemaglutinin protein, which has been described by Wilson *et al., Cell 37:767* (1984), for instance.

Preferably, a chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g, a GST polypeptide). A lipolytic enzyme-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the lipolytic enzyme protein.

Functional equivalents

The terms "functional equivalents" and "functional variants" are used interchangeably herein. Functional equivalents of lipolytic enzyme encoding DNA are isolated DNA fragments that encode a polypeptide that exhibits a particular function of the *Aspergillus niger* lipolytic enzyme as defined herein. A functional equivalent of a lipolytic enzyme polypeptide according to the invention is a polypeptide that exhibits at least one function of an *Aspergillus niger* lipolytic enzyme as defined herein. Functional equivalents therefore also encompass biologically active fragments.

Functional protein or polypeptide equivalents may contain only conservative substitutions of one or more amino acids in the amino acid sequences selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or substitutions, insertions or deletions of non-essential amino acids. Accordingly, a non-

essential amino acid is a residue that can be altered in the amino acid sequences selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 without substantially altering the biological function. For example, amino acid residues that are conserved among the lipolytic enzyme proteins of the present invention, are predicted to be particularly unamenable to alteration. Furthermore, amino acids conserved among the lipolytic enzyme proteins according to the present invention and other lipolytic enzymes are not likely to be amenable to alteration.

The term "conservative substitution" is intended to mean that a substitution in which the amino acid residue is replaced with an amino acid residue having a similar side chain. These families are known in the art and include amino acids with basic side chains (e.g.lysine, arginine and hystidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagines, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine tryptophan, histidine).

Functional nucleic acid equivalents may typically contain silent mutations or mutations that do not alter the biological function of encoded polypeptide. Accordingly, the invention provides nucleic acid molecules encoding lipolytic enzyme proteins that contain changes in amino acid residues that are not essential for a particular biological activity. Such lipolytic enzyme proteins differ in amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 yet retain at least one biological activity. In one embodiment the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises a substantially homologous amino acid sequence of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39.

For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie, J.U. et al., Science 247:1306-1310 (1990) wherein the authors indicate that there are two main approaches for studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. The

second approach uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene and selects or screens to identify sequences that maintain functionality. As the authors state, these studies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which changes are likely to be permissive at a certain position of the protein. For example, most buried amino acid residues require non-polar side chains, whereas few features of surface side chains are generally conserved. Other such phenotypically silent substitutions are described in Bowie et al, supra, and the references cited therein.

An isolated nucleic acid molecule encoding a protein homologous to the protein selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 can be created by introducing one or more nucleotide substitutions, additions or deletions into the corresponding coding nucleotide sequences (Table 1) such that one or more amino acid substitutions, deletions or insertions are introduced into the encoded protein. Such mutations may be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis.

The term "functional equivalents" also encompasses orthologues of the *Aspergillus niger* lipolytic enzymes provided herein. Orthologues of the *Aspergillus niger* lipolytic enzymes are proteins that can be isolated from other strains or species and possess a similar or identical biological activity. Such orthologues can readily be identified as comprising an amino acid sequence that is substantially homologous to the amino acid sequences selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39.

As defined herein, the term "substantially homologous" refers to a first amino acid or nucleotide sequence which contains a sufficient or minimum number of identical or equivalent (e.g., with similar side chain) amino acids or nucleotides to a second amino acid or nucleotide sequence such that the first and the second amino acid or nucleotide sequences have a common domain. For example, amino acid or nucleotide sequences which contain a common domain having about 60%, preferably 65%, more preferably 70%, even more preferably 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity or more are defined herein as sufficiently identical.

Also, nucleic acids encoding other lipolytic enzyme family members, which thus have a nucleotide sequence that differs from a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25,

26, 28, 29, 31, 32, 34, 35, 37 and 38, are within the scope of the invention. Moreover, nucleic acids encoding lipolytic enzyme proteins from different species which thus have a nucleotide sequence which differs from a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 are within the scope of the invention.

Nucleic acid molecules corresponding to variants (e.g. natural allelic variants) and homologues of the polynucleotides of the invention can be isolated based on their homology to the nucleic acids disclosed herein using the cDNAs disclosed herein or a suitable fragment thereof, as a hybridisation probe according to standard hybridisation techniques preferably under highly stringent hybridisation conditions.

In addition to naturally occurring allelic variants of the *Aspergillus niger* sequences provided herein, the skilled person will recognise that changes can be introduced by mutation into the nucleotide sequences selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 thereby leading to changes in the amino acid sequence of the lipolytic enzyme protein without substantially altering the function of the protein.

In another aspect of the invention, improved lipolytic enzymes are provided. Improved lipolytic enzymes are proteins wherein at least one biological activity is improved. Such proteins may be obtained by randomly introducing mutations along all or part of the lipolytic enzyme coding sequence, such as by saturation mutagenesis, and the resulting mutants can be expressed recombinantly and screened for biological activity. For instance, the art provides for standard assays for measuring the enzymatic activity of lipolytic enzymes and thus improved proteins may easily be selected.

In a preferred embodiment the lipolytic enzyme has an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39. In another embodiment, the lipolytic enzyme is substantially homologous to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 and retains at least one biological activity of a polypeptide selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39, yet differs in amino acid sequence due to natural variation or mutagenesis as described above.

In a further preferred embodiment, the lipolytic enzyme has an amino acid sequence encoded by an isolated nucleic acid fragment capable of hybridising to a

nucleic acid selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38, preferably under highly stringent hybridisation conditions.

Accordingly, the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 and retains at least one functional activity of the polypeptide selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39.

In particular, the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 3 or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 6, or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 9, or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 12 or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 15, or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 18 or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 21, or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 24 or the lipolytic enzyme is a protein which comprises an amino

acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 27, or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 30 or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 33, or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 36 or the lipolytic enzyme is a protein which comprises an amino acid sequence at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homologous to the amino acid sequence shown in SEQ ID NO: 39.

Functional equivalents of a protein according to the invention can also be identified e.g. by screening combinatorial libraries of mutants, e.g. truncation mutants, of the protein of the invention for lipolytic enzyme activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential protein sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display). There are a variety of methods that can be used to produce libraries of potential variants of the polypeptides of the invention from a degenerate oligonucleotide sequence. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 53:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acid Res. 11:477).

In addition, libraries of fragments of the coding sequence of a polypeptide of the invention can be used to generate a variegated population of polypeptides for screening a subsequent selection of variants. For example, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of the coding sequence of interest with a nuclease under conditions wherein nicking occurs only about once per

molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the protein of interest.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations of truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify variants of a protein of the invention (Arkin and Yourvan (1992) Proc. Natl. Acad. Sci. USA 89:7811-7815; Delgrave et al. (1993) Protein Engineering 6(3):327-331).

It will be apparent for the person skilled in the art that DNA sequence polymorphisms that may lead to changes in the amino acid sequence of the lipolytic enzyme may exist within a given population. Such genetic polymorphisms may exist in cells from different populations or within a population due to natural allelic variation. Allelic variants may also include functional equivalents.

Fragments of a polynucleotide according to the invention may also comprise polynucleotides not encoding functional polypeptides. Such polynucleotides may function as probes or primers for a PCR reaction.

Nucleic acids according to the invention irrespective of whether they encode functional or non-functional polypeptides, can be used as hybridization probes or polymerase chain reaction (PCR) primers. Uses of the nucleic acid molecules of the present invention that do not encode a polypeptide having a lipolytic enzyme activity include, inter alia, (1) isolating the gene encoding the lipolytic enzyme protein, or allelic variants thereof from a cDNA library e.g. from other organisms than *Aspergillus niger*; (2) in situ hybridization (e.g. FISH) to metaphase chromosomal spreads to provide precise

chromosomal location of the lipolytic enzyme gene as described in Verma et al., Human Chromosomes: a Manual of Basic Techniques, Pergamon Press, New York (1988); (3) Northern blot analysis for detecting expression of lipolytic enzyme mRNA in specific tissues and/or cells and 4) probes and primers that can be used as a diagnostic tool to analyse the presence of a nucleic acid hybridisable to the lipolytic enzyme probe in a given biological (e.g. tissue) sample.

Also encompassed by the invention is a method of obtaining a functional equivalent of a lipolytic enzyme-encoding gene or cDNA. Such a method entails obtaining a labelled probe that includes an isolated nucleic acid which encodes all or a portion of the sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or a variant thereof; screening a nucleic acid fragment library with the labelled probe under conditions that allow hybridisation of the probe to nucleic acid fragments in the library, thereby forming nucleic acid duplexes, and preparing a full-length gene sequence from the nucleic acid fragments in any labelled duplex to obtain a gene related to the lipolytic enzyme gene.

In one embodiment, a nucleic acid of the invention is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 2, 4, 5, 7, 8, 10, 11, 13, 14, 16, 17, 19, 20, 22, 23, 25, 26, 28, 29, 31, 32, 34, 35, 37 and 38 or the complement thereof.

In another preferred embodiment a polypeptide of the invention is at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more homologous to an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39.

Host cells

In another embodiment, the invention features cells, e.g., transformed host cells or recombinant host cells that contain a nucleic acid encompassed by the invention. A "transformed cell" or "recombinant cell" is a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a nucleic acid according to the invention. Both prokaryotic and eukaryotic cells are included, e.g., bacteria, fungi, yeast, and the like, especially preferred are cells from filamentous fungi,

in particular Aspergillus niger.

A host cell can be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in a specific, desired fashion. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may facilitate optimal functioning of the protein.

Various host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems familiar to those of skill in the art of molecular biology and/or microbiology can be chosen to ensure the desired and correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such host cells are well known in the art.

Host cells also include, but are not limited to, mammalian cell lines such as CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and choroid plexus cell lines.

If desired, the polypeptides according to the invention can be produced by a stably-transfected cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public, methods for constructing such cell lines are also publicly known, e.g., in Ausubel et al. (supra).

Antibodies

The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind lipolytic enzyme proteins according to the invention.

As used herein, the term "antibody" (Ab) or "monoclonal antibody" (Mab) is meant to include intact molecules as well as antibody fragments (such as, for example, Fab and $F(ab')_2$ fragments) which are capable of specifically binding to lipolytic enzyme protein. Fab and $F(ab')_2$ fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation, and may have less non-specific tissue binding of an intact antibody (Wahl *et al., J. Nucl. Med. 24*:316-325 (1983)). Thus, these fragments are preferred.

The antibodies of the present invention may be prepared by any of a variety of methods. For example, cells expressing the lipolytic enzyme protein or an antigenic

fragment thereof can be administered to an animal in order to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of lipolytic enzyme protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or lipolytic enzyme protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology (Kohler *et al., Nature 256*:495 (1975); Kohler *et al., Eur. J. Immunol.* 6:511 (1976); Hammerling *et al.*, In: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981)). In general, such procedures involve immunizing an animal (preferably a mouse) with a lipolytic enzyme protein antigen or, with a lipolytic enzyme protein expressing cell. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present inventoin; however, it is preferably to employ the parent myeloma cell line (SP_2O), available from the American Type Culture Collection, Rockville, Maryland. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al. (Gastro-enterology 80*:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the lipolytic enzyme protein antigen. In general, the polypeptides can be coupled to a carrier protein, such as KLH, as described in Ausubel et al., supra, mixed with an adjuvant, and injected into a host mammal.

In particular, various host animals can be immunized by injection of a polypeptide of interest. Examples of suitable host animals include rabbits, mice, guinea pigs, and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), adjuvant mineral gels such as aluminum hydroxide, surface actve substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Such antibodies can be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD, and any subclass thereof. The hybridomas producing the mAbs of this

invention can be cultivated *in vitro* or *in vivo*.

Once produced, polyclonal or monoclonal antibodies are tested for specific recognition of a protein according to the invention or functional equivalent thereof in an immunoassay, such as a Western blot or immunoprecipitation analysis using standard techniques, e.g., as described in Ausubel et al., supra. Antibodies that specifically bind to a protein according to the invention or functional equivalents thereof are useful in the invention. For example, such antibodies can be used in an immunoassay to detect a protein according to the invention in pathogenic or non-pathogenic strains of *Aspergillus* (e.g., in *Aspergillus* extracts).

Preferably, antibodies of the invention are produced using fragments of a protein according to the invention that appear likely to be antigenic, by criteria such as high frequency of charged residues. For example, such fragments may be generated by standard techniques of PCR, and then cloned into the pGEX expression vector (Ausubel et al., supra). Fusion proteins may then be expressed in *E. coli* and purified using a glutathione agarose affinity matrix as described in Ausubel, et al., supra. If desired, several (e.g., two or three) fusions can be generated for each protein, and each fusion can be injected into at least two rabbits. Antisera can be raised by injections in a series, typically including at least three booster injections. Typically, the antisera are checked for their ability to immunoprecipitate the protein according to the invention or functional equivalents thereof whereas unrelated proteins may serve as a control for the specificity of the immune reaction.

Alternatively, techniques decribed for the production of single chain antibodies (U.S. Patent 4,946,778 and 4,704,692) can be adapted to produce single chain antibodies against a protein according to the invention or functional equivalents thereof. Kits for generating and screening phage display libraries are commercially available e.g. from Pharmacia.

Additionally, examples of methods and reagents particularly amenable for use in generating and screening antibody display library can be found in, for example, U.S. Patent No. 5,223, 409; PCT Publication No. WO 92/18619; PCT Publication No. WO 91/17271; PCT Publication No. WO 20791; PCT Publication No. WO 92/20791; PCT Publication No. WO 92/15679; PCT Publication No. WO 93/01288; PCT Publication No. WO 92/01047; PCT Publication No. WO 92/09690; PCT Publication No. WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum. Antibod.*

Hybridomas 3:81-85; Huse et al. (1989) *Science* 246;1275-1281; Griffiths et al. (1993) *EMBO J.* 12:725-734.

Polyclonal and monoclonal antibodies that specifically bind a protein according to the invention of functional equivalents thereof can be used, for example, to detect expression of a gene encoding a protein according to the invention or a functional equivalent thereof e.g. in another strain of *Aspergillus*. For example, a protein according to the invention can be readily detected in conventional immunoassays of *Aspergillus* cells or extracts. Examples of suitable assays include, without limitation, Western blotting, ELISAs, radioimmune assays, and the like.

By "specifically binds" is meant that an antibody recognizes and binds a particular antigen, e.g., a protein according to the invention, but does not substantially recognize and bind other unrelated molecules in a sample.

Antibodies can be purified, for example, by affinity chromatography methods in which the polypeptide antigen is immobilized on a resin.

An antibody directed against a polypeptide of the invention (e.g., monoclonal antibody) can be used to isolate the polypeptide by standard techniques, such as affinity chromatography or immunoprecipitation. Moreover, such an antibody can be used to detect the protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the polypeptide. The antibodies can also be used diagnostically to monitor protein levels in cells or tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen or in the diagnosis of Aspergillosis..

Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive materials include ^{125}I, ^{131}I, ^{35}S or ^{3}H.

Preferred epitopes encompassed by the antigenic peptide are regions that are

located on the surface of the protein, e.g., hydrophilic regions. Hydrophobicity plots of the proteins of the invention can be used to identify hydrophilic regions.

The antigenic peptide of a protein of the invention comprises at least 7 (preferably 10, 15, 20, or 30) contiguous amino acid residues of the amino acid sequense selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 and encompasses an epitope of the protein such that an antibody raised against the peptide forms a specific immune complex with the protein.

Preferred epitopes encompassed by the antigenic peptide are regions of the protein according to the invention that are located on the surface of the protein, e.g., hydrophilic regions, hydrophobic regions, alpha regions, beta regions, coil regions, turn regions and flexible regions.

Immunoassays

Qualitative or quantitative determination of a polypeptide according to the present invention in a biological sample can occur using any art-known method. Antibody-based techniques provide special advantages for assaying specific polypeptide levels in a biological sample.

In these, the specific recognition is provided by the primary antibody (polyclonal or monoclonal) but the secondary detection system can utilize fluorescent, enzyme, or other conjugated secondary antibodies. As a result, an immunocomplex is obtained.

Accordingly, the invention provides a method for diagnosing whether a certain organism is infected with Aspergillus comprising the steps of:

- Isolating a biological sample from said organism suspected to be infected with Aspergillus,
- reacting said biological sample with an antibody according to the invention,
- determining whether immunecomplexes are formed.

Tissues can also be extracted, e.g., with urea and neutral detergent, for the liberation of protein for Western-blot or dot/slot assay. This technique can also be applied to body fluids.

Other antibody-based methods useful for detecting a protein according to the invention include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). For example, monoclonal antibodies against

a protein according to the invention can be used both as an immunoabsorbent and as an enzyme-labeled probe to detect and quantify the protein according to the invention. The amount of protein present in the sample can be calculated by reference to the amount present in a standard preparation using a linear regression computer algorithm. In another ELISA assay, two distinct specific monoclonal antibodies can be used to detect a protein according to the invention in a biological fluid. In this assay, one of the antibodies is used as the immuno-absorbent and the other as the enzyme-labeled probe.

The above techniques may be conducted essentially as a "one-step" or "two-step" assay. The "one-step" assay involves contacting a protein according to the invention with immobilized antibody and, without washing, contacting the mixture with the labeled antibody. The "two-step" assay involves washing before contacting the mixture with the labeled antibody. Other conventional methods may also be employed as suitable. It is usually desirable to immobilize one component of the assay system on a support, thereby allowing other components of the system to be brought into contact with the component and readily removed from the sample.

Suitable enzyme labels include, for example, those from the oxidase group, which catalyze the production of hydrogen peroxide by reacting with substrate. Activity of an oxidase label may be assayed by measuring the concentration of hydrogen peroxide formed by the enzyme-labelled antibody/substrate reaction.

Besides enzymes, other suitable labels include radioisotopes, such as iodine (^{125}I, ^{121}I), carbon (^{14}C), sulphur (^{35}S), tritium (^{3}H), indium (^{112}In), and technetium (^{99m}Tc), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

Specific binding of a test compound to a protein according to the invention can be detected, for example, in vitro by reversibly or irreversibly immobilizing the protein according to the invention on a substrate, e.g., the surface of a well of a 96-well polystyrene microtitre plate. Methods for immobilizing polypeptides and other small molecules are well known in the art. For example, the microtitre plates can be coated with a protein according to the invention by adding the protein in a solution (typically, at a concentration of 0.05 to 1 mg/ml in a volume of 1-100 ul) to each well, and incubating the plates at room temperature to 37 °C for 0.1 to 36 hours. Proteins that are not bound to the plate can be removed by shaking the excess solution from the plate, and then washing the plate (once or repeatedly) with water or a buffer. Typically, the protein is contained in water or a buffer. The plate is then washed with a buffer that lacks the

bound protein. To block the free protein-binding sites on the plates, the plates are blocked with a protein that is unrelated to the bound protein. For example, 300 ul of bovine serum albumin (BSA) at a concentration of 2 mg/ml in Tris-HCl is suitable. Suitable substrates include those substrates that contain a defined cross-linking chemistry (e.g., plastic substrates, such as polystyrene, styrene, or polypropylene substrates from Corning Costar Corp. (Cambridge, MA), for example). If desired, a beaded particle, e.g., beaded agarose or beaded sepharose, can be used as the substrate.

Binding of the test compound to the polypeptides according to the invention can be detected by any of a variety of artknown methods. For example, a specific antibody can be used in an immunoassay. If desired, the antibody can be labeled (e.g., fluorescently or with a radioisotope) and detected directly (see, e.g., West and McMahon, J. Cell Biol. 74:264, 1977). Alternatively, a second antibody can be used for detection (e.g., a labeled antibody that binds the Fc portion of an anti-AN97 antibody). In an alternative detection method, the protein according to the invention is labeled, and the label is detected (e.g., by labeling a protein according to the invention with a radioisotope, fluorophore, chromophore, or the like). In still another method, the protein according to the invention is produced as a fusion protein with a protein that can be detected optically, e.g., green fluorescent protein (which can be detected under UV light). In an alternative method, the protein according to the invention can be covalently attached to or fused with an enzyme having a detectable enzymatic activity, such as horse radish peroxidase, alkaline phosphatase, alpha-galactosidase, or glucose oxidase. Genes encoding all of these enzymes have been cloned and are readily available for use by those of skill in the art. If desired, the fusion protein can include an antigen, and such an antigen can be detected and measured with a polyclonal or monoclonal antibody using conventional methods. Suitable antigens include enzymes (e.g., horse radish peroxidase, alkaline phosphatase, and alpha-galactosidase) and non-enzymatic polypeptides (e.g., serum proteins, such as BSA and globulins, and milk proteins, such as caseins).

Epitopes, antigens and immunogens.

In another aspect, the invention provides a peptide or polypeptide comprising

an epitope-bearing portion of a polypeptide of the invention. The epitope of this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. An "immunogenic epitope" is defined as a part of a protein that elicits an antibody response when the whole protein is the immunogen. These immunogenic epitopes are believed to be confined to a few loci on the molecule. On the other hand, a region of a protein molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a protein generally is less than the number of antigenic epitopes. See, for instance, Geysen, H. M. et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984).

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain a region of a protein molecule to which an antibody can bind), it is well known in that art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See, for instance, Sutcliffe, J. G. et al., Science 219:660-666 (1984). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins (i.e., immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer, soluble peptides, especially those containing proline residues, usually are effective. Sutcliffe et al., supra, at 661. For instance, 18 of 20 peptides designed according to these guidelines, containing 8-39 residues covering 75% of the sequence of the influenza virus hemagglutinin HA1 polypeptide chain, induced antibodies that reacted with the HA1 protein or intact virus; and 12/12 peptides from the MuLV polymerase and 18/18 from the rabies glycoprotein induced antibodies that precipitated the respective proteins.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention. Thus, a high proportion of hybridomas obtained by fusion of spleen cells from donors immunized with an antigen epitope-bearing peptide generally secrete antibody reactive with the native protein. Sutcliffe et al., supra, at 663. The antibodies raised by antigenic epitope bearing peptides or polypeptides are useful to detect the mimicked protein, and antibodies to different

peptides may be used for tracking the fate of various regions of a protein precursor which undergoes posttranslation processing. The peptides and anti-peptide antibodies may be used in a variety of qualitative or quantitative assays for the mimicked protein, for instance in competition assays since it has been shown that even short peptides (e.g., about 9 amino acids) can bind and displace the larger peptides in immunoprecipitation assays. See, for instance, Wilson, I.A. et al., Cell 37:767-778 at 777 (1984). The anti-peptide antibodies of the invention also are useful for purification of the mimicked protein, for instance, by adsorption chromatography using methods well known in the art.

Antigenic epitope-bearing peptides and polypeptides of the invention designed according to the above guidelines preferably contain a sequence of at least seven, more preferably at least nine and most preferably between about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of a polypeptide of the invention, containing about 30 to about 50 amino acids, or any length up to and including the entire amino acid sequence of a polypeptide of the invention, also are considered epitope-bearing peptides or polypeptides of the invention and also are useful for inducing antibodies that react with the mimicked protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents (i.e., the sequence includes relatively hydrophilic residues and highly hydrophobic sequences are preferably avoided); and sequences containing proline residues are particularly preferred.

The epitope-bearing peptides and polypeptides of the invention may be produced by any conventional means for making peptides or polypeptides including recombinant means using nucleic acid molecules of the invention. For instance, a short epitope-bearing amino acid sequence may be fused to a larger polypeptide which acts as a carrier during recombinant production and purification, as well as during immunization to produce anti-peptide antibodies.

Epitope-bearing peptides also may be synthesized using known methods of chemical synthesis. For instance, Houghten has described a simple method for synthesis of large numbers of peptides, such as 10-20 mg of 248 different 13 residue peptides representing single amino acid variants of a segment of the HAI polypeptide which were prepared and characterized (by ELISA-type binding studies) in less than four

weeks. Houghten, R. A., Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten et al. (1986). In this procedure the individual resins for the solid-phase synthesis of various peptides are contained in separate solvent-permeable packets, enabling the optimal use of the many identical repetitive steps involved in solid-phase methods.

A completely manual procedure allows 500-1000 or more syntheses to be conducted simultaneously. Houghten et al., supra, at 5134.

Epitope-bearing peptides and polypeptides of the invention are used to induce antibodies according to methods well known in the art. See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow, M. et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle, F.J. et al., J. Gen. Virol. 66:2347-2354 (1985).

Generally, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling of the peptide to a macromolecular carrier, such as keyhole limpet hemocyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine may be coupled to carrier using a linker such as maleimidobenzoyl-N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carrier using a more general linking agent such as glutaraldehyde.

Animals such as rabbits, rats and mice are immunized with either free or carriercoupled peptides, for instance, by intraperitoneal and/or intradermal injection of emulsions containing about 100 ug peptide or carrier protein and Freund's adjuvant. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

Immunogenic epitope-bearing peptides of the invention, i.e., those parts of a protein that elicit an antibody response when the whole protein is the immunogen, are identified according to methods known in the art. For instance, Geysen et al., 1984, supra, discloses a procedure for rapid concurrent synthesis on solid supports of hundreds of peptides of sufficient purity to react in an enzyme-linked immunosorbent assay. Interaction of synthesized peptides with antibodies is then easily detected without

removing them from the support. In this manner a peptide bearing an immunogenic epitope of a desired protein may be identified routinely by one of ordinary skill in the art. For instance, the immunologically important epitope in the coat protein of foot-and-mouth disease virus was located by Geysen et al. with a resolution of seven amino acids by synthesis of an overlapping set of all 208 possible hexapeptides covering the entire 213 amino acid sequence of the protein. Then, a complete replacement set of peptides in which all 20 amino acids were substituted in turn at every position within the epitope were synthesized, and the particular amino acids conferring specificity for the reaction with antibody were determined. Thus, peptide analogs of the epitope-bearing peptides of the invention can be made routinely by this method. U.S. Patent No. 4,708,781 to Geysen (1987) further describes this method of identifying a peptide bearing an immunogenic epitope of a desired protein.

Further still, U.S. Patent No. 5,194,392 to Geysen (1990) describes a general method of detecting or determining the sequence of monomers (amino acids or other compounds) which is a topological equivalent of the epitope (i.e., a "mimotope") which is complementary to a particular paratope (antigen binding site) of an antibody of interest. More generally, U.S. Patent No. 4,433,092 to Geysen (1989) describes a method of detecting or determining a sequence of monomers which is a topographical equivalent of a ligand which is complementary to the ligand binding site of a particular receptor of interest. Similarly, U.S. Patent No. 5,480,971 to Houghten, R. A. et al. (1996) on Peralkylated Oligopeptide Mixtures discloses linear C1-C7-alkyl peralkylated oligopeptides and sets and libraries of such peptides, as well as methods for using such oligopeptide sets and libraries for determining the sequence of a peralkylated oligopeptide that preferentially binds to an acceptor molecule of interest. Thus, non-peptide analogs of the epitope-bearing peptides of the invention also can be made routinely by these methods.

Use of lipolytic enzymes in industrial processes

The invention also relates to the use of the lipolytic enzyme according to the invention in a selected number of industrial processes. Despite the long-term experience obtained with these processes, the lipolytic enzyme according to the invention features a number of significant advantages over the enzymes currently used. Depending on the

specific application, these advantages can include aspects like lower production costs, higher specificity towards the substrate, less antigenic, less undesirable side activities, higher yields when produced in a suitable microorganism, more suitable pH and temperature ranges, better tastes of the final product as well as food grade and kosher aspects.

The present invention also relates to methods for preparing a dough or a baked product comprising incorporating into the dough an effective amount of a lipolytic enzyme of the present invention which improves one or more properties of the dough or the baked product obtained from the dough relative to a dough or a baked product in which the polypeptide is not incorporated.

The phrase "incorporating into the dough" is defined herein as adding the lipolytic enzyme according to the invention to the dough, any ingredient from which the dough is to be made, and/or any mixture of dough ingredients form which the dough is to be made. In other words, the lipolytic enzyme according to the invention may be added in any step of the dough preparation and may be added in one, two or more steps. The lipolytic enzyme according to the invention is added to the ingredients of a dough that is kneaded and baked to make the baked product using methods well known in the art. See, for example, U.S. Patent No. 4,567,046, EP-A-426,211, JP-A-60-78529, JP-A-62-111629, and JP-A-63-258528.

The term "effective amount" is defined herein as an amount of the lipolytic enzyme according to the invention that is sufficient for providing a measurable effect on at least one property of interest of the dough and/or baked product.

The term "improved property" is defined herein as any property of a dough and/or a product obtained from the dough, particularly a baked product, which is improved by the action of the lipolytic enzyme according to the invention relative to a dough or product in which the lipolytic enzyme according to the invention is not incorporated. The improved property may include, but is not limited to, increased strength of the dough, increased elasticity of the dough, increased stability of the dough, reduced stickiness of the dough, improved extensibility of the dough, improved flavour of the baked product, improved anti-staling of the baked product.

The improved property may be determined by comparison of a dough and/or a baked product prepared with and without addition of a polypeptide of the present invention in accordance with the methods of present invention are described below in

the Examples. Organoleptic qualities may be evaluated using procedures well established in the baking industry, and may include, for example, the use of a panel of trained taste-testers.

The term "increased strength of the dough" is defined herein as the property of a dough that has generally more elastic properties and/or requires more work input to mould and shape.

The term "increased elasticity of the dough" is defined herein as the property of a dough which has a higher tendency to regain its original shape after being subjected to a certain physical strain.

The term "increased stability of the dough" is defined herein as the property of a dough that is less susceptible to mechanical abuse thus better maintaining its shape and volume.

The term "reduced stickiness of the dough" is defined herein as the property of a dough that has less tendency to adhere to surfaces, e.g., in the dough production machinery, and is either evaluated empirically by the skilled test baker or measured by the use of a texture analyser (e.g., TAXT2) as known in the art.

The term "improved extensibility of the dough" is defined herein as the property of a dough that can be subjected to increased strain or stretching without rupture.

The term "improved machineability of the dough" is defined herein as the property of a dough that is generally less sticky and/or more firm and/or more elastic.

The term "increased volume of the baked product" is measured as the specific volume of a given loaf of bread (volume/weight) determined typically by the traditional rapeseed displacement method.

The term "improved crumb structure of the baked product" is defined herein as the property of a baked product with finer and/or thinner cell walls in the crumb and/or more uniform/homogenous distribution of cells in the crumb and is usually evaluated empirically by the skilled test baker.

The term "improved softness of the baked product" is the opposite of "firmness" and is defined herein as the property of a baked product that is more easily compressed and is evaluated either empirically by the skilled test baker or measured by the use of a texture analyzer (e.g., TAXT2) as known in the art.

The term "improved flavor of the baked product" is evaluated by a trained test panel.

The term "improved anti-staling of the baked product" is defined herein as the properties of a baked product that have a reduced rate of deterioration of quality parameters, e.g., softness and/or elasticity, during storage.

The term "dough" is defined herein as a mixture of flour and other ingredients firm enough to knead or roll. The dough may be fresh, frozen, pre-bared, or pre-baked. The preparation of frozen dough is described by Kulp and Lorenz in Frozen and Refrigerated Doughs and Batters.

The term "baked product" is defined herein as any product prepared from a dough, either of a soft or a crisp character. Examples of baked products, whether of a white, light or dark type, which may be advantageously produced by the present invention are bread (in particular white, whole-meal or rye bread), typically in the form of loaves or rolls, French baguette-type bread, pasta, pita bread, tortillas, tacos, cakes, pancakes, biscuits, cookies, pie crusts, steamed bread, and crisp bread, and the like.

Lipolytic enzyme of the present invention and/or additional enzymes to be used in the methods of the present invention may be in any form suitable for the use in question, e.g., in the form of a dry powder, agglomerated powder, or granulate, in particular a non-dusting granulate, liquid, in particular a stabilized liquid, or protected enzyme such described in WO01/11974 and WO02/26044. Granulates and agglomerated powders may be prepared by conventional methods, e.g., by spraying the lipolytic enzyme according to the invention onto a carrier in a fluid-bed granulator. The carrier may consist of particulate cores having a suitable particle size. The carrier may be soluble or insoluble, e.g., a salt (such as NaCl or sodium sulphate), sugar (such as sucrose or lactose), sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy. The lipolytic enzyme according to the invention and/or additional enzymes may be contained in slow-release formulations. Methods for preparing slow-release formulations are well known in the art. Adding nutritionally acceptable stabilizers such as sugar, sugar alcohol, or another polyol, and/or lactic acid or another organic acid according to established methods may for instance, stabilize liquid enzyme preparations.

The lipolytic enzyme according to the invention may also be incorporated in yeast comprising compositions such as disclosed in EP-A-0619947, EP-A-0659344 and WO02/49441.

For inclusion in pre-mixes of flour it is advantageous that the polypeptide according to the invention is in the form of a dry product, e.g., a non-dusting granulate,

whereas for inclusion together with a liquid it is advantageously in a liquid form.

One or more additional enzymes may also be incorporated into the dough. The additional enzyme may be of any origin, including mammalian and plant, and preferably of microbial (bacterial, yeast or fungal) origin and may be obtained by techniques conventionally used in the art.

In a preferred embodiment, the additional enzyme may be an amylase, such as an alpha-amylase (useful for providing sugars fermentable by yeast and retarding staling) or beta-amylase, cyclodextrin glucanotransferase, peptidase, in particular, an exopeptidase (useful in flavour enhancement), transglutaminase, lipase (useful for the modification of lipids present in the dough or dough constituents so as to soften the dough), phospholipase, cellulase, hemicellulase, in particular a pentosanase such as xylanase (useful for the partial hydrolysis of pentosans which increases the extensibility of the dough), protease (useful for gluten weakening in particular when using hard wheat flour), protein disulfide isomerase, e.g., a protein disulfide isomerase as disclosed in WO 95/00636, glycosyltransferase, peroxidase (useful for improving the dough consistency), laccase, or oxidase, e.g., an glucose oxidase, hexose oxidase, aldose oxidase, pyranose oxidase, lipoxygenase or L-amino acid oxidase (useful in improving dough consistency).

When one or more additional enzyme activities are to be added in accordance with the methods of the present invention, these activities may be added separately or together with the polypeptide according to the invention, optionally as constituent(s) of the bread-improving and/or dough-improving composition. The other enzyme activities may be any of the enzymes described above and may be dosed in accordance with established baking practices.

The present invention also relates to methods for preparing a baked product comprising baking a dough obtained by a method of the present invention to produce a baked product. The baking of the dough to produce a baked product may be performed using methods well known in the art.

The present invention also relates to doughs and baked products, respectively, produced by the methods of the present invention.

The present invention further relates to a pre-mix, e.g., in the form of a flour composition, for dough and/or baked products made from dough, in which the pre-mix comprises a polypeptide of the present invention. The term "pre-mix" is defined herein to

be understood in its conventional meaning, i.e., as a mix of baking agents, generally including flour, which may be used not only in industrial bread-baking plants/facilities, but also in retail bakeries. The pre-mix may be prepared by mixing the polypeptide or a bread-improving and/or dough-improving composition of the invention comprising the polypeptide with a suitable carrier such as flour, starch, a sugar, or a salt. The pre-mix may contain other dough-improving and/or bread-improving additives, e.g., any of the additives, including enzymes, mentioned above.

The present invention further relates to baking additives in the form of a granulate or agglomerated powder, which comprise a polypeptide of the present invention. The baking additive preferably has a narrow particle size distribution with more than 95% (by weight) of the particles in the range from 25 to 500 μm.

In dough and bread making the present invention may be used in combination with the processing aids defined hereinbefore such as the chemical processing aids like oxidants (e.g. ascorbic acid), reducing agents (e.g. L-cysteine), oxidoreductases (e.g. glucose oxidase) and/or other enzymes such as polysaccharide modifying enzymes (e.g. α–amylase, hemicellulase, branching enzymes, etc.) and/or protein modifying enzymes (endoprotease, exoprotease, branching enzymes, etc.).

EXAMPLE 1

Fermentation of *Aspergillus niger*

Lipolytic enzymes encoded by the nucleotide sequence as provided herein were obtained by constructing expression plasmids containing the DNA sequences, transforming an *A. niger* strain with this plasmid and growing the *Aspergillus niger* strains in thw following way.

Fresh spores (10^6-10^7) of *A. niger* strains were inoculated in 20 ml CSL-medium (100 ml flask, baffle) and grown for 20-24 hours at 34°C and 170 rpm. After inoculation of 5-10 ml CSL pre-culture in 100 ml CSM medium (500 ml flask, baffle) the strains were fermented at 34°C and 170 rpm for 3-5 days.

Cell-free supernatants were obtained by centrifugation in 50 ml Greiner tubes (30 minutes, 5000 rpm). The supernatants were pre-filtered over a GF/A Whatman Glass microfiber filter (150 mm Æ) to remove the larger particles, adjusted to pH 5 with 4 N

KOH (if necessary) and sterile filtrated over a 0.2 µm (bottle-top) filter with suction to remove the fungal material. The supernatants were stored at 4°C (or -20°C).

The CSL medium consisted of (in amount per litre): 100 g Corn Steep Solids (Roquette), 1 g NaH_2PO4*H_2O, 0.5 g $MgSO_4*7H_2O$, 10 g glucose*H_2O and 0.25 g Basildon (antifoam). The ingredients were dissolved in demi-water and the pH was adjusted to pH 5.8 with NaOH or H_2SO_4; 100 ml flasks with baffle and foam ball were filled with 20 ml fermentation broth and sterilized for 20 minutes at 120°C after which 200 µl of a solution containing 5000 IU/ml penicillin and 5 mg/ml Streptomycin was added to each flask after cooling to room temperature.

The CSM medium consisted of (in amount per litre): 150 g maltose*H2O, 60 g Soytone (pepton), 1 g NaH_2PO4*H_2O, 15 g $MgSO_4*7H_2O$, 0.08 g Tween 80, 0.02 g Basildon (antifoam), 20 g MES, 1 g L-arginine. The ingredients were dissolved in demi-water and the pH was adjusted to pH 6.2 with NaOH or H_2SO_4; 500 ml flasks with baffle and foam ball were filled with 100 ml fermentation broth and sterilized for 20 minutes at 120°C after which 1 ml of a solution containing 5000 IU/ml penicillin and 5 mg/ml Streptomycin was added to each flask after cooling to room temperature.

EXAMPLE 2

Purification of the lipolytic enzymes of the Invention

Step 1 - Preparation of ultrafiltrates

The supernatants of the cultures, as obtained in Example1, were ultrafiltrated to remove the low molecular contaminations that could interfere with the enzymatic activity determinations and the baking tests. Ultrafiltration of 30 ml supernatant was performed in a Millipore Labscale TFF system equipped with a filter with a 10 kDa cut-off.

Depending on their colour, the samples were washed 3–5 times with 40 ml volumes of cold 100 mM phosphate buffer pH 6.0 including 0.5 mM $CaCl_2$. The final volume of the enzyme solution was 30 ml and is further referred to as "ultrafiltrate".

Step 2 - Determination of the lipolytic enzymes concentration by A280 and HPSEC.

The concentration of the lipolytic enzymes in the ultrafiltrate was calculated from the extinction at 280 nm (A280) attributable to the lipolytic enzymes and the calculated molecular extinction coefficient of the lipolytic enzymes. Measurement of the A280 was

performed in an Uvikon XL Secomam spectrophotometer (Beun de Ronde, Abcoude, The Netherlands).

The molecular extinction coefficient of an enzyme can be calculated from the number of tyrosine, tryptophan and cysteïne residues per enzyme molecule (S.C. Gill and P.H. von Hippel, Anal. Biochem. 182, 319-326 (1989)). The molecular extinction coefficient of these amino acids are 1280, 5690 and 120 $M^{-1}.cm^{-1}$ respectively. The number of tyrosine, tryptophan and cysteïne residues in the lipolytic enzymes of the invention can be deduced from the protein sequences selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39. The calculated extinction coefficients of the lipolytic enzymes of the invention are summarized in Table 2.

Table 2

Lipolytic enzyme	SEQ ID NO:	# amino acids			Calculated M.W. (Da)	Calculated extinction coefficient at 280 nm	
		Trp	Tyr	Cys		$M^{-1}.cm^{-1}$	$(1\ mg/ml)^{-1}.cm^{-1}$
NBE028	3	13	26	6	64141	107970	1.7
NBE029	6	14	27	6	63250	114940	1.8
NBE030	9	17	26	6	59952	130730	2.2
NBE031	12	9	27	4	61173	86250	1.4
NBE032	15	3	13	6	29683	34430	1.2
NBE033	18	7	24	2	44890	70790	1.6
NBE034	21	11	19	7	53796	87750	1.6
NBE036	24	10	23	7	64945	87180	1.3
NBE038	27	13	29	4	55161	111570	2.2
NBE039	30	11	26	6	59298	96590	1.6
NBE043	33	16	35	8	62564	136800	2.2
NBE045	36	0	6	6	26688	8400	0.31
NBE042	39	14	30	7	61593	118900	1.9

The extinction of the ultrafiltrate at 280 nm (A280) that is attributable to the lipolytic enzymes depends on the purity of the enzyme sample. This purity was

determined using HPSEC (High Performance Size Exclusion Chromatography) with a TSK SW-XL column (300*7,8 mm; MW range 10-300 kDa). The elution buffer consisted of 25 mM sodium phosphate buffer pH 6.0 and was used at a flow of 1 ml/min. Samples of 5—100 µl were injected. The absorbance at 280 nm was measured.

The A280 in the ultrafiltrate attributable to the lipolytic enzyme of the invention was obtained from the ratio of the peak surface of the respective lipolytic enzyme peak in the chromatogram and the total surface of the peaks absorbing at 280 nm. The lipolytic enzyme concentration in the ultrafiltrate was then calculated by multiplying the A280 of the ultrafiltrate by the ratio described above and divided by the calculated extinction coefficient (1 mg/ml solution – Table 2 most right column) for each lipolytic enzyme.

EXAMPLE 3

Activity measurements

The cell-free supernatants obtained in Example 1 were subjected to the lipase, phospholipase and galactolipase assays as summarized in Table 3.

Table 3. Lipolytic enzyme activities in the cell free supernants as prepared in Example 1.

Lipolytic enzyme	Lipase	phospho lipase A	lyso phospho lipase	galacto lipase
NBE028	+	+	+	0
NBE029	+	+	+	0
NBE031	+++	+	+	+
NBE032	++	+	+	0
NBE033	+	++	+	+
NBE034	0	+	0	0
NBE036	0	+	+	0
NBE038	0	+	0	0
NBE039	+	0	0	0
NBE043	+	0	0	0

0 = not different from blanc; +/++/+++ = higher than blanc;

Lipase activity was determined spectrophotometrically by using 2,3-mercapto-1-propanol-tributyrate (TBDMP) as a substrate. Lipase hydrolyses the sulphide bond of

TBDMP thereby liberating thio-butanoic acid which in a subsequent reaction with 4,4,-dithiodipyridine (DTDP) forms 4-thiopyridone. The latter is in a tautomeric equilibrium with 4-mercapthopyridine which absorbs at 334 nm. The reaction is carried out in 0.1 M acetate buffer pH 5.0 containing 0.2 % Triton-X100, 0.65 mM TBDMP and 0.2 mM DTDP at 37°C. One lipase unit is defined as the amount of enzyme that liberates 1 micromole of 4 thio-butanoic acid per minute at the reaction conditions stated.

Phospholipase A was determined spectrophotometrically by using 1,2-dithiodioctanoyl-phosphatidylcholine as a substrate. Phospholipase A hydrolyses the sulphide bond at the 1 position (PLA1) or the 2 position (PLA2) thereby liberating 4 thio-octanoic acid which, in a subsequent reaction reacts with 4,4'-dithiopyridine to form 4-thiopyridone. The latter is in tautomeric equilibrium with 4-mercaptopyridine that absorbs at 334 nm. The reaction is carried out in 0.1 M acetate buffer pH 4.0 containing 0.2 % Triton-X100, 0.65 mM substrate and 0.2 mM DTDP at 37°C. One phospholipase A unit (PLA) is defined as the amount of enzyme that liberates 1 micromole of 4 thio-octanoic acid per minute at the reaction conditions stated.

Lysophospholipase activity was determined with ^{31}P-NMR spectroscopy by using lysophosphatidyl-choline as a substrate. Lysophospholipase hydrolyses the ester bond thereby liberating the fatty acid from the glycerol moiety. The so-formed glycerolphosphocholine is quantified using NMR.
The reaction is carried out in 50 mM acetic acid buffer pH 4.5 further containing 1 mg/ml lysophosphatidylcholine and 5 mM $CaCl_2$ for 30 minutes at 55°C.
One lysophospholipase unit (LPC) is defined as the amount of enzyme that forms 1 micromole of 4 glycerolphosphocholine per minute at the reaction conditions stated.

Galactolipase activity was determined with H-NMR spectroscopy by using digalactosyldiglyceride as a substrate, according to the method described by Hirayama and Matsuda (1972) Agric. Biol. Chem. 36, 1831. Galactolipase hydrolyses the ester bond between the fatty acids and the glycerol backbone thereby liberating one or both fatty acids. The reaction is carried out in 50 mM acetic acid buffer pH 4.5 further containing 4 mM $CaCl_2$, 0.2% Triton X-100 and 1 mg/ml digalactosyldiglyceride (Lipid Products) for 30 minutes at 30°C. One galactolipase unit is defined as the amount of

enzyme that forms 1 micromole of fatty acid per minute at the reaction conditions stated.

The ultrafiltrates obtained in Example 2, were subjected to the FAU enzyme activity measurement. The activity of the fungal alpha-amylase was measured using Phadebas Amylase test tablets (Pharmacia). Phadebas tablets contain a water insoluble starch substrate and a blue dye, bound by cross-linking to the substrate. The substrate is hydolysed by fungal amylase, releasing dyed soluble maltodextrines that go into solution. A calibration curve was prepared with a solution containing a reference fungal alpha amylase activity. From the reference and unknown samples appropriate dilutions were prepared in 50 mM malic acid buffer pH 5.5. Samples of 5 ml were incubated with 30°C for 5 minutes, a Phadebas tablet was added and after 15 minutes the reaction was stopped by the addition of 1.0 ml 0.5 N sodium hydroxide. The mixtures were allowed to cool down to room temperature for 5 minutes after which 4.0 ml water was added, shaken by hand and after 15 minutes the samples were centrifuged at 4700 rpm for 10 minutes. The extinction of the top layers was measured at 620 nm. The OD 620 nm is a measure for fungal alpha amylase activity. One fungal amylase unit (FAU) is defined herein as the amount of enzyme that converts 1 gram of starch (100% dry matter) per hour into a product having a transmission at 620 nm after reaction with a iodine solution of known strength at the reaction conditions stated.

Table 4. FAU and protein in the ultrafiltrates as prepared in Example 2.

lipolytic enzyme	Protein (mg/ml) from the 280 nm analysis	fungal amylase (FAU/ml)
NBE028	2.3	4.5
NBE029	1.3	3.0
NBE030	0.4	2.6
NBE031	0.1	2.5
NBE032	1.0	0.3
NBE033	ND	0.3

NBE034	ND	2.7
NBE036	ND	3.4
NBE038	2.0	3.7
NBE039	2.2	0.6
NBE043	0.1	0.2
NBE045	ND	4.0
NBE042	1.6	1.5

In addition to the activities mentioned in Table 4, minor activities of glucoamylase was also present, however in such low amounts that these enzymes did not interfere in the baking experiments described in example 4.

EXAMPLE 4

Baking experiments 1 – pup loaves

Pup loaves were baked from 150 gram dough pieces obtained by mixing 200 g flour (Kolibri™/Ibis™ in a ratio of 80/20), 1,4 g dried baker's yeast (Fermipan®), 4 g salt, 3 g sugar, 10 mg ascorbic acid, 116 g water and 2 g fat. After mixing for 6 minutes and 15 seconds in a pin mixer, the dough was divided into pieces of 150 grams and proofed for 45 minutes at 30°C, punched, proofed for another 25 minutes, moulded and panned. Proofing took place at a relative humidity of 90-100%. After a final proof of 70 minutes at 30°C, the dough was baked for 20 minutes at 225°C.

The various effects (Tables 5 and 6) of the different lipolytic enzymes in the baking experiments were compared with a control containing the same amount of fungal amylase that was added otherwise by the dosage of the ultrafiltrate (for the fungal amylase activity in the ultrafiltrates see Table 4). This was necessary since the amounts of fungal amylase added with the lipolytic enzymes in particular affected the loaf volume, not the other parameters. The volume of the breads with the control amount of fungal amylase added was taken as 100%.

Table 5.

effect		Score				
		1	2	3	4	5
Dough	dough stickiness	too sticky	sticky	control bread	much better	excellent dry
Dough	dough extensibility	Too short	Shorter than the control	control bread	good	too long
baked bread	crumb structure	poor	non-uniform	control bread	good	excellent
baked bread	crust colour	Nearly white	too light	control bread	excellent	too dark
baked bread	crumb colour	Far too yellow	too yellow	control bread	excellent	absolutely white
baked bread	staling	Far too firm	too firm	control bread	softer	excellent

Loaf volume was determined by the Bread Volume Measurer BVM-3 (RI Cards Instruments AB, Viken, Sweden). The principle of this measurement is based on the reflection of ultrasound measured by a sensor around a rotating bread. A measurement time was taken of 45 seconds.

Dough stickiness and extensibility were evaluated by a qualified baker using the scale depicted in Table 5. The average of 2 loaves per object was measured.

After these tests the dough pieces were rounded and a first proof was performed for 45 minutes at 30°C and hereafter the dough was punched, moulded, panned, proofed for 75 minutes at 30°C. The relative humidity during the proofs was set at 85%.

Subsequently the stability of the proofed dough was judged by the presence of bladders, torn side crust and irregular curved surfaces of the crust. The dough pieces were baked for 20 minutes at 225°C. Loaf volumes were determined by the BVM-3 method: in the table the average is presented of 2 breads that are baked from the same object.

The crumb structure was judged by a qualified baker using the scale depicted in Table 5. After storing the loaves for three days in polyethylene bags at room temperature crumb firmness was measured using a Stevens Texture Analyser. Two slices of 2 cm thickness from the centre of each loaf were analysed by the texture analyser using a probe of 1.5 inch diameter, a compression depth of 5 mm (25%) and a rate of compression of 0.5 mm/sec. In the table the average is shown of two measurements.

Crust colour was judged by a qualified baker according to the scale depicted in Table 5. As a reference the standard recipe for Dutch tin bread was used.

Crumb colour was judged by a qualified baker according to the scale depicted in Table 5. The colour of the crumb of the control breads was judged as normal (3). As a positive control the breads of 2 objects are used with the same composition as the control plus 0.5% soya flour. The proofing and baking procedure are the same as that of the control without soya flour. The latter is judged as "excellent".

The overhanging top of the bread was judged by the hanging of the top in relation to the baking tin, the lower the edges of the top the lower the judgement. The less hanging, the better the judgement,

Staling of the bread was judged by feeling the firmness of the crumb of slices of the bread. Before slicing took place, the bread was stored in a plastic bag at room temperature for 4 days. The softer the crumb of the slices is, the better the judgement.

Table 6. Baking performance of the lipolytic enzymes of the invention

Lipolytic enzyme	Parameter								
	Volume (%)	Dough stickyness	Dough extensibility	Dough stability	Crumb structure	Crust colour	Crumb colour	Overhanging top	Staling
NBE028	100	3	3	4	2	3	3	3	4
NBE029	104	3	3	4	3	4	4	4	3
NBE030	107	3	2	4	4	4	4	3	3
NBE031	102	3	2	4	5	4	4	4	4
NBE032	98	3	3	4	2	3	3	3	3

NBE033	105	3	2	4	2	4	3	3	3
NBE034	104	3	3	4	4	4	4	4	3
NBE036	100	3	3	4	3	4	4	4	3
NBE038	109	3	3	4	5	4	4	3	3
NBE039	109	3	3	4	4	3	4	3	3
NBE043	106	3	3	4	3	4	4	3	3
NBE045	110	3	3	4	4	3	4	4	4
NBE042	110	3	4	4	4	3	4	3	3

EXAMPLE 5

Baking experiments 2 – batard

The baking performance of lipolytic enzymes according to the invention was tested in the French type of bread called "batard". Preparation of batards in a standard baking process was done by mixing 3000 g of wheat flour at circa 20°C, 70 g compressed yeast, 60 g salt, 68 ppm ascorbic acid, 30 ppm Bakezyme® HS_{2000} (fungal hemicellulase), 7 ppm Bakezyme® P500 (fungal α–amylase) and 1680 ml water (8–10°C) in a spiral mixer (Diosna: 2 minutes in speed 1; 100 Wh input in speed 2). The dough temperature was 27°C. The machineability of the dough was analysed by hand by a baker. The dough was given a bulk proof of 15 minutes in a proofing cabinet at 32°C and 90% RH. Afterwards the dough was divided into 6 pieces of 350 g, rounded and proofed for 15 minutes at 32°C and 90% RH. At the end of this period the dough pieces were moulded and shaped and given a final proof of 90 minutes at 32°C and 90% RH. The fully proofed doughs were cut in the length of the dough piece and baked in an oven at 240°C for 30 minutes with initial steam addition. After cooling down to room temperature the volumes of the loaves were determined by the BVM-method (see example 4).

Break, shred and shape of the breads were analysed directly after cooling down to room temperature by a qualified baker using the score in Table 7. After 16 hours (overnight) storage in a closed box at room temperature the crumb quality was assessed a qualified baker. The value for the breads (Table 8) was derived from 1 object.

Table 7

Effect		Score				
		1	2	3	4	5
Break and shred		extremely weak and soft	weak and soft	control bread	thin and crispy crust firm break of the cut	crust too thin, too hard
Crumb structure		poor	not uniform	control bread	good	excellent
shape	height	flat	medium	control bread	larger than (3)	Much larger than (3)
	cut	cut closed	cut closed	control bread	completely opened	completely opened; teared

Table 8. Baking performance of the lipolytic enzymes of the invention

lipolytic enzyme	parameter				
	Dosage*	Loaf volume (%)	Break & Shred	Shape	Crumb structure
None	0	100	3	3	3
NBE028	0.75	3	4	4	4
NBE030	3	103	4	4	3
NBE031	2.5	95	4	4	3
NBE036	ND	88	3	3	3
NBE038	30	100	4	4	3

10. A vector according to claim 9 wherein said polynucleotide sequence according to claims 1 to 8 is operatively linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.

11. A vector according to claim 10 wherein said suitable host cell is a filamentous fungus.

12. A method for manufacturing a polynucleotide according to claims 1 – 8 or a vector according to claims 9 to 11 comprising the steps of culturing a host cell transformed with said polynucleotide or said vector and isolating said polynucleotide or said vector from said host cell.

13. An isolated lipolytic enzyme selected from the group consisting of SEQ ID NO: 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and 39 or functional equivalents thereof.

14. An isolated lipolytic enzyme according to claim 13 obtainable from Aspergillus niger.

15. An isolated lipolytic enzyme obtainable by expressing a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11 in an appropriate host cell, e.g. *Aspergillus niger*.

16. Recombinant lipolytic enzyme comprising a functional domain of any of the lipolytic enzymes according to claims 13-15.

17. A method for manufacturing a lipolytic enzyme according to claims 13 to 16 comprising the steps of transforming a suitable host cell with an isolated polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11, culturing said cell under conditions allowing expression of said polynucleotide and optionally purifying the encoded polypeptide from said cell or culture medium.

18. A recombinant host cell comprising a polynucleotide according to claims 1 to 8 or a vector according to claims 9 to 11.

19. A recombinant host cell expressing a lipolytic enzyme according to claims 13 to 16.

20. Purified antibodies reactive with a lipolytic enzyme according to claims 13 to 16.

21. Fusion protein comprising a lipolytic enzyme sequence according to claims 13 to 16.

22. A process for the production of dough comprising adding a lipolytic enzyme according to anyone of claims 13-16.

23. A process for the production of a baked product from a dough as prepared by the process of claim 22.

24. Use of a lipolytic enzyme according to anyone of claims 13-16 for the preparation of a dough *and/or* the baked product thereof.

21078WO.ST25.txt

SEQUENCE LISTING

<110> DSM IP Assets B.V.

<120> NOVEL LIPASES AND USES THEREOF

<130> 21078WO

<160> 39

<170> PatentIn version 3.1

<210> 1
<211> 3728
<212> DNA
<213> Aspergillus niger

<400> 1
```
cgggcaatta cgatccgagc gcgctatcta cgtgcaccgg aagcttgctc cttgatttgt      60
tgtttcataa tacttatttg tgctctttag cccgactgca gtggtggctg catgttgggc     120
aggtatttaa ctttgggcga taccaactac gcgtgcactt tgaagcatag cacggcgcgc     180
cggggatgcg tgtcgtctta tgactataat tgatgtggcc gactgactgc ttggtgttag     240
ggatcttgtg tttatcttgg ttttctgtac ttagaagaga gtgccggtgg catggtggtc     300
gatataacta gagcaatgcg tgtctccatc ctcatcctca tcggccatcc cttataccct     360
gatggcgccg aagggtgaga atggcgatgg gcgagaataa tatactgtgt atagtctgtc     420
ctatcctcct tgtgcactgc aaagtcagtt gatcatcatc cccactcaat cgtccactca     480
tgctctatat ccgagacaaa ccacaactta ttcaatttaa gcccgagtcc ataatcatcc     540
acaaccaccc cacagccagg gtacatccag ggtctctttc ccgccggaga aactaagccc     600
ttagctcctc actaggacct cccgccgcgt cttggctcct catcaccaac tttccaccta     660
taaactgcat caaacatgct gcaaagccac gactgctgct gcatgcaccc caacatcatc     720
cccgcataat acatccatcc ctgaagcaat caagcttgac tctgttgttt cttcggagat     780
gttaaccatt cgtactttcc aaatgacatc aatccaactg atagacatcg ccatcctcct     840
caataccatg gacgccccac gtccatgtca aaagtaagac tagctcagct cggcgttaat     900
caattatgat tgcgagtctc aatccctgag tcatgtgttc tctgtgtcgg agaattagac     960
tgaattcagc tgctcgttgc cactcctagc tccctgataa aggtcctcac ttcgtctcgt    1020
agctggctgg ctgcatattc tccggtgact aagttaacag aaccagcaac ttagtagcca    1080
tggcgagcgc actcctctgg ctctccctgc tgggtggcag caccctagcc tcaactctag    1140
acaccagtaa taccccctacc atcaagagag cagacgcagg aaacaacacc tcctcaatcc    1200
caacagccac cctcaacaac accgtcttca tcggccgttc cctgcccgag ttcgagcagg    1260
agttgttcct gggtatcaag tttgctgatg agcccgtgcg attcaccccg tcgacgttga    1320
aaaccgtcta tcgcgccaat gacagcgaca acggggtgta tcatgcttcc acagcatccg    1380
gactgcagac ttcctcgggg accgtgctct acaacgccac agagtatggg tatgattgcc    1440
ccgggtatgg atccgatgag acggagctgg cggaggaagg atatgcgcgg ttcgatgaga    1500
```

actgtatgaa cctgaatata attcggccca agagagagaa agaggatgag ttgttgcctg 1560
tgatgatttg gatctttggt ggtggttggg tgcagggtgc gactgctgat ccgaggtagg 1620
atactatagt tttgtgctgt gctgtgtggg gttgatgctg acgatgtgca aggtacaata 1680
tgagctatat tgttcgccag ggtgcgttga atgataagcc tgtcttgggt gtctcgatca 1740
attaccgtgt ggctgcgttt ggattccttg actctgtcga ggttatggtg cgtttcttcc 1800
ttcaccgtca agtatatggg tttcagctga catgacatct gtaggaatcc ggcaacacga 1860
acctaggact tcgtgatcag cgcgtcgcca tgcattgggt caaacaaaac atcaaggcgt 1920
ttggtggtga cccggacaag atcaccatct ggggagaatc agcgtgagat tataccctaa 1980
tagcattcga tatacagcgc ctgacatggc acagtggtgc ctacagcgtc ggagcccacc 2040
tggtcaccaa cgacggtgac aacgagggtc tattcagagc cggtatgcac accactcccc 2100
aattctcgtc tcctcatctg ctaaccagca tagccatcat ggaatccggc aacgcagtcg 2160
gacccccccta caacggcacg gactggtacc agccgatgta cgaccagatc gtgaacgcaa 2220
ccaagtatgt cctcaccttc cccaaaagac aatactcaaa tgactagtat atatactaac 2280
tacatgaaag ctgcaccacc tcaagcaaca cccttcaatg cctccgcgaa gtccccttct 2340
caacgatcta caccgccgca gacatcggcc tggaatggtt cgccaccatc gacggcacct 2400
tcatcaaaga atatccccaa atcagcatta cggagggccg cttcgccaag gtccccatcc 2460
tccatggcac caacaccgac gagggcgtga gtttcggtac gacgggcgtg aacactgatg 2520
ccgaagcgat ccagcagttg atgggtgagc ccccccccccc ccccccttccc accaatcccc 2580
aagatatata tatagtacga gatactaagg tgaaatgaaa atgatagcat ccaaacgctg 2640
ggtcctaaac gaaacccaag ccacgaccct cctatcgcac tatcccaaca tctccgccct 2700
aggctgtccc tacggatggg gcaacacgac ctggccgaag ctggggtatg aatataagcg 2760
ctacgagtcg atggcgggcg atctgtgcat ggttgctccg aggaggttgc tcagtcagaa 2820
gatgaaggag tatgaggagc aagtgtttgc gtatcggtgg gatgtcgctg cgttgaatga 2880
ttcgagtacg attggggtgg cgcattttgc tgaggtaatg ccatccatcc atcccctatt 2940
attggtttc cctgcggtat gatatttggt atgctaatga tgtgttactg cgtgcatgca 3000
tagatcccgt ttgttttcgc caaccctgtg cagaacatca ctccgttggg aagtgatccc 3060
gcaagactgg agttgggtaa tctggccgcg aggatgtgga cggctttgt gacggatttg 3120
gatccgaatg ggcatggtgg tacgttcctc ttctccatct tattagaatt gtgaaatgaa 3180
gcgtgtggtt ctaatgaggg tgacagtctc tggtatcccc cactggccga aatacaacct 3240
cactgatccg agggactttg tgttccggct accgagggat ggaagttatg tggagaagga 3300
tacttttagg acgggggga ttgattatat taatacaatt gtgcggtaag ttgctgctaa 3360
gtagtactac tatatgtata taggagggtg tgggtgaaaa gtagatagta gtactatatc 3420
aaggatggtt agatactata tactatttac tactactgta atgttactat aatcaagact 3480
agaagaaagt ctactgattg attacttcga ctgatcgatt gtattgatct agttagtata 3540
tcaaatcgac aaagagccgc cgtttttatt cattcatatt tcccgccact aagccagtat 3600
actataccat agtagtatag ctggtttagt tgatgccgag cagctcaacc tcgctaattg 3660
atatcagcat tccaatccat tttttcactg gcaaagaata ttagaagagg aaggaggagg 3720
aggataac 3728

<210> 2
<211> 1749
<212> DNA
<213> Aspergillus niger

21078WO.ST25.txt

<220>
<221> CDS
<222> (1)..(1749)

<400> 2
atg gcg agc gca ctc ctc tgg ctc tcc ctg ctg ggt ggc agc acc cta 48
Met Ala Ser Ala Leu Leu Trp Leu Ser Leu Leu Gly Gly Ser Thr Leu
1 5 10 15
gcc tca act cta gac acc agt aat acc cct acc atc aag aga gca gac 96
Ala Ser Thr Leu Asp Thr Ser Asn Thr Pro Thr Ile Lys Arg Ala Asp
20 25 30
gca gga aac aac acc tcc tca atc cca aca gcc acc ctc aac aac acc 144
Ala Gly Asn Asn Thr Ser Ser Ile Pro Thr Ala Thr Leu Asn Asn Thr
35 40 45
gtc ttc atc ggc cgt tcc ctg ccc gag ttc gag cag gag ttg ttc ctg 192
Val Phe Ile Gly Arg Ser Leu Pro Glu Phe Glu Gln Glu Leu Phe Leu
50 55 60
ggt atc aag ttt gct gat gag ccc gtg cga ttc acc ccg tcg acg ttg 240
Gly Ile Lys Phe Ala Asp Glu Pro Val Arg Phe Thr Pro Ser Thr Leu
65 70 75 80
aaa acc gtc tat cgc gcc aat gac agc gac aac ggg gtg tat cat gct 288
Lys Thr Val Tyr Arg Ala Asn Asp Ser Asp Asn Gly Val Tyr His Ala
85 90 95
tcc aca gca tcc gga ctg cag act tcc tcg ggg acc gtg ctc tac aac 336
Ser Thr Ala Ser Gly Leu Gln Thr Ser Ser Gly Thr Val Leu Tyr Asn
100 105 110
gcc aca gag tat ggg tat gat tgc ccc ggg tat gga tcc gat gag acg 384
Ala Thr Glu Tyr Gly Tyr Asp Cys Pro Gly Tyr Gly Ser Asp Glu Thr
115 120 125
gag ctg gcg gag gaa gga tat gcg cgg ttc gat gag aac tgt atg aac 432
Glu Leu Ala Glu Glu Gly Tyr Ala Arg Phe Asp Glu Asn Cys Met Asn
130 135 140
ctg aat ata att cgg ccc aag aga gag aaa gag gat gag ttg ttg cct 480
Leu Asn Ile Ile Arg Pro Lys Arg Glu Lys Glu Asp Glu Leu Leu Pro
145 150 155 160
gtg atg att tgg atc ttt ggt ggt ggt tgg gtg cag ggt gcg act gct 528
Val Met Ile Trp Ile Phe Gly Gly Gly Trp Val Gln Gly Ala Thr Ala
165 170 175
gat ccg agg tac aat atg agc tat att gtt cgc cag ggt gcg ttg aat 576
Asp Pro Arg Tyr Asn Met Ser Tyr Ile Val Arg Gln Gly Ala Leu Asn
180 185 190
gat aag cct gtc ttg ggt gtc tcg atc aat tac cgt gtg gct gcg ttt 624
Asp Lys Pro Val Leu Gly Val Ser Ile Asn Tyr Arg Val Ala Ala Phe

```
        195                 200                 205
gga ttc ctt gac tct gtc gag gtt atg gaa tcc ggc aac acg aac cta        672
Gly Phe Leu Asp Ser Val Glu Val Met Glu Ser Gly Asn Thr Asn Leu
    210                 215                 220
gga ctt cgt gat cag cgc gtc gcc atg cat tgg gtc aaa caa aac atc        720
Gly Leu Arg Asp Gln Arg Val Ala Met His Trp Val Lys Gln Asn Ile
225                 230                 235                 240
aag gcg ttt ggt ggt gac ccg gac aag atc acc atc tgg gga gaa tca        768
Lys Ala Phe Gly Gly Asp Pro Asp Lys Ile Thr Ile Trp Gly Glu Ser
                245                 250                 255
gct ggt gcc tac agc gtc gga gcc cac ctg gtc acc aac gac ggt gac        816
Ala Gly Ala Tyr Ser Val Gly Ala His Leu Val Thr Asn Asp Gly Asp
            260                 265                 270
aac gag ggt cta ttc aga gcc gcc atc atg gaa tcc ggc aac gca gtc        864
Asn Glu Gly Leu Phe Arg Ala Ala Ile Met Glu Ser Gly Asn Ala Val
        275                 280                 285
gga ccc ccc tac aac ggc acg gac tgg tac cag ccg atg tac gac cag        912
Gly Pro Pro Tyr Asn Gly Thr Asp Trp Tyr Gln Pro Met Tyr Asp Gln
    290                 295                 300
atc gtg aac gca acc aac tgc acc acc tca agc aac acc ctt caa tgc        960
Ile Val Asn Ala Thr Asn Cys Thr Thr Ser Ser Asn Thr Leu Gln Cys
305                 310                 315                 320
ctc cgc gaa gtc ccc ttc tca acg atc tac acc gcc gca gac atc ggc        1008
Leu Arg Glu Val Pro Phe Ser Thr Ile Tyr Thr Ala Ala Asp Ile Gly
                325                 330                 335
ctg gaa tgg ttc gcc acc atc gac ggc acc ttc atc aaa gaa tat ccc        1056
Leu Glu Trp Phe Ala Thr Ile Asp Gly Thr Phe Ile Lys Glu Tyr Pro
            340                 345                 350
caa atc agc att acg gag ggc cgc ttc gcc aag gtc ccc atc ctc cat        1104
Gln Ile Ser Ile Thr Glu Gly Arg Phe Ala Lys Val Pro Ile Leu His
        355                 360                 365
ggc acc aac acc gac gag ggc gtg agt ttc ggt acg acg ggc gtg aac        1152
Gly Thr Asn Thr Asp Glu Gly Val Ser Phe Gly Thr Thr Gly Val Asn
    370                 375                 380
act gat gcc gaa gcg atc cag cag ttg atg gca tcc aaa cgc tgg gtc        1200
Thr Asp Ala Glu Ala Ile Gln Gln Leu Met Ala Ser Lys Arg Trp Val
385                 390                 395                 400
cta aac gaa acc caa gcc acg acc ctc cta tcg cac tat ccc aac atc        1248
Leu Asn Glu Thr Gln Ala Thr Thr Leu Leu Ser His Tyr Pro Asn Ile
                405                 410                 415
tcc gcc cta ggc tgt ccc tac gga tgg ggc aac acg acc tgg ccg aag        1296
Ser Ala Leu Gly Cys Pro Tyr Gly Trp Gly Asn Thr Thr Trp Pro Lys
            420                 425                 430
ctg ggg tat gaa tat aag cgc tac gag tcg atg gcg ggc gat ctg tgc        1344
```

21078WO.ST25.txt

```
Leu Gly Tyr Glu Tyr Lys Arg Tyr Glu Ser Met Ala Gly Asp Leu Cys
        435                 440                 445

atg gtt gct ccg agg agg ttg ctc agt cag aag atg aag gag tat gag      1392
Met Val Ala Pro Arg Arg Leu Leu Ser Gln Lys Met Lys Glu Tyr Glu
    450                 455                 460

gag caa gtg ttt gcg tat cgg tgg gat gtc gct gcg ttg aat gat tcg      1440
Glu Gln Val Phe Ala Tyr Arg Trp Asp Val Ala Ala Leu Asn Asp Ser
465                 470                 475                 480

agt acg att ggg gtg gcg cat ttt gct gag atc ccg ttt gtt ttc gcc      1488
Ser Thr Ile Gly Val Ala His Phe Ala Glu Ile Pro Phe Val Phe Ala
                485                 490                 495

aac cct gtg cag aac atc act ccg ttg gga agt gat ccc gca aga ctg      1536
Asn Pro Val Gln Asn Ile Thr Pro Leu Gly Ser Asp Pro Ala Arg Leu
            500                 505                 510

gag ttg ggt aat ctg gcc gcg agg atg tgg acg gct ttt gtg acg gat      1584
Glu Leu Gly Asn Leu Ala Ala Arg Met Trp Thr Ala Phe Val Thr Asp
        515                 520                 525

ttg gat ccg aat ggg cat ggt gtc tct ggt atc ccc cac tgg ccg aaa      1632
Leu Asp Pro Asn Gly His Gly Val Ser Gly Ile Pro His Trp Pro Lys
    530                 535                 540

tac aac ctc act gat ccg agg gac ttt gtg ttc cgg cta ccg agg gat      1680
Tyr Asn Leu Thr Asp Pro Arg Asp Phe Val Phe Arg Leu Pro Arg Asp
545                 550                 555                 560

gga agt tat gtg gag aag gat act ttt agg acg ggg ggg att gat tat      1728
Gly Ser Tyr Val Glu Lys Asp Thr Phe Arg Thr Gly Gly Ile Asp Tyr
                565                 570                 575

att aat aca att gtg cgg taa                                          1749
Ile Asn Thr Ile Val Arg
            580


&lt;210&gt; 3
&lt;211&gt; 582
&lt;212&gt; PRT
&lt;213&gt; Aspergillus niger

&lt;400&gt; 3
Met Ala Ser Ala Leu Leu Trp Leu Ser Leu Leu Gly Gly Ser Thr Leu
1               5                   10                  15
Ala Ser Thr Leu Asp Thr Ser Asn Thr Pro Thr Ile Lys Arg Ala Asp
            20                  25                  30
Ala Gly Asn Asn Thr Ser Ser Ile Pro Thr Ala Thr Leu Asn Asn Thr
        35                  40                  45
Val Phe Ile Gly Arg Ser Leu Pro Glu Phe Glu Gln Glu Leu Phe Leu
```

21078WO.ST25.txt

```
        50                  55                  60
Gly Ile Lys Phe Ala Asp Glu Pro Val Arg Phe Thr Pro Ser Thr Leu
65                  70                  75                  80
Lys Thr Val Tyr Arg Ala Asn Asp Ser Asp Asn Gly Val Tyr His Ala
                85                  90                  95
Ser Thr Ala Ser Gly Leu Gln Thr Ser Ser Gly Thr Val Leu Tyr Asn
            100                 105                 110
Ala Thr Glu Tyr Gly Tyr Asp Cys Pro Gly Tyr Gly Ser Asp Glu Thr
        115                 120                 125
Glu Leu Ala Glu Glu Gly Tyr Ala Arg Phe Asp Glu Asn Cys Met Asn
    130                 135                 140
Leu Asn Ile Ile Arg Pro Lys Arg Glu Lys Glu Asp Glu Leu Leu Pro
145                 150                 155                 160
Val Met Ile Trp Ile Phe Gly Gly Gly Trp Val Gln Gly Ala Thr Ala
                165                 170                 175
Asp Pro Arg Tyr Asn Met Ser Tyr Ile Val Arg Gln Gly Ala Leu Asn
            180                 185                 190
Asp Lys Pro Val Leu Gly Val Ser Ile Asn Tyr Arg Val Ala Ala Phe
        195                 200                 205
Gly Phe Leu Asp Ser Val Glu Val Met Glu Ser Gly Asn Thr Asn Leu
    210                 215                 220
Gly Leu Arg Asp Gln Arg Val Ala Met His Trp Val Lys Gln Asn Ile
225                 230                 235                 240
Lys Ala Phe Gly Gly Asp Pro Asp Lys Ile Thr Ile Trp Gly Glu Ser
                245                 250                 255
Ala Gly Ala Tyr Ser Val Gly Ala His Leu Val Thr Asn Asp Gly Asp
            260                 265                 270
Asn Glu Gly Leu Phe Arg Ala Ala Ile Met Glu Ser Gly Asn Ala Val
        275                 280                 285
Gly Pro Pro Tyr Asn Gly Thr Asp Trp Tyr Gln Pro Met Tyr Asp Gln
    290                 295                 300
Ile Val Asn Ala Thr Asn Cys Thr Thr Ser Ser Asn Thr Leu Gln Cys
305                 310                 315                 320
Leu Arg Glu Val Pro Phe Ser Thr Ile Tyr Thr Ala Ala Asp Ile Gly
                325                 330                 335
Leu Glu Trp Phe Ala Thr Ile Asp Gly Thr Phe Ile Lys Glu Tyr Pro
            340                 345                 350
Gln Ile Ser Ile Thr Glu Gly Arg Phe Ala Lys Val Pro Ile Leu His
        355                 360                 365
Gly Thr Asn Thr Asp Glu Gly Val Ser Phe Gly Thr Thr Gly Val Asn
    370                 375                 380
Thr Asp Ala Glu Ala Ile Gln Gln Leu Met Ala Ser Lys Arg Trp Val
385                 390                 395                 400
Leu Asn Glu Thr Gln Ala Thr Thr Leu Leu Ser His Tyr Pro Asn Ile
```

```
                405                 410                 415
Ser Ala Leu Gly Cys Pro Tyr Gly Trp Gly Asn Thr Thr Trp Pro Lys
            420                 425                 430
Leu Gly Tyr Glu Tyr Lys Arg Tyr Glu Ser Met Ala Gly Asp Leu Cys
        435                 440                 445
Met Val Ala Pro Arg Arg Leu Leu Ser Gln Lys Met Lys Glu Tyr Glu
    450                 455                 460
Glu Gln Val Phe Ala Tyr Arg Trp Asp Val Ala Ala Leu Asn Asp Ser
465                 470                 475                 480
Ser Thr Ile Gly Val Ala His Phe Ala Glu Ile Pro Phe Val Phe Ala
                485                 490                 495
Asn Pro Val Gln Asn Ile Thr Pro Leu Gly Ser Asp Pro Ala Arg Leu
            500                 505                 510
Glu Leu Gly Asn Leu Ala Ala Arg Met Trp Thr Ala Phe Val Thr Asp
        515                 520                 525
Leu Asp Pro Asn Gly His Gly Val Ser Gly Ile Pro His Trp Pro Lys
    530                 535                 540
Tyr Asn Leu Thr Asp Pro Arg Asp Phe Val Phe Arg Leu Pro Arg Asp
545                 550                 555                 560
Gly Ser Tyr Val Glu Lys Asp Thr Phe Arg Thr Gly Gly Ile Asp Tyr
                565                 570                 575
Ile Asn Thr Ile Val Arg
            580


<210> 4
<211> 3853
<212> DNA
<213> Aspergillus niger

<400> 4
ctttcctgtt gcccggtctt tgttgttgtc ataggataca attacccaga caacgttcgg      60
tttgtcgatc agttttaagt gtgcgtggac tgacagccaa ggccactggg gcccctgcct     120
ctatcattta attccacacg ctcgcctctg cagctctggc accagcgttg caaattccag     180
gggtcagcct acgtggcatt aggctctaag agaatctgag ggaaaggatt tcacttagaa     240
aaatttatcg gtccggcttg tccgatcggt aggaaggcat tgcttcccct catatgcggc     300
cccggttccc aagcagctga ttcgggacgt tttccggctt gatcgctata ctctcataat     360
ctctcctgca agagctggat aaacttggtt tcttatcttc cgtggggatg ccatagtcca     420
gtagacgctg tctcgaaatt gagtagcacc actatttacg ggcaagttaa tggcacatgt     480
attagctttg tactgacggt tgaaatgtgg agcaatttcc ggctatgtac cggatctgtt     540
ccggatatct tcatcgcaat tagttagtac ataaaactcc ctagtcacgc aagaacggtt     600
cgaacataac gaattaaaaa ttctcattct ctggcaaggc ttcgaaatgt ttgtttcctc     660
gcttgctcta ttagcactta ttgctccttt gatcgcaatt gcggtaaaaa tagaacagcc     720
aggaataaat ccaaatccca cagctactgt acgaaatggc acctactatg gtctccataa     780
```

21078WO.ST25.txt

ccagcactat aatcaagacc tctttctcgg tattccatat gcacagcaac ctattggtga 840
ccttcgcttg cggaccccac gatcaatgaa cacctcctgg ccagtaccaa gaaatgcaac 900
agaatattca cccgcatgtg ttggatttaa tcagacagag ggtgcttccg aagcctgcct 960
tactctcaat gtcgtccgcc cggcaagcat cgctctttct gaaagtcttc ccgttgctgg 1020
tcagtatata ccccaaatct gatcagaagg gccagaactg actttgcgct cggccccagt 1080
ctggattcat ggcgggggat tcacctccgg ctcttcatca gagaaacaat acaatctgtc 1140
cttcatcgtt gatcagtcag tccaaatgga aaagcccgtt atcgcagtca gtctaaatta 1200
tcgtcttcaa tgctggggtt ttatgtggag caaggagatg aaggaagccg gagtagggaa 1260
cctgggactt agagaccaac gattagctct gcattggata caagaaagta ggtatctcga 1320
tagtgaagct cttccaagta cggatctgac catgacttag acattgctgc gtttggtgga 1380
gaccctgctc aggttacaat ttggggtgaa agtgccggcg ctaatagtgt tggcacacat 1440
ctggttgctt acggagggcg cgatgatggt atattccgtg cagctatcag tgaaagtggt 1500
gccccaagtg tttaccaacg ttatccaaca cctgctgaat ggcagcccta ttatgatggt 1560
attgtgaatg catcaggctg cagttcagca acggatactt tggcttgtct ccgaacaatt 1620
ccaactaaca tattgcatgg catctttgac aacacgtcta ttgtacccat gcacgctatt 1680
tcaggcctca gcggagcaaa attcattcct gtcatagatg acgacttcat taaagagagt 1740
gccacggttc agctccagaa gggcaacttc gtcaaagttc cctacttgat tggagctaac 1800
gccgacgaag ggactgcatt tgctgtggag ggagtcaaca cagatgctga gtttcgcgag 1860
ctagtcaaag gttggggcct caacaacgct accacggata tcttggaggc cctataccca 1920
gacattcctc agataggaat ccccgccata atggttggaa ggccaccgtc cggatatgga 1980
aatcaataca agcgtgtggc cgcatttcag ggtgatgtta acatccatgc cgcacgtagg 2040
ttgaccagtc agatctggtc atcccgcaat atctcagtat atagctacat gtttgacgtt 2100
atcagccctg gatatggccc ctctgctggt tcctatgctg gggctactca tggtactgat 2160
attccgtacg ttttctataa tctggatggc ctggggtatg actcgaacaa caagtccata 2220
gaaagcatac ctaacagtta ttcccgcatg agcaaaatta tgtcaagaat gtgggtcagt 2280
tttgtgacaa cattggaccc aaatcattct ggaggtatgg tcccacatcc cattcctatg 2340
attgcgcaat gtcagacccg agctgaatca actatcttct taggaactaa tgttcagtgg 2400
ccgccataca atatcgataa tccggagata atcttttcg ataccgatgt cacgaacctc 2460
acatatgtga gttctgacgt ttaccgtgcg gagggcataa aatacatcag tgatcacctt 2520
gcaagtgatt tcgggcactg agatcacata tcttctcggt ctaattttag aatgactgtg 2580
gtctcatcta accagacttg gcccgcaggt ctttacgccc actggtggta attgatgcaa 2640
cccccaagct atatagtgtc tggggctttg aactactgtc aatgagcgaa aattgactat 2700
ttccctttat gactcatgta gtagcatttg tgctggcact gtgatcaaga tatgtttttc 2760
gagattaccg gtagcagagt agtcgatgtc gccaatatta ttcatctata atgaatagta 2820
ataacttagg agtcattcag tatagtcgat actgacataa gtatcttttc ttgtgatatt 2880
tataatatgt cccgtttggc cttgtttgta gtaactctca tagcctgctg cttgagaact 2940
catctgttca atcatagaga taccaattat ggaaggatag gttggcatcg gtgtttgttt 3000
catcaagact actacctaat aagtcactga agaaggctgt agactgaaag cgcgacattg 3060
atgattagaa ttccaacttt ggtcaacata tgcattagac tataaaaggg acatgttaga 3120
agaactaagt acatacgacc atagggtgtg gaaaacaggg cttcccgtcc gctcagccgt 3180
acttaagcca cacgccggga ggttagtagt tgggtgggtg accaccagcg aatcccttct 3240
gttgtatgtt tttgtttctc tataaaactt ttggtcgggc atctcgagat gtcttccagg 3300
atgctaaaac cttcgggttc ctcacagcgg agatggtgtc aactggcttt tttaatgcat 3360
tcttggctaa agtgctcgtg aacacggcaa tatagtacga tgatatctga agtttgtggt 3420

```
gtcaagacat atgcttattg tgaccaccag accataaatc ggagtattca cagcttatat     3480
catcctcaaa cattgattgc atagtagagt gtctaactct tgactcaagg gattgaaaat     3540
gattatttga aaatataggt agttttgaat aacattctgg cacacgagct ttagctggat     3600
tagtaagatg tgacgccgat tttgggtttg attatgtcat catttggcag ttcccccaga     3660
ggacagcccg gttaagaacg aacctttttct gagcccgtat acaaatgcgg ggaacagaga     3720
tgaggagatg ccgaagcatg ctttggcaaa cagaagccac tgtgaaaaac cattcacaga     3780
tatcttgtga tagttggatt gcactgactg tccgcgaaag cgagcatatc tatcccgtat     3840
actgagaact agt                                                       3853


<210> 5
<211> 1743
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1743)

<400> 5
atg ttt gtt tcc tcg ctt gct cta tta gca ctt att gct cct ttg atc       48
Met Phe Val Ser Ser Leu Ala Leu Leu Ala Leu Ile Ala Pro Leu Ile
1               5                  10                  15
gca att gcg gta aaa ata gaa cag cca gga ata aat cca aat ccc aca       96
Ala Ile Ala Val Lys Ile Glu Gln Pro Gly Ile Asn Pro Asn Pro Thr
            20                  25                  30
gct act gta cga aat ggc acc tac tat ggt ctc cat aac cag cac tat      144
Ala Thr Val Arg Asn Gly Thr Tyr Tyr Gly Leu His Asn Gln His Tyr
        35                  40                  45
aat caa gac ctc ttt ctc ggt att cca tat gca cag caa cct att ggt      192
Asn Gln Asp Leu Phe Leu Gly Ile Pro Tyr Ala Gln Gln Pro Ile Gly
    50                  55                  60
gac ctt cgc ttg cgg acc cca cga tca atg aac acc tcc tgg cca gta      240
Asp Leu Arg Leu Arg Thr Pro Arg Ser Met Asn Thr Ser Trp Pro Val
65                  70                  75                  80
cca aga aat gca aca gaa tat tca ccc gca tgt gtt gga ttt aat cag      288
Pro Arg Asn Ala Thr Glu Tyr Ser Pro Ala Cys Val Gly Phe Asn Gln
                85                  90                  95
aca gag ggt gct tcc gaa gcc tgc ctt act ctc aat gtc gtc cgc ccg      336
Thr Glu Gly Ala Ser Glu Ala Cys Leu Thr Leu Asn Val Val Arg Pro
            100                 105                 110
gca agc atc gct ctt tct gaa agt ctt ccc gtt gct gtc tgg att cat      384
Ala Ser Ile Ala Leu Ser Glu Ser Leu Pro Val Ala Val Trp Ile His
        115                 120                 125
```

```
ggc ggg gga ttc acc tcc ggc tct tca tca gag aaa caa tac aat ctg      432
Gly Gly Gly Phe Thr Ser Gly Ser Ser Ser Glu Lys Gln Tyr Asn Leu
    130                 135                 140
tcc ttc atc gtt gat cag tca gtc caa atg gaa aag ccc gtt atc gca      480
Ser Phe Ile Val Asp Gln Ser Val Gln Met Glu Lys Pro Val Ile Ala
145                 150                 155                 160
gtc agt cta aat tat cgt ctt caa tgc tgg ggt ttt atg tgg agc aag      528
Val Ser Leu Asn Tyr Arg Leu Gln Cys Trp Gly Phe Met Trp Ser Lys
                165                 170                 175
gag atg aag gaa gcc gga gta ggg aac ctg gga ctt aga gac caa cga      576
Glu Met Lys Glu Ala Gly Val Gly Asn Leu Gly Leu Arg Asp Gln Arg
            180                 185                 190
tta gct ctg cat tgg ata caa gaa aac att gct gcg ttt ggt gga gac      624
Leu Ala Leu His Trp Ile Gln Glu Asn Ile Ala Ala Phe Gly Gly Asp
        195                 200                 205
cct gct cag gtt aca att tgg ggt gaa agt gcc ggc gct aat agt gtt      672
Pro Ala Gln Val Thr Ile Trp Gly Glu Ser Ala Gly Ala Asn Ser Val
    210                 215                 220
ggc aca cat ctg gtt gct tac gga ggg cgc gat gat ggt ata ttc cgt      720
Gly Thr His Leu Val Ala Tyr Gly Gly Arg Asp Asp Gly Ile Phe Arg
225                 230                 235                 240
gca gct atc agt gaa agt ggt gcc cca agt gtt tac caa cgt tat cca      768
Ala Ala Ile Ser Glu Ser Gly Ala Pro Ser Val Tyr Gln Arg Tyr Pro
                245                 250                 255
aca cct gct gaa tgg cag ccc tat tat gat ggt att gtg aat gca tca      816
Thr Pro Ala Glu Trp Gln Pro Tyr Tyr Asp Gly Ile Val Asn Ala Ser
            260                 265                 270
ggc tgc agt tca gca acg gat act ttg gct tgt ctc cga aca att cca      864
Gly Cys Ser Ser Ala Thr Asp Thr Leu Ala Cys Leu Arg Thr Ile Pro
        275                 280                 285
act aac ata ttg cat ggc atc ttt gac aac acg tct att gta ccc atg      912
Thr Asn Ile Leu His Gly Ile Phe Asp Asn Thr Ser Ile Val Pro Met
    290                 295                 300
cac gct att tca ggc ctc agc gga gca aaa ttc att cct gtc ata gat      960
His Ala Ile Ser Gly Leu Ser Gly Ala Lys Phe Ile Pro Val Ile Asp
305                 310                 315                 320
gac gac ttc att aaa gag agt gcc acg gtt cag ctc cag aag ggc aac     1008
Asp Asp Phe Ile Lys Glu Ser Ala Thr Val Gln Leu Gln Lys Gly Asn
                325                 330                 335
ttc gtc aaa gtt ccc tac ttg att gga gct aac gcc gac gaa ggg act     1056
Phe Val Lys Val Pro Tyr Leu Ile Gly Ala Asn Ala Asp Glu Gly Thr
            340                 345                 350
gca ttt gct gtg gag gga gtc aac aca gat gct gag ttt cgc gag cta     1104
Ala Phe Ala Val Glu Gly Val Asn Thr Asp Ala Glu Phe Arg Glu Leu
```

```
        355                 360                 365
gtc aaa ggt tgg ggc ctc aac aac gct acc acg gat atc ttg gag gcc      1152
Val Lys Gly Trp Gly Leu Asn Asn Ala Thr Thr Asp Ile Leu Glu Ala
    370                 375                 380
cta tac cca gac att cct cag ata gga atc ccc gcc ata atg gtt gga      1200
Leu Tyr Pro Asp Ile Pro Gln Ile Gly Ile Pro Ala Ile Met Val Gly
385                 390                 395                 400
agg cca ccg tcc gga tat gga aat caa tac aag cgt gtg gcc gca ttt      1248
Arg Pro Pro Ser Gly Tyr Gly Asn Gln Tyr Lys Arg Val Ala Ala Phe
                405                 410                 415
cag ggt gat gtt aac atc cat gcc gca cgt agg ttg acc agt cag atc      1296
Gln Gly Asp Val Asn Ile His Ala Ala Arg Arg Leu Thr Ser Gln Ile
            420                 425                 430
tgg tca tcc cgc aat atc tca gta tat agc tac atg ttt gac gtt atc      1344
Trp Ser Ser Arg Asn Ile Ser Val Tyr Ser Tyr Met Phe Asp Val Ile
        435                 440                 445
agc cct gga tat ggc ccc tct gct ggt tcc tat gct ggg gct act cat      1392
Ser Pro Gly Tyr Gly Pro Ser Ala Gly Ser Tyr Ala Gly Ala Thr His
    450                 455                 460
ggt act gat att ccg tac gtt ttc tat aat ctg gat ggc ctg ggg tat      1440
Gly Thr Asp Ile Pro Tyr Val Phe Tyr Asn Leu Asp Gly Leu Gly Tyr
465                 470                 475                 480
gac tcg aac aac aag tcc ata gaa agc ata cct aac agt tat tcc cgc      1488
Asp Ser Asn Asn Lys Ser Ile Glu Ser Ile Pro Asn Ser Tyr Ser Arg
                485                 490                 495
atg agc aaa att atg tca aga atg tgg gtc agt ttt gtg aca aca ttg      1536
Met Ser Lys Ile Met Ser Arg Met Trp Val Ser Phe Val Thr Thr Leu
            500                 505                 510
gac cca aat cat tct gga ggt atg gtc cca cat ccc att cct atg att      1584
Asp Pro Asn His Ser Gly Gly Met Val Pro His Pro Ile Pro Met Ile
        515                 520                 525
gcg caa tgt cag acc cga gct gaa tca act atc ttc tta gga act aat      1632
Ala Gln Cys Gln Thr Arg Ala Glu Ser Thr Ile Phe Leu Gly Thr Asn
    530                 535                 540
gtt cag tgg ccg cca tac aat atc gat aat ccg gag ata atc ttt ttc      1680
Val Gln Trp Pro Pro Tyr Asn Ile Asp Asn Pro Glu Ile Ile Phe Phe
545                 550                 555                 560
gat acc gat gtc acg aac ctc aca tat act tgg ccc gca ggt ctt tac      1728
Asp Thr Asp Val Thr Asn Leu Thr Tyr Thr Trp Pro Ala Gly Leu Tyr
                565                 570                 575
gcc cac tgg tgg taa                                                 1743
Ala His Trp Trp
            580
```

<210> 6
<211> 580
<212> PRT
<213> Aspergillus niger

<400> 6
Met Phe Val Ser Ser Leu Ala Leu Leu Ala Leu Ile Ala Pro Leu Ile
1 5 10 15
Ala Ile Ala Val Lys Ile Glu Gln Pro Gly Ile Asn Pro Asn Pro Thr
20 25 30
Ala Thr Val Arg Asn Gly Thr Tyr Tyr Gly Leu His Asn Gln His Tyr
35 40 45
Asn Gln Asp Leu Phe Leu Gly Ile Pro Tyr Ala Gln Gln Pro Ile Gly
50 55 60
Asp Leu Arg Leu Arg Thr Pro Arg Ser Met Asn Thr Ser Trp Pro Val
65 70 75 80
Pro Arg Asn Ala Thr Glu Tyr Ser Pro Ala Cys Val Gly Phe Asn Gln
85 90 95
Thr Glu Gly Ala Ser Glu Ala Cys Leu Thr Leu Asn Val Val Arg Pro
100 105 110
Ala Ser Ile Ala Leu Ser Glu Ser Leu Pro Val Ala Val Trp Ile His
115 120 125
Gly Gly Gly Phe Thr Ser Gly Ser Ser Ser Glu Lys Gln Tyr Asn Leu
130 135 140
Ser Phe Ile Val Asp Gln Ser Val Gln Met Glu Lys Pro Val Ile Ala
145 150 155 160
Val Ser Leu Asn Tyr Arg Leu Gln Cys Trp Gly Phe Met Trp Ser Lys
165 170 175
Glu Met Lys Glu Ala Gly Val Gly Asn Leu Gly Leu Arg Asp Gln Arg
180 185 190
Leu Ala Leu His Trp Ile Gln Glu Asn Ile Ala Ala Phe Gly Gly Asp
195 200 205
Pro Ala Gln Val Thr Ile Trp Gly Glu Ser Ala Gly Ala Asn Ser Val
210 215 220
Gly Thr His Leu Val Ala Tyr Gly Gly Arg Asp Asp Gly Ile Phe Arg
225 230 235 240
Ala Ala Ile Ser Glu Ser Gly Ala Pro Ser Val Tyr Gln Arg Tyr Pro
245 250 255
Thr Pro Ala Glu Trp Gln Pro Tyr Tyr Asp Gly Ile Val Asn Ala Ser
260 265 270
Gly Cys Ser Ser Ala Thr Asp Thr Leu Ala Cys Leu Arg Thr Ile Pro
275 280 285
Thr Asn Ile Leu His Gly Ile Phe Asp Asn Thr Ser Ile Val Pro Met

gcgggatgtt tcaattcatc tatcccattc agaatctggg ggtagcctat acacaccatc 2640
atcagagtag tatatacatc atatccacaa atccatctcc acctatatac ataaacccca 2700
actgaatcta caacagcgcc tggtccttct tcccctcccc ctctttaatt tccctcgcct 2760
tctccccat 2769

<210> 8
<211> 1623
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1623)

<400> 8
atg gtg cag ggt gtg gct ttt gga ctg ctc ggg ctg gct gcc tct gct 48
Met Val Gln Gly Val Ala Phe Gly Leu Leu Gly Leu Ala Ala Ser Ala
1 5 10 15
ttg ggc act tat gcg ccc tac tac gcg aat ttg aca tgg gag caa cca 96
Leu Gly Thr Tyr Ala Pro Tyr Tyr Ala Asn Leu Thr Trp Glu Gln Pro
20 25 30
cgg act ctg tcc aac tgg tcc aac ctt acc gtc gag aca cgg aca ggg 144
Arg Thr Leu Ser Asn Trp Ser Asn Leu Thr Val Glu Thr Arg Thr Gly
35 40 45
acg ttc att ggt atg ctc aat gac act tac cca gac gtt cga cag ttt 192
Thr Phe Ile Gly Met Leu Asn Asp Thr Tyr Pro Asp Val Arg Gln Phe
50 55 60
ctg cga gtt cct tat gcc aag cct cct att ggg gat tta aga tgg ctt 240
Leu Arg Val Pro Tyr Ala Lys Pro Pro Ile Gly Asp Leu Arg Trp Leu
65 70 75 80
cct cct cat cgg ctt gac aac tca agc aga aca tat gac tcc acc ttc 288
Pro Pro His Arg Leu Asp Asn Ser Ser Arg Thr Tyr Asp Ser Thr Phe
85 90 95
tat ggc cca gcc tgt ccg cag tat gtt cca gca gag agc gat ttt tgg 336
Tyr Gly Pro Ala Cys Pro Gln Tyr Val Pro Ala Glu Ser Asp Phe Trp
100 105 110
aat gaa tat gaa ccg gag aat ttg ctg ctc aat gtc ggc gaa agg ctc 384
Asn Glu Tyr Glu Pro Glu Asn Leu Leu Leu Asn Val Gly Glu Arg Leu
115 120 125
aac cag ggc tct acg gca tgg tcc tcg tca gag gat tgc ctg tcc cta 432
Asn Gln Gly Ser Thr Ala Trp Ser Ser Ser Glu Asp Cys Leu Ser Leu
130 135 140
gcg gta tgg act cca tcg tat gct aat gag aca tcc aag ctg cca gtt 480

```
Ala Val Trp Thr Pro Ser Tyr Ala Asn Glu Thr Ser Lys Leu Pro Val
145                 150                 155                 160
gcg ctg ttt gtc acg gga ggt ggt ggc atc aca ggg ggt atc aac att      528
Ala Leu Phe Val Thr Gly Gly Gly Gly Ile Thr Gly Gly Ile Asn Ile
                165                 170                 175
ccg tcc cag ctg ccc tct gct tgg gta tct cgc tct cag gag cat atc      576
Pro Ser Gln Leu Pro Ser Ala Trp Val Ser Arg Ser Gln Glu His Ile
            180                 185                 190
gtt gtt acc atc aat tac cgc gtc aat att ttt ggc aat ccc aaa tcg      624
Val Val Thr Ile Asn Tyr Arg Val Asn Ile Phe Gly Asn Pro Lys Ser
        195                 200                 205
cgt gcg ttg aat gat acg tcg ctt acg ctg atg gac gtg cgc gct gct      672
Arg Ala Leu Asn Asp Thr Ser Leu Thr Leu Met Asp Val Arg Ala Ala
    210                 215                 220
gtg gag tgg gta tat gag aac att gaa gcg ttc ggt ggt aat ccc gaa      720
Val Glu Trp Val Tyr Glu Asn Ile Glu Ala Phe Gly Gly Asn Pro Glu
225                 230                 235                 240
aat att atg gtc aga cta caa gtt tcc tct cac atg act aga gct aac      768
Asn Ile Met Val Arg Leu Gln Val Ser Ser His Met Thr Arg Ala Asn
                245                 250                 255
agt aag cag cta tgg gga cag tca caa ggt gct ttg ctg acg cat ctg      816
Ser Lys Gln Leu Trp Gly Gln Ser Gln Gly Ala Leu Leu Thr His Leu
            260                 265                 270
tac acc ctc gca tgg cca gaa gag cct ctt gcc gcc aag ttc ggc gtc      864
Tyr Thr Leu Ala Trp Pro Glu Glu Pro Leu Ala Ala Lys Phe Gly Val
        275                 280                 285
atc tcc caa gga gca tct gcc aca ctc aac ctc tct acc acg ccc gat      912
Ile Ser Gln Gly Ala Ser Ala Thr Leu Asn Leu Ser Thr Thr Pro Asp
    290                 295                 300
gtg tac caa gac ttt gac atc gtg gcc aag gga cta ggc tgc aat tat      960
Val Tyr Gln Asp Phe Asp Ile Val Ala Lys Gly Leu Gly Cys Asn Tyr
305                 310                 315                 320
ggt gat gat gcc gag gcc gag ctg gag tgc atg cgt ggg att tcc tgg     1008
Gly Asp Asp Ala Glu Ala Glu Leu Glu Cys Met Arg Gly Ile Ser Trp
                325                 330                 335
gtg cag atc gag gag tat atc aac cgc tac aat agc tct cct tct att     1056
Val Gln Ile Glu Glu Tyr Ile Asn Arg Tyr Asn Ser Ser Pro Ser Ile
            340                 345                 350
gct ttc acg aac tat att ccc gat gag aaa tac atc ttc tcc gac gaa     1104
Ala Phe Thr Asn Tyr Ile Pro Asp Glu Lys Tyr Ile Phe Ser Asp Glu
        355                 360                 365
aga cag cgt tac ctt gag cgg aag gtt gcc cga ggc ccg tca att cga     1152
Arg Gln Arg Tyr Leu Glu Arg Lys Val Ala Arg Gly Pro Ser Ile Arg
    370                 375                 380
```

```
tct gac acg gcg cga gaa ttc cct agc aca aac acg acc tca gta aat      1200
Ser Asp Thr Ala Arg Glu Phe Pro Ser Thr Asn Thr Thr Ser Val Asn
385                 390                 395                 400
att gaa gaa ggc gaa tca gac tgt ctg gca gtg act gac ctt gcg cta      1248
Ile Glu Glu Gly Glu Ser Asp Cys Leu Ala Val Thr Asp Leu Ala Leu
                405                 410                 415
cgt gcg tcc att ggg ctc gag acc tat cgc tac tac tgg gct ggc aac      1296
Arg Ala Ser Ile Gly Leu Glu Thr Tyr Arg Tyr Tyr Trp Ala Gly Asn
            420                 425                 430
ttc tcc aat atc agt ccc gta ccg tgg cta gga gca ttc cac tgg acc      1344
Phe Ser Asn Ile Ser Pro Val Pro Trp Leu Gly Ala Phe His Trp Thr
        435                 440                 445
gac ctg ctg atg atc ttc ggt acg tat aat ctg gac gtc ggc gag atc      1392
Asp Leu Leu Met Ile Phe Gly Thr Tyr Asn Leu Asp Val Gly Glu Ile
    450                 455                 460
tcg cag ttg gaa gtc gac acc tct gcc acg atg caa gat tat cta ctc      1440
Ser Gln Leu Glu Val Asp Thr Ser Ala Thr Met Gln Asp Tyr Leu Leu
465                 470                 475                 480
gcc ttt ctg aag gac tca tca acc gtc agc gag acg gtc gga tgg ccg      1488
Ala Phe Leu Lys Asp Ser Ser Thr Val Ser Glu Thr Val Gly Trp Pro
                485                 490                 495
tta tat ctg ggc aac gag acc aac gga gga ctc atc ctg gag ttc ggt      1536
Leu Tyr Leu Gly Asn Glu Thr Asn Gly Gly Leu Ile Leu Glu Phe Gly
            500                 505                 510
aac ggc aca gca gtg cgg acc atc aca ggt gac tgg ctc gac gcg gga      1584
Asn Gly Thr Ala Val Arg Thr Ile Thr Gly Asp Trp Leu Asp Ala Gly
        515                 520                 525
tgt ttc aat tca tct atc cca ttc aga atc tgg ggg tag                  1623
Cys Phe Asn Ser Ser Ile Pro Phe Arg Ile Trp Gly
    530                 535                 540
```

<210> 9
<211> 540
<212> PRT
<213> Aspergillus niger

<400> 9

```
Met Val Gln Gly Val Ala Phe Gly Leu Leu Gly Leu Ala Ala Ser Ala
1               5                  10                  15
Leu Gly Thr Tyr Ala Pro Tyr Tyr Ala Asn Leu Thr Trp Glu Gln Pro
            20                  25                  30
Arg Thr Leu Ser Asn Trp Ser Asn Leu Thr Val Glu Thr Arg Thr Gly
        35                  40                  45
```

21078WO.ST25.txt

```
Thr Phe Ile Gly Met Leu Asn Asp Thr Tyr Pro Asp Val Arg Gln Phe
    50                  55                  60
Leu Arg Val Pro Tyr Ala Lys Pro Pro Ile Gly Asp Leu Arg Trp Leu
65                  70                  75                  80
Pro Pro His Arg Leu Asp Asn Ser Ser Arg Thr Tyr Asp Ser Thr Phe
                85                  90                  95
Tyr Gly Pro Ala Cys Pro Gln Tyr Val Pro Ala Glu Ser Asp Phe Trp
            100                 105                 110
Asn Glu Tyr Glu Pro Glu Asn Leu Leu Leu Asn Val Gly Glu Arg Leu
        115                 120                 125
Asn Gln Gly Ser Thr Ala Trp Ser Ser Ser Glu Asp Cys Leu Ser Leu
    130                 135                 140
Ala Val Trp Thr Pro Ser Tyr Ala Asn Glu Thr Ser Lys Leu Pro Val
145                 150                 155                 160
Ala Leu Phe Val Thr Gly Gly Gly Gly Ile Thr Gly Gly Ile Asn Ile
                165                 170                 175
Pro Ser Gln Leu Pro Ser Ala Trp Val Ser Arg Ser Gln Glu His Ile
            180                 185                 190
Val Val Thr Ile Asn Tyr Arg Val Asn Ile Phe Gly Asn Pro Lys Ser
        195                 200                 205
Arg Ala Leu Asn Asp Thr Ser Leu Thr Leu Met Asp Val Arg Ala Ala
    210                 215                 220
Val Glu Trp Val Tyr Glu Asn Ile Glu Ala Phe Gly Gly Asn Pro Glu
225                 230                 235                 240
Asn Ile Met Val Arg Leu Gln Val Ser Ser His Met Thr Arg Ala Asn
                245                 250                 255
Ser Lys Gln Leu Trp Gly Gln Ser Gln Gly Ala Leu Leu Thr His Leu
            260                 265                 270
Tyr Thr Leu Ala Trp Pro Glu Glu Pro Leu Ala Ala Lys Phe Gly Val
        275                 280                 285
Ile Ser Gln Gly Ala Ser Ala Thr Leu Asn Leu Ser Thr Thr Pro Asp
    290                 295                 300
Val Tyr Gln Asp Phe Asp Ile Val Ala Lys Gly Leu Gly Cys Asn Tyr
305                 310                 315                 320
Gly Asp Asp Ala Glu Ala Glu Leu Glu Cys Met Arg Gly Ile Ser Trp
                325                 330                 335
Val Gln Ile Glu Glu Tyr Ile Asn Arg Tyr Asn Ser Ser Pro Ser Ile
            340                 345                 350
Ala Phe Thr Asn Tyr Ile Pro Asp Glu Lys Tyr Ile Phe Ser Asp Glu
        355                 360                 365
Arg Gln Arg Tyr Leu Glu Arg Lys Val Ala Arg Gly Pro Ser Ile Arg
    370                 375                 380
Ser Asp Thr Ala Arg Glu Phe Pro Ser Thr Asn Thr Thr Ser Val Asn
385                 390                 395                 400
```

Ile Glu Glu Gly Glu Ser Asp Cys Leu Ala Val Thr Asp Leu Ala Leu
405 410 415
Arg Ala Ser Ile Gly Leu Glu Thr Tyr Arg Tyr Tyr Trp Ala Gly Asn
420 425 430
Phe Ser Asn Ile Ser Pro Val Pro Trp Leu Gly Ala Phe His Trp Thr
435 440 445
Asp Leu Leu Met Ile Phe Gly Thr Tyr Asn Leu Asp Val Gly Glu Ile
450 455 460
Ser Gln Leu Glu Val Asp Thr Ser Ala Thr Met Gln Asp Tyr Leu Leu
465 470 475 480
Ala Phe Leu Lys Asp Ser Ser Thr Val Ser Glu Thr Val Gly Trp Pro
485 490 495
Leu Tyr Leu Gly Asn Glu Thr Asn Gly Gly Leu Ile Leu Glu Phe Gly
500 505 510
Asn Gly Thr Ala Val Arg Thr Ile Thr Gly Asp Trp Leu Asp Ala Gly
515 520 525
Cys Phe Asn Ser Ser Ile Pro Phe Arg Ile Trp Gly
530 535 540

<210> 10
<211> 3235
<212> DNA
<213> Aspergillus niger

<400> 10
gttttcaatt tggactgaat tttggcggca tttcttgtat aaaattaaaa ggggcgttga 60
ctggattttg gtacttggga tttattctta gctttgactg tacatagttt gggcgtggtt 120
tgatagccga cgatcggccg acccacgaac cagatttgca tatgattaca ttccttcaat 180
tttggtccga gtcccaaccc gcctttcaac cccaacaact acaagcacgt tgtgtttgct 240
acattgactc actcgatatt gctgaaccat gcaggccgcc caactgagtt attacaccaa 300
gcatgcgaat cggaaagttc gacaaagcgg gtgaaatgtc cgagttggcg aaccaaagcg 360
caacggtcga ggctcctttc cccgcagagg cagccattct gcagcctttg aactgcgggg 420
gaaacggcat ttgatcaact cggcactgat gcagtgacca acaggatgtt agcaatgttg 480
gcctaatata ttcttactga tctgctgata cgtccctccc ttgcatcagc ctcggtttgc 540
gcatgagaac gggttcgaac gttcctgggc cacccggttg gcgtgatatt ctccgcccac 600
gctgtctgtc cccctgatgg gaaaccttcg gatcagcgat catcaggcca gttggctatg 660
agaatagggg ctttgctgtc ttgatgccta aaatgcaggt ctcatagcaa gatccacagc 720
cgaggaggca catggcgatg tcgaaaccca tgggagctga tttttcggtt ctcggatcgt 780
gctccaagac atagaaggat attgagcact tgaaacgaag gggtgaaaaa tggaactgta 840
tatagagtta ctcccagccc gatccgagag cctatgaccc atagcggtac agatcatggc 900
catcatgaag gccctccttt ggctctccct ttccctcgcc gtctgggcga ctccagttca 960
acgggatgca gctcctactg tcactattgc gcatccatcg gccaccgtca ttggaaaatc 1020
tggcaatgtc gagagcttca acaatattcc ctttgcgcag gcccccacag gctcgctgcg 1080

tctgaagccc ccacaaccct tggaaactgc cctcggcact gttcaggcca caggagcctc 1140
gcaatcgtgt ccgcagatgt acttcaccac ggatgagagc gaattcccga catcggtcat 1200
tggcctcctc gctgatctcc ctttggtaca gtcggctacc aatgctctcg aggattgcct 1260
gaacattgac attcggcgtc cggccgggac caccgcggac tcgaagctgc ctgtgctggt 1320
ctggatcttt ggcggaggct ttgaacttgg ttcaaaggcg atgtatgatg gtacaacgat 1380
ggtatcatcg tcgatagaca agaacatgcc tatcgtgttt gtagcaatga attatcgcgt 1440
gggaggtttc gggttcttgc ccggaaagga gatcctggag gacgggtccg cgaacctagg 1500
gctcctggac caacgccttg ccctgcagtg ggttgccgac aacatcgagg cctttggtgg 1560
agacccggac aaggtgacga tttggggaga atcagcagga gccatttccg tttttgatca 1620
gatgatcttg tacgacggaa acatcactta caaggataag cccttgttcc gggggccat 1680
catggactcc ggtagtgttg ttcccgcaga ccccgtcgat ggggtcaagg gacagcaagt 1740
atatgatgcg gtagtggaat ctgcaggctg ttcctcttct aacgacaccc tagcttgtct 1800
gcgtgaacta gactacaccg acttcctcaa tgcggcaaac tccgtgccag gcattttaag 1860
ctaccattct gtggcgttat catatgtgcc tcgaccggac gggacggcgt tgtcggcatc 1920
accggacgtt ttgggcaaag cagggaaata tgctcgggtc ccgttcatcg tgggcgacca 1980
agaggatgag gggaccttat tcgccttgtt tcagtccaac attacgacga tcgacgaggt 2040
ggtcgactac ctggcctcat acttcttcta tgacgctagc cgagagcagc ttgaagaact 2100
agtggccctg tacccagaca ccaccacgta cgggtctccg ttcaggacag gcgcggccaa 2160
caactggtat ccgcaattta agcgattggc cgccattctc ggcgacttgg tcttcaccat 2220
tacccggcgg gcattcctct cgtatgcaga ggaaatctcc cctgatcttc cgaactggtc 2280
gtacctggcg acctatgact atggcacccc agttctgggg accttccacg gaagtgacct 2340
gctgcaggtg ttctatggga tcaagccaaa ctatgcagct agttctagcc acacgtacta 2400
tctgagcttt gtgtatacgc tggatccgaa ctccaaccgg ggggagtaca ttgagtggcc 2460
gcagtggaag gaatcgcggc agttgatgaa tttcggagcg aacgacgcca gtctccttac 2520
ggatgatttc cgcaacggga catatgagtt catcctgcag aataccgcgg cgttccacat 2580
ctgatgccat tggcggaggg gtccggacgg tcaggaactt agccttatga gatgaatgat 2640
ggacgtgtct ggcctcggaa aaggatatat ggggatcatg atagtactag ccatattaat 2700
gaagggcata taccacgcgt tggacctgcg ttatagcttc ccgttagtta tagtaccatc 2760
gttataccag ccaatcaagt caccacgcac gaccggggac ggcgaatccc cgggaattga 2820
aagaaattgc atcccaggcc agtgaggcca gcgattggcc acctctccaa ggcacagggc 2880
cattctgcag cgctggtgga ttcatcgcaa tttcccccgg cccggcccga caccgctata 2940
ggctggttct cccacaccat cggagattcg tcgcctaatg tctcgtccgt tcacaagctg 3000
aagagcttga agtggcgaga tgtctctgca ggaattcaag ctagatgcta agcgatattg 3060
catggcaata tgtgttgatg catgtgcttc ttccttcagc ttcccctcgt gcagatgagg 3120
tttggctata aattgaagtg gttggtcggg gttccgtgag gggctgaagt gcttcctccc 3180
ttttagacgc aactgagagc ctgagcttca tccccagcat cattacacct cagca 3235

<210> 11
<211> 1689
<212> DNA
<213> Aspergillus niger

<220>

<221> CDS
<222> (1)..(1689)

<400> 11

```
atg gcc atc atg aag gcc ctc ctt tgg ctc tcc ctt tcc ctc gcc gtc      48
Met Ala Ile Met Lys Ala Leu Leu Trp Leu Ser Leu Ser Leu Ala Val
1               5                  10                  15
tgg gcg act cca gtt caa cgg gat gca gct cct act gtc act att gcg      96
Trp Ala Thr Pro Val Gln Arg Asp Ala Ala Pro Thr Val Thr Ile Ala
            20                  25                  30
cat cca tcg gcc acc gtc att gga aaa tct ggc aat gtc gag agc ttc     144
His Pro Ser Ala Thr Val Ile Gly Lys Ser Gly Asn Val Glu Ser Phe
        35                  40                  45
aac aat att ccc ttt gcg cag gcc ccc aca ggc tcg ctg cgt ctg aag     192
Asn Asn Ile Pro Phe Ala Gln Ala Pro Thr Gly Ser Leu Arg Leu Lys
    50                  55                  60
ccc cca caa ccc ttg gaa act gcc ctc ggc act gtt cag gcc aca gga     240
Pro Pro Gln Pro Leu Glu Thr Ala Leu Gly Thr Val Gln Ala Thr Gly
65                  70                  75                  80
gcc tcg caa tcg tgt ccg cag atg tac ttc acc acg gat gag agc gaa     288
Ala Ser Gln Ser Cys Pro Gln Met Tyr Phe Thr Thr Asp Glu Ser Glu
                85                  90                  95
ttc ccg aca tcg gtc att ggc ctc ctc gct gat ctc cct ttg gta cag     336
Phe Pro Thr Ser Val Ile Gly Leu Leu Ala Asp Leu Pro Leu Val Gln
            100                 105                 110
tcg gct acc aat gct ctc gag gat tgc ctg aac att gac att cgg cgt     384
Ser Ala Thr Asn Ala Leu Glu Asp Cys Leu Asn Ile Asp Ile Arg Arg
        115                 120                 125
ccg gcc ggg acc acc gcg gac tcg aag ctg cct gtg ctg gtc tgg atc     432
Pro Ala Gly Thr Thr Ala Asp Ser Lys Leu Pro Val Leu Val Trp Ile
    130                 135                 140
ttt ggc gga ggc ttt gaa ctt ggt tca aag gcg atg tat gat ggt aca     480
Phe Gly Gly Gly Phe Glu Leu Gly Ser Lys Ala Met Tyr Asp Gly Thr
145                 150                 155                 160
acg atg gta tca tcg tcg ata gac aag aac atg cct atc gtg ttt gta     528
Thr Met Val Ser Ser Ser Ile Asp Lys Asn Met Pro Ile Val Phe Val
                165                 170                 175
gca atg aat tat cgc gtg gga ggt ttc ggg ttc ttg ccc gga aag gag     576
Ala Met Asn Tyr Arg Val Gly Gly Phe Gly Phe Leu Pro Gly Lys Glu
            180                 185                 190
atc ctg gag gac ggg tcc gcg aac cta ggg ctc ctg gac caa cgc ctt     624
Ile Leu Glu Asp Gly Ser Ala Asn Leu Gly Leu Leu Asp Gln Arg Leu
        195                 200                 205
gcc ctg cag tgg gtt gcc gac aac atc gag gcc ttt ggt gga gac ccg     672
```

```
Ala Leu Gln Trp Val Ala Asp Asn Ile Glu Ala Phe Gly Gly Asp Pro
    210                 215                 220
gac aag gtg acg att tgg gga gaa tca gca gga gcc att tcc gtt ttt      720
Asp Lys Val Thr Ile Trp Gly Glu Ser Ala Gly Ala Ile Ser Val Phe
225                 230                 235                 240
gat cag atg atc ttg tac gac gga aac atc act tac aag gat aag ccc      768
Asp Gln Met Ile Leu Tyr Asp Gly Asn Ile Thr Tyr Lys Asp Lys Pro
                245                 250                 255
ttg ttc cgg ggg gcc atc atg gac tcc ggt agt gtt gtt ccc gca gac      816
Leu Phe Arg Gly Ala Ile Met Asp Ser Gly Ser Val Val Pro Ala Asp
            260                 265                 270
ccc gtc gat ggg gtc aag gga cag caa gta tat gat gcg gta gtg gaa      864
Pro Val Asp Gly Val Lys Gly Gln Gln Val Tyr Asp Ala Val Val Glu
        275                 280                 285
tct gca ggc tgt tcc tct tct aac gac acc cta gct tgt ctg cgt gaa      912
Ser Ala Gly Cys Ser Ser Ser Asn Asp Thr Leu Ala Cys Leu Arg Glu
    290                 295                 300
cta gac tac acc gac ttc ctc aat gcg gca aac tcc gtg cca ggc att      960
Leu Asp Tyr Thr Asp Phe Leu Asn Ala Ala Asn Ser Val Pro Gly Ile
305                 310                 315                 320
tta agc tac cat tct gtg gcg tta tca tat gtg cct cga ccg gac ggg     1008
Leu Ser Tyr His Ser Val Ala Leu Ser Tyr Val Pro Arg Pro Asp Gly
                325                 330                 335
acg gcg ttg tcg gca tca ccg gac gtt ttg ggc aaa gca ggg aaa tat     1056
Thr Ala Leu Ser Ala Ser Pro Asp Val Leu Gly Lys Ala Gly Lys Tyr
            340                 345                 350
gct cgg gtc ccg ttc atc gtg ggc gac caa gag gat gag ggg acc tta     1104
Ala Arg Val Pro Phe Ile Val Gly Asp Gln Glu Asp Glu Gly Thr Leu
        355                 360                 365
ttc gcc ttg ttt cag tcc aac att acg acg atc gac gag gtg gtc gac     1152
Phe Ala Leu Phe Gln Ser Asn Ile Thr Thr Ile Asp Glu Val Val Asp
    370                 375                 380
tac ctg gcc tca tac ttc ttc tat gac gct agc cga gag cag ctt gaa     1200
Tyr Leu Ala Ser Tyr Phe Phe Tyr Asp Ala Ser Arg Glu Gln Leu Glu
385                 390                 395                 400
gaa cta gtg gcc ctg tac cca gac acc acc acg tac ggg tct ccg ttc     1248
Glu Leu Val Ala Leu Tyr Pro Asp Thr Thr Thr Tyr Gly Ser Pro Phe
                405                 410                 415
agg aca ggc gcg gcc aac aac tgg tat ccg caa ttt aag cga ttg gcc     1296
Arg Thr Gly Ala Ala Asn Asn Trp Tyr Pro Gln Phe Lys Arg Leu Ala
            420                 425                 430
gcc att ctc ggc gac ttg gtc ttc acc att acc cgg cgg gca ttc ctc     1344
Ala Ile Leu Gly Asp Leu Val Phe Thr Ile Thr Arg Arg Ala Phe Leu
        435                 440                 445
```

```
tcg tat gca gag gaa atc tcc cct gat ctt ccg aac tgg tcg tac ctg      1392
Ser Tyr Ala Glu Glu Ile Ser Pro Asp Leu Pro Asn Trp Ser Tyr Leu
    450                 455                 460
gcg acc tat gac tat ggc acc cca gtt ctg ggg acc ttc cac gga agt      1440
Ala Thr Tyr Asp Tyr Gly Thr Pro Val Leu Gly Thr Phe His Gly Ser
465                 470                 475                 480
gac ctg ctg cag gtg ttc tat ggg atc aag cca aac tat gca gct agt      1488
Asp Leu Leu Gln Val Phe Tyr Gly Ile Lys Pro Asn Tyr Ala Ala Ser
                485                 490                 495
tct agc cac acg tac tat ctg agc ttt gtg tat acg ctg gat ccg aac      1536
Ser Ser His Thr Tyr Tyr Leu Ser Phe Val Tyr Thr Leu Asp Pro Asn
            500                 505                 510
tcc aac cgg ggg gag tac att gag tgg ccg cag tgg aag gaa tcg cgg      1584
Ser Asn Arg Gly Glu Tyr Ile Glu Trp Pro Gln Trp Lys Glu Ser Arg
        515                 520                 525
cag ttg atg aat ttc gga gcg aac gac gcc agt ctc ctt acg gat gat      1632
Gln Leu Met Asn Phe Gly Ala Asn Asp Ala Ser Leu Leu Thr Asp Asp
    530                 535                 540
ttc cgc aac ggg aca tat gag ttc atc ctg cag aat acc gcg gcg ttc      1680
Phe Arg Asn Gly Thr Tyr Glu Phe Ile Leu Gln Asn Thr Ala Ala Phe
545                 550                 555                 560
cac atc tga                                                         1689
His Ile
```

<210> 12
<211> 562
<212> PRT
<213> Aspergillus niger

<400> 12

```
Met Ala Ile Met Lys Ala Leu Leu Trp Leu Ser Leu Ser Leu Ala Val
1               5                  10                  15
Trp Ala Thr Pro Val Gln Arg Asp Ala Ala Pro Thr Val Thr Ile Ala
            20                  25                  30
His Pro Ser Ala Thr Val Ile Gly Lys Ser Gly Asn Val Glu Ser Phe
        35                  40                  45
Asn Asn Ile Pro Phe Ala Gln Ala Pro Thr Gly Ser Leu Arg Leu Lys
    50                  55                  60
Pro Pro Gln Pro Leu Glu Thr Ala Leu Gly Thr Val Gln Ala Thr Gly
65                  70                  75                  80
Ala Ser Gln Ser Cys Pro Gln Met Tyr Phe Thr Thr Asp Glu Ser Glu
                85                  90                  95
Phe Pro Thr Ser Val Ile Gly Leu Leu Ala Asp Leu Pro Leu Val Gln
```

100 105 110
Ser Ala Thr Asn Ala Leu Glu Asp Cys Leu Asn Ile Asp Ile Arg Arg
115 120 125
Pro Ala Gly Thr Thr Ala Asp Ser Lys Leu Pro Val Leu Val Trp Ile
130 135 140
Phe Gly Gly Gly Phe Glu Leu Gly Ser Lys Ala Met Tyr Asp Gly Thr
145 150 155 160
Thr Met Val Ser Ser Ser Ile Asp Lys Asn Met Pro Ile Val Phe Val
165 170 175
Ala Met Asn Tyr Arg Val Gly Gly Phe Gly Phe Leu Pro Gly Lys Glu
180 185 190
Ile Leu Glu Asp Gly Ser Ala Asn Leu Gly Leu Leu Asp Gln Arg Leu
195 200 205
Ala Leu Gln Trp Val Ala Asp Asn Ile Glu Ala Phe Gly Gly Asp Pro
210 215 220
Asp Lys Val Thr Ile Trp Gly Glu Ser Ala Gly Ala Ile Ser Val Phe
225 230 235 240
Asp Gln Met Ile Leu Tyr Asp Gly Asn Ile Thr Tyr Lys Asp Lys Pro
245 250 255
Leu Phe Arg Gly Ala Ile Met Asp Ser Gly Ser Val Val Pro Ala Asp
260 265 270
Pro Val Asp Gly Val Lys Gly Gln Gln Val Tyr Asp Ala Val Val Glu
275 280 285
Ser Ala Gly Cys Ser Ser Ser Asn Asp Thr Leu Ala Cys Leu Arg Glu
290 295 300
Leu Asp Tyr Thr Asp Phe Leu Asn Ala Ala Asn Ser Val Pro Gly Ile
305 310 315 320
Leu Ser Tyr His Ser Val Ala Leu Ser Tyr Val Pro Arg Pro Asp Gly
325 330 335
Thr Ala Leu Ser Ala Ser Pro Asp Val Leu Gly Lys Ala Gly Lys Tyr
340 345 350
Ala Arg Val Pro Phe Ile Val Gly Asp Gln Glu Asp Glu Gly Thr Leu
355 360 365
Phe Ala Leu Phe Gln Ser Asn Ile Thr Thr Ile Asp Glu Val Val Asp
370 375 380
Tyr Leu Ala Ser Tyr Phe Phe Tyr Asp Ala Ser Arg Glu Gln Leu Glu
385 390 395 400
Glu Leu Val Ala Leu Tyr Pro Asp Thr Thr Thr Tyr Gly Ser Pro Phe
405 410 415
Arg Thr Gly Ala Ala Asn Asn Trp Tyr Pro Gln Phe Lys Arg Leu Ala
420 425 430
Ala Ile Leu Gly Asp Leu Val Phe Thr Ile Thr Arg Arg Ala Phe Leu
435 440 445
Ser Tyr Ala Glu Glu Ile Ser Pro Asp Leu Pro Asn Trp Ser Tyr Leu

```
    450                 455                 460
Ala Thr Tyr Asp Tyr Gly Thr Pro Val Leu Gly Thr Phe His Gly Ser
465                 470                 475                 480
Asp Leu Leu Gln Val Phe Tyr Gly Ile Lys Pro Asn Tyr Ala Ala Ser
                485                 490                 495
Ser Ser His Thr Tyr Tyr Leu Ser Phe Val Tyr Thr Leu Asp Pro Asn
            500                 505                 510
Ser Asn Arg Gly Glu Tyr Ile Glu Trp Pro Gln Trp Lys Glu Ser Arg
        515                 520                 525
Gln Leu Met Asn Phe Gly Ala Asn Asp Ala Ser Leu Leu Thr Asp Asp
    530                 535                 540
Phe Arg Asn Gly Thr Tyr Glu Phe Ile Leu Gln Asn Thr Ala Ala Phe
545                 550                 555                 560
His Ile
```

<210> 13
<211> 2097
<212> DNA
<213> Aspergillus niger

<400> 13

```
cctggctgac gctataccga agacgatgtc gatgtcgtct ttgctcagag gccccgagtc     60
gtttggggca cgtcaagaaa gtagtcttcg ctgctgcttg aagacatgat caggacacgc     120
ggttcgacct tcgagtgtac atgatatccg tagaatttgc ttgtgactac caaggcatat     180
gttagttcgt gcagtggtaa aagcggcttc tcttcttcaa tctgcgaggt ggagatgcct     240
actatgatcg tcatccaact tggtgtctac aagacgaaca caagcttagt tccgacgaac     300
cagtgaaaac tctgtaagat atataagagc atcaagagtc ggacttgctt aggagagtgg     360
atagttgttg atgctcgcgg aagctctcat atagtataga tatgaagtat cggtgagtcg     420
tagtagtctt tgtattatat agggagaggc tgaatggtgt gggtcatgat aatttccaca     480
taatagcgat taaagcccta gatcgagggt atcttgaggc ataaatgata gtatcagtgg     540
acatatcctg agatgaggat gatatgagat gatagagatg aggaagaaag aggaaagaga     600
gaggcaagaa cagagatttt tatacctttg cagagcagcc catccgtcac tgaattcagg     660
catcttcact ccatactatc acgagtcaac gtgaagttgt ataagcgtag tgacaggccg     720
cagtgacgat gatccgtcac tgcggtggct atccgcgact gatcttgcta tccgtgactg     780
cgttgactct ggtgaaccaa gtgttcggga aggggtgaaa atgaagctga agcgggtcag     840
ggaacattcc aagcaacact agacgagtca gcgacgagtc agcgatccac tcggtctcac     900
acgctcccaa tagtctcaat ttggtgccaa tggcaactaa gtattccatc cacttttaat     960
taaagtgatc agcggtgcac gaattcacat gctggatctg gtacagatca gattaatatc    1020
tcctggaata cgatgaaggc ccacctcagg attcacgata aatttctggt gactgccagc    1080
tcgaatggca ttctccgtca ctctacacct gccgttggtt aattctccga acctctaatt    1140
gtcaatttct gccaaaatgc gtctatcatc gctggccctg gcatccagcg ccatcctacc    1200
cgccttaggc tacagcatca acgacttctc ctgcaatagc accgaacacc cgaatccagt    1260
tgtgctccta catgggctag gcgccaccta ctacgaagac ttgaattacc tgcaaggttg    1320
```

gctacagacc caaggctatt gcacttacgc caaaacctac ggtgcatatg aaggcttccc 1380
ctttgtcggc ggcctcaagg ccatcgccga atcggccacg gaaatcgccg cgtacatccg 1440
cgaggtgaaa gaaaagacgg gcgccgacaa gattgacctt gtcggtcact ccgaaggcgc 1500
cttccagacc ctctacgtcc ctaagttcga ggatggtatc tcggagatgc tggataagct 1560
ggtggccatt gcacctccca ccagaggcac caacttggcg gggatctatg acatcgcata 1620
tgttctggga aatctatcgc gcgatctgat aggcgacgtc ctggataccg tgggctgcgc 1680
cgcctgtgat gatctgggtc cggatggagc agcgattgac cgcttgaacg atggcgagcc 1740
tatcgtgcag ccgggaaata atctaacggt gattgcatcg cggtccgacg aattggtcac 1800
cccaaccacc acctccttcg tgcatgaaga tggggtgacc aatgaatggg tgcaagacac 1860
ttgtcctcta gaccctgtcg gtcatatcgg tgaggcatac gatctgaacg tctggaattt 1920
ggtcaaaaac gccttggact ctacgccgaa gcgtgagttc gtctgctcgc tgggatctcc 1980
cggcaggtga gactatcatc ttctgaaaat ttgtatataa gcatttatat ttggataccc 2040
ggttaccagt cattagtgtc ataatgtata ataatatcac cacaacttcc tccaagc 2097

<210> 14
<211> 834
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(834)

<400> 14
atg cgt cta tca tcg ctg gcc ctg gca tcc agc gcc atc cta ccc gcc 48
Met Arg Leu Ser Ser Leu Ala Leu Ala Ser Ser Ala Ile Leu Pro Ala
1 5 10 15
tta ggc tac agc atc aac gac ttc tcc tgc aat agc acc gaa cac ccg 96
Leu Gly Tyr Ser Ile Asn Asp Phe Ser Cys Asn Ser Thr Glu His Pro
20 25 30
aat cca gtt gtg ctc cta cat ggg cta ggc gcc acc tac tac gaa gac 144
Asn Pro Val Val Leu Leu His Gly Leu Gly Ala Thr Tyr Tyr Glu Asp
35 40 45
ttg aat tac ctg caa ggt tgg cta cag acc caa ggc tat tgc act tac 192
Leu Asn Tyr Leu Gln Gly Trp Leu Gln Thr Gln Gly Tyr Cys Thr Tyr
50 55 60
gcc aaa acc tac ggt gca tat gaa ggc ttc ccc ttt gtc ggc ggc ctc 240
Ala Lys Thr Tyr Gly Ala Tyr Glu Gly Phe Pro Phe Val Gly Gly Leu
65 70 75 80
aag gcc atc gcc gaa tcg gcc acg gaa atc gcc gcg tac atc cgc gag 288
Lys Ala Ile Ala Glu Ser Ala Thr Glu Ile Ala Ala Tyr Ile Arg Glu
85 90 95
gtg aaa gaa aag acg ggc gcc gac aag att gac ctt gtc ggt cac tcc 336

```
Val Lys Glu Lys Thr Gly Ala Asp Lys Ile Asp Leu Val Gly His Ser
            100                 105                 110
gaa ggc gcc ttc cag acc ctc tac gtc cct aag ttc gag gat ggt atc      384
Glu Gly Ala Phe Gln Thr Leu Tyr Val Pro Lys Phe Glu Asp Gly Ile
        115                 120                 125
tcg gag atg ctg gat aag ctg gtg gcc att gca cct ccc acc aga ggc      432
Ser Glu Met Leu Asp Lys Leu Val Ala Ile Ala Pro Pro Thr Arg Gly
    130                 135                 140
acc aac ttg gcg ggg atc tat gac atc gca tat gtt ctg gga aat cta      480
Thr Asn Leu Ala Gly Ile Tyr Asp Ile Ala Tyr Val Leu Gly Asn Leu
145                 150                 155                 160
tcg cgc gat ctg ata ggc gac gtc ctg gat acc gtg ggc tgc gcc gcc      528
Ser Arg Asp Leu Ile Gly Asp Val Leu Asp Thr Val Gly Cys Ala Ala
                165                 170                 175
tgt gat gat ctg ggt ccg gat gga gca gcg att gac cgc ttg aac gat      576
Cys Asp Asp Leu Gly Pro Asp Gly Ala Ala Ile Asp Arg Leu Asn Asp
            180                 185                 190
ggc gag cct atc gtg cag ccg gga aat aat cta acg gtg att gca tcg      624
Gly Glu Pro Ile Val Gln Pro Gly Asn Asn Leu Thr Val Ile Ala Ser
        195                 200                 205
cgg tcc gac gaa ttg gtc acc cca acc acc acc tcc ttc gtg cat gaa      672
Arg Ser Asp Glu Leu Val Thr Pro Thr Thr Thr Ser Phe Val His Glu
    210                 215                 220
gat ggg gtg acc aat gaa tgg gtg caa gac act tgt cct cta gac cct      720
Asp Gly Val Thr Asn Glu Trp Val Gln Asp Thr Cys Pro Leu Asp Pro
225                 230                 235                 240
gtc ggt cat atc ggt gag gca tac gat ctg aac gtc tgg aat ttg gtc      768
Val Gly His Ile Gly Glu Ala Tyr Asp Leu Asn Val Trp Asn Leu Val
                245                 250                 255
aaa aac gcc ttg gac tct acg ccg aag cgt gag ttc gtc tgc tcg ctg      816
Lys Asn Ala Leu Asp Ser Thr Pro Lys Arg Glu Phe Val Cys Ser Leu
            260                 265                 270
gga tct ccc ggc agg tga                                             834
Gly Ser Pro Gly Arg
        275
```

<210> 15
<211> 277
<212> PRT
<213> Aspergillus niger

<400> 15
Met Arg Leu Ser Ser Leu Ala Leu Ala Ser Ser Ala Ile Leu Pro Ala

```
1               5                  10                  15
Leu Gly Tyr Ser Ile Asn Asp Phe Ser Cys Asn Ser Thr Glu His Pro
            20                  25                  30
Asn Pro Val Val Leu Leu His Gly Leu Gly Ala Thr Tyr Tyr Glu Asp
        35                  40                  45
Leu Asn Tyr Leu Gln Gly Trp Leu Gln Thr Gln Gly Tyr Cys Thr Tyr
    50                  55                  60
Ala Lys Thr Tyr Gly Ala Tyr Glu Gly Phe Pro Phe Val Gly Gly Leu
65                  70                  75                  80
Lys Ala Ile Ala Glu Ser Ala Thr Glu Ile Ala Ala Tyr Ile Arg Glu
                85                  90                  95
Val Lys Glu Lys Thr Gly Ala Asp Lys Ile Asp Leu Val Gly His Ser
            100                 105                 110
Glu Gly Ala Phe Gln Thr Leu Tyr Val Pro Lys Phe Glu Asp Gly Ile
        115                 120                 125
Ser Glu Met Leu Asp Lys Leu Val Ala Ile Ala Pro Pro Thr Arg Gly
    130                 135                 140
Thr Asn Leu Ala Gly Ile Tyr Asp Ile Ala Tyr Val Leu Gly Asn Leu
145                 150                 155                 160
Ser Arg Asp Leu Ile Gly Asp Val Leu Asp Thr Val Gly Cys Ala Ala
                165                 170                 175
Cys Asp Asp Leu Gly Pro Asp Gly Ala Ala Ile Asp Arg Leu Asn Asp
            180                 185                 190
Gly Glu Pro Ile Val Gln Pro Gly Asn Asn Leu Thr Val Ile Ala Ser
        195                 200                 205
Arg Ser Asp Glu Leu Val Thr Pro Thr Thr Thr Ser Phe Val His Glu
    210                 215                 220
Asp Gly Val Thr Asn Glu Trp Val Gln Asp Thr Cys Pro Leu Asp Pro
225                 230                 235                 240
Val Gly His Ile Gly Glu Ala Tyr Asp Leu Asn Val Trp Asn Leu Val
                245                 250                 255
Lys Asn Ala Leu Asp Ser Thr Pro Lys Arg Glu Phe Val Cys Ser Leu
            260                 265                 270
Gly Ser Pro Gly Arg
        275
```

<210> 16
<211> 1881
<212> DNA
<213> Aspergillus niger

<400> 16
ccgagtgatc cgcgacttct gggtcagctt tgttctgcgg gctccaccag tgccgtcatc 60

gcacgcgaga cccgccccgg atgcttagct gaagccggca tagtccatcc ccgctcgggc 120
gtgatgccca acggtcactg gaggagaggt gcagggagga tgccgttgca tgaatcaagc 180
ccggggtttg actttcatcc gctcgtttcc tactggcggg ttcgccctct ccatcgaagc 240
cacggatcct tccatccgga tcctggcaga acagtgagga agcagagctt ggttatagta 300
gaaattatta ataccgagct ggtctgccca ttttttcccaa accttccctc tttccatccc 360
tctcgcctcg caccccctttt atcctccctc ccgccatgta tatcccctcg gtgctgcttc 420
tggccgcgag cctgttccat ggcgcaacgg cgctgcccac gcccggctcc acgcccatcc 480
cgcccagcca ggatccctgg tacagtgcgc ccgagggctt cgaggaggct gatcccggtg 540
ccatcctgcg cgtgcggccc gcgcccggca acttgaccgt ggtagtgggc aatgcgtcgg 600
cggcctacaa catcctctac cgcactacag acagtcagta caagccctcc tgggctgtga 660
ccaccctgct ggtgcccccc gtggccgcct ccgccgccgt caaccagagt gtcctgctct 720
cccaccagat cgcctacgat tcgttcgacg tcaatgccag tcccagctac gccatgtaca 780
ccagcccgcc ctccgatatt atcctcgccc tgcagcgcgg ctggttcgtt aacgtccccg 840
attacgaggg ccccaatgcc tctttcaccg ccggtgtgca gtccggccat gccaccctcg 900
actcggtccg cagcgtgctc gcctccggat tcggcctgaa cgaggacgcc cagtacgctc 960
tgtggggtta ctctggcggt gccttggcca gcgaatgggc tgctgaactg cagatgcaat 1020
acgctcccga gttgaacatt gccggtctgg ccgtgggtgg tctcactccc aatgttacca 1080
gcgtcatgga cacggtgacc tcgaccatca gtgcgggact catccccgcc gccgccctgg 1140
gtctgtcgag ccagcacccc gagacctacg agttcatcct cagccagctc aagacgacgg 1200
gaccctacaa ccgcacagga ttcctagccg ccaaggacct gaccctgtcc gaggcggagg 1260
tcttctacgc cttccagaac atcttcgatt actttgtcaa cggatcggcc acgttccagg 1320
cggaggtggt gcagaaggcg ctgaaccagg acggatacat gggctaccat gggttcccgc 1380
agatgccggt gctcgcgtac aaggctattc acgatgagat cagtcccatc caggatacgg 1440
atcgcgtgat caagcgctac tgtggtctgg gattgaacat cttgtatgag cggaacacca 1500
tcggtggcca ctcggcagag caggtgaatg gcaacgccag ggcgtggaac tggttgacga 1560
gcattttcga cggaacgtat gcgcagcagt acaagaccga ggggtgcacg atccgcaatg 1620
tcactctgaa cacgacttcc tccgtttatt agagaggggg ctgttgttat gtgaataatg 1680
ctgaagatgg ctgtgtatgg acggtccgct ctcctgtata gtaatgggct aatgcatgcg 1740
gcttcatgaa catggtacga aagattagat tatgtatata gtgtggaagt ggtaatgatg 1800
atataatatc tgtctatgat ctatgttcct gctattctat acaaacgcga ccattcacag 1860
aatgactact ggcacatctg c 1881

<210> 17
<211> 1257
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1257)

<400> 17
atg tat atc ccc tcg gtg ctg ctt ctg gcc gcg agc ctg ttc cat ggc 48

```
Met Tyr Ile Pro Ser Val Leu Leu Leu Ala Ala Ser Leu Phe His Gly
1               5                  10                  15
gca acg gcg ctg ccc acg ccc ggc tcc acg ccc atc ccg ccc agc cag      96
Ala Thr Ala Leu Pro Thr Pro Gly Ser Thr Pro Ile Pro Pro Ser Gln
            20                  25                  30
gat ccc tgg tac agt gcg ccc gag ggc ttc gag gag gct gat ccc ggt     144
Asp Pro Trp Tyr Ser Ala Pro Glu Gly Phe Glu Glu Ala Asp Pro Gly
        35                  40                  45
gcc atc ctg cgc gtg cgg ccc gcg ccc ggc aac ttg acc gtg gta gtg     192
Ala Ile Leu Arg Val Arg Pro Ala Pro Gly Asn Leu Thr Val Val Val
    50                  55                  60
ggc aat gcg tcg gcg gcc tac aac atc ctc tac cgc act aca gac agt     240
Gly Asn Ala Ser Ala Ala Tyr Asn Ile Leu Tyr Arg Thr Thr Asp Ser
65                  70                  75                  80
cag tac aag ccc tcc tgg gct gtg acc acc ctg ctg gtg ccc ccc gtg     288
Gln Tyr Lys Pro Ser Trp Ala Val Thr Thr Leu Leu Val Pro Pro Val
                85                  90                  95
gcc gcc tcc gcc gcc gtc aac cag agt gtc ctg ctc tcc cac cag atc     336
Ala Ala Ser Ala Ala Val Asn Gln Ser Val Leu Leu Ser His Gln Ile
            100                 105                 110
gcc tac gat tcg ttc gac gtc aat gcc agt ccc agc tac gcc atg tac     384
Ala Tyr Asp Ser Phe Asp Val Asn Ala Ser Pro Ser Tyr Ala Met Tyr
        115                 120                 125
acc agc ccg ccc tcc gat att atc ctc gcc ctg cag cgc ggc tgg ttc     432
Thr Ser Pro Pro Ser Asp Ile Ile Leu Ala Leu Gln Arg Gly Trp Phe
    130                 135                 140
gtt aac gtc ccc gat tac gag ggc ccc aat gcc tct ttc acc gcc ggt     480
Val Asn Val Pro Asp Tyr Glu Gly Pro Asn Ala Ser Phe Thr Ala Gly
145                 150                 155                 160
gtg cag tcc ggc cat gcc acc ctc gac tcg gtc cgc agc gtg ctc gcc     528
Val Gln Ser Gly His Ala Thr Leu Asp Ser Val Arg Ser Val Leu Ala
                165                 170                 175
tcc gga ttc ggc ctg aac gag gac gcc cag tac gct ctg tgg ggt tac     576
Ser Gly Phe Gly Leu Asn Glu Asp Ala Gln Tyr Ala Leu Trp Gly Tyr
            180                 185                 190
tct ggc ggt gcc ttg gcc agc gaa tgg gct gct gaa ctg cag atg caa     624
Ser Gly Gly Ala Leu Ala Ser Glu Trp Ala Ala Glu Leu Gln Met Gln
        195                 200                 205
tac gct ccc gag ttg aac att gcc ggt ctg gcc gtg ggt ggt ctc act     672
Tyr Ala Pro Glu Leu Asn Ile Ala Gly Leu Ala Val Gly Gly Leu Thr
    210                 215                 220
ccc aat gtt acc agc gtc atg gac acg gtg acc tcg acc atc agt gcg     720
Pro Asn Val Thr Ser Val Met Asp Thr Val Thr Ser Thr Ile Ser Ala
225                 230                 235                 240
```

gga ctc atc ccc gcc gcc gcc ctg ggt ctg tcg agc cag cac ccc gag 768
Gly Leu Ile Pro Ala Ala Ala Leu Gly Leu Ser Ser Gln His Pro Glu
245 250 255

acc tac gag ttc atc ctc agc cag ctc aag acg acg gga ccc tac aac 816
Thr Tyr Glu Phe Ile Leu Ser Gln Leu Lys Thr Thr Gly Pro Tyr Asn
260 265 270

cgc aca gga ttc cta gcc gcc aag gac ctg acc ctg tcc gag gcg gag 864
Arg Thr Gly Phe Leu Ala Ala Lys Asp Leu Thr Leu Ser Glu Ala Glu
275 280 285

gtc ttc tac gcc ttc cag aac atc ttc gat tac ttt gtc aac gga tcg 912
Val Phe Tyr Ala Phe Gln Asn Ile Phe Asp Tyr Phe Val Asn Gly Ser
290 295 300

gcc acg ttc cag gcg gag gtg gtg cag aag gcg ctg aac cag gac gga 960
Ala Thr Phe Gln Ala Glu Val Val Gln Lys Ala Leu Asn Gln Asp Gly
305 310 315 320

tac atg ggc tac cat ggg ttc ccg cag atg ccg gtg ctc gcg tac aag 1008
Tyr Met Gly Tyr His Gly Phe Pro Gln Met Pro Val Leu Ala Tyr Lys
325 330 335

gct att cac gat gag atc agt ccc atc cag gat acg gat cgc gtg atc 1056
Ala Ile His Asp Glu Ile Ser Pro Ile Gln Asp Thr Asp Arg Val Ile
340 345 350

aag cgc tac tgt ggt ctg gga ttg aac atc ttg tat gag cgg aac acc 1104
Lys Arg Tyr Cys Gly Leu Gly Leu Asn Ile Leu Tyr Glu Arg Asn Thr
355 360 365

atc ggt ggc cac tcg gca gag cag gtg aat ggc aac gcc agg gcg tgg 1152
Ile Gly Gly His Ser Ala Glu Gln Val Asn Gly Asn Ala Arg Ala Trp
370 375 380

aac tgg ttg acg agc att ttc gac gga acg tat gcg cag cag tac aag 1200
Asn Trp Leu Thr Ser Ile Phe Asp Gly Thr Tyr Ala Gln Gln Tyr Lys
385 390 395 400

acc gag ggg tgc acg atc cgc aat gtc act ctg aac acg act tcc tcc 1248
Thr Glu Gly Cys Thr Ile Arg Asn Val Thr Leu Asn Thr Thr Ser Ser
405 410 415

gtt tat tag 1257
Val Tyr

<210> 18
<211> 418
<212> PRT
<213> Aspergillus niger

<400> 18
Met Tyr Ile Pro Ser Val Leu Leu Leu Ala Ala Ser Leu Phe His Gly

21078WO.ST25.txt

```
1               5                   10                  15
Ala Thr Ala Leu Pro Thr Pro Gly Ser Thr Pro Ile Pro Pro Ser Gln
            20                  25                  30
Asp Pro Trp Tyr Ser Ala Pro Glu Gly Phe Glu Glu Ala Asp Pro Gly
        35                  40                  45
Ala Ile Leu Arg Val Arg Pro Ala Pro Gly Asn Leu Thr Val Val Val
    50                  55                  60
Gly Asn Ala Ser Ala Ala Tyr Asn Ile Leu Tyr Arg Thr Thr Asp Ser
65                  70                  75                  80
Gln Tyr Lys Pro Ser Trp Ala Val Thr Thr Leu Leu Val Pro Pro Val
                85                  90                  95
Ala Ala Ser Ala Ala Val Asn Gln Ser Val Leu Leu Ser His Gln Ile
            100                 105                 110
Ala Tyr Asp Ser Phe Asp Val Asn Ala Ser Pro Ser Tyr Ala Met Tyr
        115                 120                 125
Thr Ser Pro Pro Ser Asp Ile Ile Leu Ala Leu Gln Arg Gly Trp Phe
    130                 135                 140
Val Asn Val Pro Asp Tyr Glu Gly Pro Asn Ala Ser Phe Thr Ala Gly
145                 150                 155                 160
Val Gln Ser Gly His Ala Thr Leu Asp Ser Val Arg Ser Val Leu Ala
                165                 170                 175
Ser Gly Phe Gly Leu Asn Glu Asp Ala Gln Tyr Ala Leu Trp Gly Tyr
            180                 185                 190
Ser Gly Gly Ala Leu Ala Ser Glu Trp Ala Ala Glu Leu Gln Met Gln
        195                 200                 205
Tyr Ala Pro Glu Leu Asn Ile Ala Gly Leu Ala Val Gly Gly Leu Thr
    210                 215                 220
Pro Asn Val Thr Ser Val Met Asp Thr Val Thr Ser Thr Ile Ser Ala
225                 230                 235                 240
Gly Leu Ile Pro Ala Ala Ala Leu Gly Leu Ser Ser Gln His Pro Glu
                245                 250                 255
Thr Tyr Glu Phe Ile Leu Ser Gln Leu Lys Thr Thr Gly Pro Tyr Asn
            260                 265                 270
Arg Thr Gly Phe Leu Ala Ala Lys Asp Leu Thr Leu Ser Glu Ala Glu
        275                 280                 285
Val Phe Tyr Ala Phe Gln Asn Ile Phe Asp Tyr Phe Val Asn Gly Ser
    290                 295                 300
Ala Thr Phe Gln Ala Glu Val Val Gln Lys Ala Leu Asn Gln Asp Gly
305                 310                 315                 320
Tyr Met Gly Tyr His Gly Phe Pro Gln Met Pro Val Leu Ala Tyr Lys
                325                 330                 335
Ala Ile His Asp Glu Ile Ser Pro Ile Gln Asp Thr Asp Arg Val Ile
            340                 345                 350
Lys Arg Tyr Cys Gly Leu Gly Leu Asn Ile Leu Tyr Glu Arg Asn Thr
```

21078WO.ST25.txt

```
            355                 360                 365
Ile Gly Gly His Ser Ala Glu Gln Val Asn Gly Asn Ala Arg Ala Trp
        370                 375                 380
Asn Trp Leu Thr Ser Ile Phe Asp Gly Thr Tyr Ala Gln Gln Tyr Lys
385                 390                 395                 400
Thr Glu Gly Cys Thr Ile Arg Asn Val Thr Leu Asn Thr Thr Ser Ser
                405                 410                 415
Val Tyr


<210> 19
<211> 2809
<212> DNA
<213> Aspergillus niger

<400> 19
agtaatgtat catttgaaag atcagtaaat gaaatctgct gcacaatgca cgctttgaga      60
acgacgatgc gaatcgtaga atgcccaagt cagtctgcgt ggtcagacga gacccataca     120
ttgcatatgt acaatctagt agtataatat ggtgtaaatc cccataacct gatactcata     180
cacactatca gggcttgggt acatgagcga agtagtccca acaatcaaac aatcatccaa     240
actccaagcc aaatgccagc gaaaacaaca aaagcacaac atgatgttac agtgcactag     300
ggaaaccaat ctgtgtcacc atcactcagg acaccagata taacgaaccc ccctcacaga     360
ccacgagtct tctccggatc catctgcacc tcatcaccgc taatttcctt gaccgtctca     420
aacgccggct tgcccgcata tagctgctgg gacgagctgg agccgccgcc ttccgtcgtc     480
gataccgaga tgggctggtt tccgcggaac cgcttgcgca tatcgatcag gccgcgtcta     540
tagaaggaca aacagttagt aaccctgatg acttggcggt gattgcgttt tacaagaagg     600
tagcggctct ttactcactt gcactcgctg aatcccttcc gcaattgctg gcatcgcatg     660
ggaagctcgt cgacgtacgg ctcactcaga cattcgcggg gcgagcgccg ttgcaccatg     720
atgcagtctg attcttggag acattgggcc agagcatttc ctgttcatcc aggtgagatt     780
gattagagag tgtggagctg aagctgaagt tggggacaat gaggtggtga tctccgttcg     840
gggatacgtc gagtatccaa gccgcaattt aagagtatgg taaaggatat aagggtcaaa     900
cgtactgatc tcttggcagg aactcggcat tttggcgaac aacaatggcc gaattgctca     960
gccaactgac aagcaggaac aataccggtc tgcggcggcg gacatctgga gataatttgt    1020
ctgatcggaa aacaaactca accaacgggc cttgccccgg attaggtaag ccatcacatg    1080
aagaaggccc ccatgacgtc tggggggaat cctgacttgc tgcttgttcc gcttgattta    1140
tcctcttccc ctagtcatgc ggtcttgggt ctttgaagca ttgcttcggc gcattatggt    1200
tcactactac tactgcaggt gataagtatt ttagttggtt gatttgcaaa ttgtccatcc    1260
cttttcgata ataggaggtt tggtcttaat cgtcatggcg cgcgttccgg tcattggacg    1320
gctgttttgg ttcgagtatt tggccctttt tgggtcgctg atttggtat tgctggaatg     1380
ggttatacat attatcacat tctgtctgcg taagtagtgt gttcattctc tggaattgtg    1440
gtctatgtcg aggggcaaga gctaactgac gcagctgaac ctgttattaa gttctgttac    1500
gatcgatcca agactatctt caacgccttc attcctcccg atgacccggc taagcgcggt    1560
aaagaagaga aaattgctgc gtcggttgct ctggcgtcgg acttcacgga tatatgcgcg    1620
ctgttcggat atgaggcgga ggaacatatc gtccagacag gggatggcta tctgcttggt    1680
```

ctgcaccgac tgccctatcg gaaaggagag gaggggagga agatcaacca gggcgaaggg 1740
agcatcaaga agaaggtcgt ctatctccac catggtctca tgatgtgcag tgaagtctgg 1800
atctgtctgt cagaggagca gcgatgcctt ccgtttcaat tagtcgaaag gggctatgac 1860
gtgtggttgg ggaacaatag aggaaacaag tactcgaaga agtccgtcaa gcattcgccc 1920
ctgtcgaacg agttctggga cttttcgatc gatcagttct cgttccatga tatcccagac 1980
agcatcaagt atatcctgga agtgacaggg cagccctccc tgtcatacgt ggggttctcg 2040
cagggaacag cgcaggcatt tgcgacgctg tccattcatc ctttgttgaa tcagaagatc 2100
gatgtctttg tggctctcgc gccggcaatg gctccgacag gtcttccaaa tcatctcgtg 2160
gactcgctca tgaaggcttc gccgaacttc ctgtttctgc tgtttggcag acgcagcatc 2220
cttagctcaa cgacgatgtg gcagacaatt ctctacccgc ctatctttgt ttggatcatc 2280
gacacgtcac ttcgcggcct gttcaattgg aggtgcaaga acatcagccg ctggcagaag 2340
ctggcagggt acctgcatct gttttccttc actagcacca agtcggtcgt ccattggttc 2400
cagattattc ggcaccggaa tttccagttc tacgatgacg aaatccatgc cccgctcagt 2460
attgtggcca gtgagcgatt ttacaagccg gtcaagtacc cgactaagaa cattaagacg 2520
cccattgtcc tgttgtatgg cggtagcgat agtctcgttg atatcaacgt gatgttgtcc 2580
gagctccctc gcgggaccgt ggcgaaggaa atcccgcagt atgagcattt agatttcttg 2640
tgggcgcgtg atgtggacca attggtattc aaccatgtct tcgaagcgct ggagcggtac 2700
agctcggaga atcagaaagg gacattgatg gagaaggtta atggtgccgc gggcacatat 2760
gtaccgacat aaagtacgag gtcctgcacc aatgaagaca cgcataatc 2809

<210> 20
<211> 1413
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1413)

<400> 20
atg gcg cgc gtt ccg gtc att gga cgg ctg ttt tgg ttc gag tat ttg 48
Met Ala Arg Val Pro Val Ile Gly Arg Leu Phe Trp Phe Glu Tyr Leu
1 5 10 15
gcc ctt ttt ggg tcg ctg att ttg gta ttg ctg gaa tgg gtt ata cat 96
Ala Leu Phe Gly Ser Leu Ile Leu Val Leu Leu Glu Trp Val Ile His
20 25 30
att atc aca ttc tgt ctg cct gaa cct gtt att aag ttc tgt tac gat 144
Ile Ile Thr Phe Cys Leu Pro Glu Pro Val Ile Lys Phe Cys Tyr Asp
35 40 45
cga tcc aag act atc ttc aac gcc ttc att cct ccc gat gac ccg gct 192
Arg Ser Lys Thr Ile Phe Asn Ala Phe Ile Pro Pro Asp Asp Pro Ala
50 55 60
aag cgc ggt aaa gaa gag aaa att gct gcg tcg gtt gct ctg gcg tcg 240

```
Lys Arg Gly Lys Glu Glu Lys Ile Ala Ala Ser Val Ala Leu Ala Ser
65                  70                  75                  80
gac ttc acg gat ata tgc gcg ctg ttc gga tat gag gcg gag gaa cat      288
Asp Phe Thr Asp Ile Cys Ala Leu Phe Gly Tyr Glu Ala Glu Glu His
                85                  90                  95
atc gtc cag aca ggg gat ggc tat ctg ctt ggt ctg cac cga ctg ccc      336
Ile Val Gln Thr Gly Asp Gly Tyr Leu Leu Gly Leu His Arg Leu Pro
            100                 105                 110
tat cgg aaa gga gag gag ggg agg aag atc aac cag ggc gaa ggg agc      384
Tyr Arg Lys Gly Glu Glu Gly Arg Lys Ile Asn Gln Gly Glu Gly Ser
        115                 120                 125
atc aag aag aag gtc gtc tat ctc cac cat ggt ctc atg atg tgc agt      432
Ile Lys Lys Lys Val Val Tyr Leu His His Gly Leu Met Met Cys Ser
    130                 135                 140
gaa gtc tgg atc tgt ctg tca gag gag cag cga tgc ctt ccg ttt caa      480
Glu Val Trp Ile Cys Leu Ser Glu Glu Gln Arg Cys Leu Pro Phe Gln
145                 150                 155                 160
tta gtc gaa agg ggc tat gac gtg tgg ttg ggg aac aat aga gga aac      528
Leu Val Glu Arg Gly Tyr Asp Val Trp Leu Gly Asn Asn Arg Gly Asn
                165                 170                 175
aag tac tcg aag aag tcc gtc aag cat tcg ccc ctg tcg aac gag ttc      576
Lys Tyr Ser Lys Lys Ser Val Lys His Ser Pro Leu Ser Asn Glu Phe
            180                 185                 190
tgg gac ttt tcg atc gat cag ttc tcg ttc cat gat atc cca gac agc      624
Trp Asp Phe Ser Ile Asp Gln Phe Ser Phe His Asp Ile Pro Asp Ser
        195                 200                 205
atc aag tat atc ctg gaa gtg aca ggg cag ccc tcc ctg tca tac gtg      672
Ile Lys Tyr Ile Leu Glu Val Thr Gly Gln Pro Ser Leu Ser Tyr Val
    210                 215                 220
ggg ttc tcg cag gga aca gcg cag gca ttt gcg acg ctg tcc att cat      720
Gly Phe Ser Gln Gly Thr Ala Gln Ala Phe Ala Thr Leu Ser Ile His
225                 230                 235                 240
cct ttg ttg aat cag aag atc gat gtc ttt gtg gct ctc gcg ccg gca      768
Pro Leu Leu Asn Gln Lys Ile Asp Val Phe Val Ala Leu Ala Pro Ala
                245                 250                 255
atg gct ccg aca ggt ctt cca aat cat ctc gtg gac tcg ctc atg aag      816
Met Ala Pro Thr Gly Leu Pro Asn His Leu Val Asp Ser Leu Met Lys
            260                 265                 270
gct tcg ccg aac ttc ctg ttt ctg ctg ttt ggc aga cgc agc atc ctt      864
Ala Ser Pro Asn Phe Leu Phe Leu Leu Phe Gly Arg Arg Ser Ile Leu
        275                 280                 285
agc tca acg acg atg tgg cag aca att ctc tac ccg cct atc ttt gtt      912
Ser Ser Thr Thr Met Trp Gln Thr Ile Leu Tyr Pro Pro Ile Phe Val
    290                 295                 300
```

```
tgg atc atc gac acg tca ctt cgc ggc ctg ttc aat tgg agg tgc aag      960
Trp Ile Ile Asp Thr Ser Leu Arg Gly Leu Phe Asn Trp Arg Cys Lys
305                 310                 315                 320
aac atc agc cgc tgg cag aag ctg gca ggg tac ctg cat ctg ttt tcc      1008
Asn Ile Ser Arg Trp Gln Lys Leu Ala Gly Tyr Leu His Leu Phe Ser
                325                 330                 335
ttc act agc acc aag tcg gtc gtc cat tgg ttc cag att att cgg cac      1056
Phe Thr Ser Thr Lys Ser Val Val His Trp Phe Gln Ile Ile Arg His
            340                 345                 350
cgg aat ttc cag ttc tac gat gac gaa atc cat gcc ccg ctc agt att      1104
Arg Asn Phe Gln Phe Tyr Asp Asp Glu Ile His Ala Pro Leu Ser Ile
        355                 360                 365
gtg gcc agt gag cga ttt tac aag ccg gtc aag tac ccg act aag aac      1152
Val Ala Ser Glu Arg Phe Tyr Lys Pro Val Lys Tyr Pro Thr Lys Asn
    370                 375                 380
att aag acg ccc att gtc ctg ttg tat ggc ggt agc gat agt ctc gtt      1200
Ile Lys Thr Pro Ile Val Leu Leu Tyr Gly Gly Ser Asp Ser Leu Val
385                 390                 395                 400
gat atc aac gtg atg ttg tcc gag ctc cct cgc ggg acc gtg gcg aag      1248
Asp Ile Asn Val Met Leu Ser Glu Leu Pro Arg Gly Thr Val Ala Lys
                405                 410                 415
gaa atc ccg cag tat gag cat tta gat ttc ttg tgg gcg cgt gat gtg      1296
Glu Ile Pro Gln Tyr Glu His Leu Asp Phe Leu Trp Ala Arg Asp Val
            420                 425                 430
gac caa ttg gta ttc aac cat gtc ttc gaa gcg ctg gag cgg tac agc      1344
Asp Gln Leu Val Phe Asn His Val Phe Glu Ala Leu Glu Arg Tyr Ser
        435                 440                 445
tcg gag aat cag aaa ggg aca ttg atg gag aag gtt aat ggt gcc gcg      1392
Ser Glu Asn Gln Lys Gly Thr Leu Met Glu Lys Val Asn Gly Ala Ala
    450                 455                 460
ggc aca tat gta ccg aca taa                                         1413
Gly Thr Tyr Val Pro Thr
465                 470
```

<210> 21
<211> 470
<212> PRT
<213> Aspergillus niger

<400> 21
Met Ala Arg Val Pro Val Ile Gly Arg Leu Phe Trp Phe Glu Tyr Leu
1   5   10   15
Ala Leu Phe Gly Ser Leu Ile Leu Val Leu Leu Glu Trp Val Ile His

```
            20                  25                  30
Ile Ile Thr Phe Cys Leu Pro Glu Pro Val Ile Lys Phe Cys Tyr Asp
        35                  40                  45
Arg Ser Lys Thr Ile Phe Asn Ala Phe Ile Pro Pro Asp Asp Pro Ala
    50                  55                  60
Lys Arg Gly Lys Glu Glu Lys Ile Ala Ala Ser Val Ala Leu Ala Ser
65                  70                  75                  80
Asp Phe Thr Asp Ile Cys Ala Leu Phe Gly Tyr Glu Ala Glu Glu His
                85                  90                  95
Ile Val Gln Thr Gly Asp Gly Tyr Leu Leu Gly Leu His Arg Leu Pro
            100                 105                 110
Tyr Arg Lys Gly Glu Glu Gly Arg Lys Ile Asn Gln Gly Glu Gly Ser
        115                 120                 125
Ile Lys Lys Lys Val Val Tyr Leu His His Gly Leu Met Met Cys Ser
    130                 135                 140
Glu Val Trp Ile Cys Leu Ser Glu Glu Gln Arg Cys Leu Pro Phe Gln
145                 150                 155                 160
Leu Val Glu Arg Gly Tyr Asp Val Trp Leu Gly Asn Asn Arg Gly Asn
                165                 170                 175
Lys Tyr Ser Lys Lys Ser Val Lys His Ser Pro Leu Ser Asn Glu Phe
            180                 185                 190
Trp Asp Phe Ser Ile Asp Gln Phe Ser Phe His Asp Ile Pro Asp Ser
        195                 200                 205
Ile Lys Tyr Ile Leu Glu Val Thr Gly Gln Pro Ser Leu Ser Tyr Val
    210                 215                 220
Gly Phe Ser Gln Gly Thr Ala Gln Ala Phe Ala Thr Leu Ser Ile His
225                 230                 235                 240
Pro Leu Leu Asn Gln Lys Ile Asp Val Phe Val Ala Leu Ala Pro Ala
                245                 250                 255
Met Ala Pro Thr Gly Leu Pro Asn His Leu Val Asp Ser Leu Met Lys
            260                 265                 270
Ala Ser Pro Asn Phe Leu Phe Leu Leu Phe Gly Arg Arg Ser Ile Leu
        275                 280                 285
Ser Ser Thr Thr Met Trp Gln Thr Ile Leu Tyr Pro Pro Ile Phe Val
    290                 295                 300
Trp Ile Ile Asp Thr Ser Leu Arg Gly Leu Phe Asn Trp Arg Cys Lys
305                 310                 315                 320
Asn Ile Ser Arg Trp Gln Lys Leu Ala Gly Tyr Leu His Leu Phe Ser
                325                 330                 335
Phe Thr Ser Thr Lys Ser Val Val His Trp Phe Gln Ile Ile Arg His
            340                 345                 350
Arg Asn Phe Gln Phe Tyr Asp Asp Glu Ile His Ala Pro Leu Ser Ile
        355                 360                 365
Val Ala Ser Glu Arg Phe Tyr Lys Pro Val Lys Tyr Pro Thr Lys Asn
```

370 375 380
Ile Lys Thr Pro Ile Val Leu Leu Tyr Gly Gly Ser Asp Ser Leu Val
385 390 395 400
Asp Ile Asn Val Met Leu Ser Glu Leu Pro Arg Gly Thr Val Ala Lys
405 410 415
Glu Ile Pro Gln Tyr Glu His Leu Asp Phe Leu Trp Ala Arg Asp Val
420 425 430
Asp Gln Leu Val Phe Asn His Val Phe Glu Ala Leu Glu Arg Tyr Ser
435 440 445
Ser Glu Asn Gln Lys Gly Thr Leu Met Glu Lys Val Asn Gly Ala Ala
450 455 460
Gly Thr Tyr Val Pro Thr
465 470

<210> 22
<211> 3328
<212> DNA
<213> Aspergillus niger

<400> 22
gatttatgaa gacaggggag ctctcagtag atgatcttcg cacaattgca cttcctgggg 60
agcctgttta gtctctagtg aattattgat agacaggtca tctgcctcga gggggttcta 120
ctaacaacgt gatatctatg ttgctccttt actttagaag aaaggttctg cttggtagct 180
ggaacccagt atatagttga tgtgagtata tgaagattcc aatgctttgg aatattccgc 240
cgtggctgaa tgatgggact ctcactgcca agccaaggga ttcctcccga aatttttgca 300
catatgttgt tgatgcctta tccctctggc attcactcgt tgctgcctcg ggtgggaccc 360
gacagtcctc aaacgatgaa atcttattgg ctctgctagt tgagctcggt ttcaccattt 420
ctattggcgc tttctcactc tactccatat tacagcttcc gctttgcaat gcggggctgt 480
gctgcgactt tgaattgctc gcatagcaag agacactgac cagcaatcca gctcttctgc 540
ccacatatgt tgcctttgcc ttagtatctc ataatttatg tgtccagtga gacagtttgt 600
ttgtactgta gcttgagttg ggaatcgtgt cctgtgacca tggaaatata tattctggat 660
ctcagaacat ctctaccgtt tgtaattttt gatatacttc ccaggatggg acaatgggga 720
cgatgagtat tgggatgcca tatcacttga aagcctctta gacagactgc acctattttt 780
attatgctaa attctttacg agacactttc ttcaagtttc tggccctttg tgaggcagag 840
tgaaacacga gcgttcaaac ttgtgttgta gatgtttatg atatttatct cagacagtct 900
ttccacatcc tgtaatcccc aacagaaaaa gatacacagt atatcactag aagctcctaa 960
tagttatcat gctgcaccct aacagcaatg cagtcaccct gctgcgtcag cgaccccgat 1020
tccggagaag tatccgagat agcgataagg atgcggagat aagattggca agtggagatg 1080
agaaagatat cctcggcctc agaagtaggc ccgatgataa ataactagtg aacaagtccc 1140
ccgcccttct ccgagcaaac tacacttcaa catgctgaat gcacgctcca ttgctctggc 1200
ctcgttgcca gttcttctcc tactattcgc ccagcaactt gcctctcacc caaccgagca 1260
gattcaagcc attctggctc cgtgggtccc ggccgcacta caagatgtcg tgctctataa 1320
tcgacctcgc gtcataatcc cccagggcac tgtcgtcggc acgaccttga cagacacgct 1380

caagtccccg gtagatgctt tccgaggaat tccatacgca ttgcctccaa ttggggatag 1440
acggtttcgc cgtgcggagg ctgtccatgc gacggacgag attatcgatg ctagtgaatt 1500
cggcccaagg tatgcttctt atacgacatt cagatcatat ctgacctttc aggtgccctg 1560
gaaagcagct cttgaatcca aatgacatag gtggtgatga agactgtctc acagtcaatg 1620
tcttccggcc tcatggcgct cagggaaaac tccctgtcgc tgtatacgtg cacggcggag 1680
cctacaatcg cggcactggt aggtgtatca ccctcagtcc tctatatacc cacagctaaa 1740
tatccagcct ccggacacaa cacggcctcg atggtcggct ggtcggacga gcccttcgtt 1800
gcagtcagct tcaactaccg gtacgtcctc aaacctgtcc tccgaatcaa ctcaactaac 1860
aacccatcag catcggcgcc ctcggcttcc tcccatccac cctaaccgcc aaagaaggaa 1920
tcctcaacct aggcctccat gaccagatcc tcctgctgca atgggtccaa gaaaacatcg 1980
cacatttcaa cggcgaccca acccaagtca ctctaatcgg cctctccgcc ggcgcgcact 2040
ccgtatgccc ccttctaaga tacaaataga actcagtccc ctacccccaa actaacgcca 2100
cacagatagc ccaccacatc atgaactaca acccaccaaa cacccccctc tttcaccgcg 2160
ccatcatcga atccggcgcc gccacctccc gcgccgtcca cccctacaac gcctccctcc 2220
acgaatccca attcacagac ttcctcactg aaacgggctg cactaacctc cccgacactg 2280
ccattttgcc ctgtctccgc gccctcccat cctcagccat taccaccgcc tccatctccg 2340
tcttcgacaa atacaacccc tccatccgct gggccttcca acccgtcatc gaccacgaga 2400
tcatccaccg ccggcccatc gacgcctggc gctcaggaaa gtggaatagg atgcccatcc 2460
taacgggctt caactcgaac gaggggacat actacgtccc tcgcaacctc tctctctccg 2520
aggatttcac ttcgttcttc cgaaccctcc tccccgcgta ccccgagagc gacatccaga 2580
ccatcgatga gatctacccc gatccgaatg tatatgctac ggcgtcgcca tacctcgaga 2640
caaggccgat cccgagtcta ggaaggcagt ttaagcggct ggaggcggcg tatgggcatt 2700
atgcgtatgc gtgtccagta cggcagacgg cggggtttgt tgctaatgat gatggttgtg 2760
gtgagccggt gtttttgtat cgctgggcgt tgaataagac tgttattgga ggcgcgaacc 2820
atggtgatca gatggagtat gagacgttta atcctgcggt tagggatatt tcggaggctc 2880
agagggaggt tgcggggttg tttcatgcgt atgtgacttc gtttgtggtg catggggatc 2940
cgaatgttct gggggtagg tatgagggga gggaggtttg ggagaggtat agtggggagg 3000
gaggggaggt gatggtgttt ggggagggga atgatgaacg tgctgggggg gatggagttg 3060
gggttgcggc gaggttgaag agggatgagt ggggggtgaa ggagtgtgga ttttggtctg 3120
ggaggagtgg gatttccgag tgatggtttg tttatatata gtctagtgga aggggatgta 3180
tatactgtag tcactatctg tagaacttta cttggtgtgt agatagtaaa tactacaact 3240
gctgaagacc ttgggataga acgacatgct gtttaatcct caaccctgac tagatatatt 3300
gtgcattact tgcatccacg cctaacat 3328

<210> 23
<211> 1779
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1779)

21078WO.ST25.txt

<400> 23

```
atg ctg aat gca cgc tcc att gct ctg gcc tcg ttg cca gtt ctt ctc      48
Met Leu Asn Ala Arg Ser Ile Ala Leu Ala Ser Leu Pro Val Leu Leu
1               5                  10                  15
cta cta ttc gcc cag caa ctt gcc tct cac cca acc gag cag att caa      96
Leu Leu Phe Ala Gln Gln Leu Ala Ser His Pro Thr Glu Gln Ile Gln
            20                  25                  30
gcc att ctg gct ccg tgg gtc ccg gcc gca cta caa gat gtc gtg ctc     144
Ala Ile Leu Ala Pro Trp Val Pro Ala Ala Leu Gln Asp Val Val Leu
        35                  40                  45
tat aat cga cct cgc gtc ata atc ccc cag ggc act gtc gtc ggc acg     192
Tyr Asn Arg Pro Arg Val Ile Ile Pro Gln Gly Thr Val Val Gly Thr
    50                  55                  60
acc ttg aca gac acg ctc aag tcc ccg gta gat gct ttc cga gga att     240
Thr Leu Thr Asp Thr Leu Lys Ser Pro Val Asp Ala Phe Arg Gly Ile
65                  70                  75                  80
cca tac gca ttg cct cca att ggg gat aga cgg ttt cgc cgt gcg gag     288
Pro Tyr Ala Leu Pro Pro Ile Gly Asp Arg Arg Phe Arg Arg Ala Glu
                85                  90                  95
gct gtc cat gcg acg gac gag att atc gat gct agt gaa ttc ggc cca     336
Ala Val His Ala Thr Asp Glu Ile Ile Asp Ala Ser Glu Phe Gly Pro
            100                 105                 110
agg tgc cct gga aag cag ctc ttg aat cca aat gac ata ggt ggt gat     384
Arg Cys Pro Gly Lys Gln Leu Leu Asn Pro Asn Asp Ile Gly Gly Asp
        115                 120                 125
gaa gac tgt ctc aca gtc aat gtc ttc cgg cct cat ggc gct cag gga     432
Glu Asp Cys Leu Thr Val Asn Val Phe Arg Pro His Gly Ala Gln Gly
    130                 135                 140
aaa ctc cct gtc gct gta tac gtg cac ggc gga gcc tac aat cgc ggc     480
Lys Leu Pro Val Ala Val Tyr Val His Gly Gly Ala Tyr Asn Arg Gly
145                 150                 155                 160
act gct aaa tat cca gcc tcc gga cac aac acg gcc tcg atg gtc ggc     528
Thr Ala Lys Tyr Pro Ala Ser Gly His Asn Thr Ala Ser Met Val Gly
                165                 170                 175
tgg tcg gac gag ccc ttc gtt gca gtc agc ttc aac tac cgc atc ggc     576
Trp Ser Asp Glu Pro Phe Val Ala Val Ser Phe Asn Tyr Arg Ile Gly
            180                 185                 190
gcc ctc ggc ttc ctc cca tcc acc cta acc gcc aaa gaa gga atc ctc     624
Ala Leu Gly Phe Leu Pro Ser Thr Leu Thr Ala Lys Glu Gly Ile Leu
        195                 200                 205
aac cta ggc ctc cat gac cag atc ctc ctg ctg caa tgg gtc caa gaa     672
Asn Leu Gly Leu His Asp Gln Ile Leu Leu Leu Gln Trp Val Gln Glu
    210                 215                 220
aac atc gca cat ttc aac ggc gac cca acc caa gtc act cta atc ggc     720
```

```
Asn Ile Ala His Phe Asn Gly Asp Pro Thr Gln Val Thr Leu Ile Gly
225                 230                 235                 240
ctc tcc gcc ggc gcg cac tcc ata gcc cac cac atc atg aac tac aac       768
Leu Ser Ala Gly Ala His Ser Ile Ala His His Ile Met Asn Tyr Asn
                245                 250                 255
cca cca aac acc ccc ctc ttt cac cgc gcc atc atc gaa tcc ggc gcc       816
Pro Pro Asn Thr Pro Leu Phe His Arg Ala Ile Ile Glu Ser Gly Ala
            260                 265                 270
gcc acc tcc cgc gcc gtc cac ccc tac aac gcc tcc ctc cac gaa tcc       864
Ala Thr Ser Arg Ala Val His Pro Tyr Asn Ala Ser Leu His Glu Ser
        275                 280                 285
caa ttc aca gac ttc ctc act gaa acg ggc tgc act aac ctc ccc gac       912
Gln Phe Thr Asp Phe Leu Thr Glu Thr Gly Cys Thr Asn Leu Pro Asp
    290                 295                 300
act gcc att ttg ccc tgt ctc cgc gcc ctc cca tcc tca gcc att acc       960
Thr Ala Ile Leu Pro Cys Leu Arg Ala Leu Pro Ser Ser Ala Ile Thr
305                 310                 315                 320
acc gcc tcc atc tcc gtc ttc gac aaa tac aac ccc tcc atc cgc tgg      1008
Thr Ala Ser Ile Ser Val Phe Asp Lys Tyr Asn Pro Ser Ile Arg Trp
                325                 330                 335
gcc ttc caa ccc gtc atc gac cac gag atc atc cac cgc cgg ccc atc      1056
Ala Phe Gln Pro Val Ile Asp His Glu Ile Ile His Arg Arg Pro Ile
            340                 345                 350
gac gcc tgg cgc tca gga aag tgg aat agg atg ccc atc cta acg ggc      1104
Asp Ala Trp Arg Ser Gly Lys Trp Asn Arg Met Pro Ile Leu Thr Gly
        355                 360                 365
ttc aac tcg aac gag ggg aca tac tac gtc cct cgc aac ctc tct ctc      1152
Phe Asn Ser Asn Glu Gly Thr Tyr Tyr Val Pro Arg Asn Leu Ser Leu
    370                 375                 380
tcc gag gat ttc act tcg ttc ttc cga acc ctc ctc ccc gcg tac ccc      1200
Ser Glu Asp Phe Thr Ser Phe Phe Arg Thr Leu Leu Pro Ala Tyr Pro
385                 390                 395                 400
gag agc gac atc cag acc atc gat gag atc tac ccc gat ccg aat gta      1248
Glu Ser Asp Ile Gln Thr Ile Asp Glu Ile Tyr Pro Asp Pro Asn Val
                405                 410                 415
tat gct acg gcg tcg cca tac ctc gag aca agg ccg atc ccg agt cta      1296
Tyr Ala Thr Ala Ser Pro Tyr Leu Glu Thr Arg Pro Ile Pro Ser Leu
            420                 425                 430
gga agg cag ttt aag cgg ctg gag gcg gcg tat ggg cat tat gcg tat      1344
Gly Arg Gln Phe Lys Arg Leu Glu Ala Ala Tyr Gly His Tyr Ala Tyr
        435                 440                 445
gcg tgt cca gta cgg cag acg gcg ggg ttt gtt gct aat gat gat ggt      1392
Ala Cys Pro Val Arg Gln Thr Ala Gly Phe Val Ala Asn Asp Asp Gly
    450                 455                 460
```

```
tgt ggt gag ccg gtg ttt ttg tat cgc tgg gcg ttg aat aag act gtt      1440
Cys Gly Glu Pro Val Phe Leu Tyr Arg Trp Ala Leu Asn Lys Thr Val
465                 470                 475                 480
att gga ggc gcg aac cat ggt gat cag atg gag tat gag acg ttt aat      1488
Ile Gly Gly Ala Asn His Gly Asp Gln Met Glu Tyr Glu Thr Phe Asn
                485                 490                 495
cct gcg gtt agg gat att tcg gag gct cag agg gag gtt gcg ggg ttg      1536
Pro Ala Val Arg Asp Ile Ser Glu Ala Gln Arg Glu Val Ala Gly Leu
            500                 505                 510
ttt cat gcg tat gtg act tcg ttt gtg gtg cat ggg gat ccg aat gtt      1584
Phe His Ala Tyr Val Thr Ser Phe Val Val His Gly Asp Pro Asn Val
        515                 520                 525
ctg ggg ggt agg tat gag ggg agg gag gtt tgg gag agg tat agt ggg      1632
Leu Gly Gly Arg Tyr Glu Gly Arg Glu Val Trp Glu Arg Tyr Ser Gly
    530                 535                 540
gag gga ggg gag gtg atg gtg ttt ggg gag ggg aat gat gaa cgt gct      1680
Glu Gly Gly Glu Val Met Val Phe Gly Glu Gly Asn Asp Glu Arg Ala
545                 550                 555                 560
ggg ggg gat gga gtt ggg gtt gcg gcg agg ttg aag agg gat gag tgg      1728
Gly Gly Asp Gly Val Gly Val Ala Ala Arg Leu Lys Arg Asp Glu Trp
                565                 570                 575
ggg gtg aag gag tgt gga ttt tgg tct ggg agg agt ggg att tcc gag      1776
Gly Val Lys Glu Cys Gly Phe Trp Ser Gly Arg Ser Gly Ile Ser Glu
            580                 585                 590
tga                                                                  1779


<210> 24
<211> 592
<212> PRT
<213> Aspergillus niger

<400> 24
Met Leu Asn Ala Arg Ser Ile Ala Leu Ala Ser Leu Pro Val Leu Leu
1               5                   10                  15
Leu Leu Phe Ala Gln Gln Leu Ala Ser His Pro Thr Glu Gln Ile Gln
            20                  25                  30
Ala Ile Leu Ala Pro Trp Val Pro Ala Ala Leu Gln Asp Val Val Leu
        35                  40                  45
Tyr Asn Arg Pro Arg Val Ile Ile Pro Gln Gly Thr Val Val Gly Thr
    50                  55                  60
Thr Leu Thr Asp Thr Leu Lys Ser Pro Val Asp Ala Phe Arg Gly Ile
65                  70                  75                  80
Pro Tyr Ala Leu Pro Pro Ile Gly Asp Arg Arg Phe Arg Arg Ala Glu
```

85 90 95
Ala Val His Ala Thr Asp Glu Ile Ile Asp Ala Ser Glu Phe Gly Pro
100 105 110
Arg Cys Pro Gly Lys Gln Leu Leu Asn Pro Asn Asp Ile Gly Gly Asp
115 120 125
Glu Asp Cys Leu Thr Val Asn Val Phe Arg Pro His Gly Ala Gln Gly
130 135 140
Lys Leu Pro Val Ala Val Tyr Val His Gly Gly Ala Tyr Asn Arg Gly
145 150 155 160
Thr Ala Lys Tyr Pro Ala Ser Gly His Asn Thr Ala Ser Met Val Gly
165 170 175
Trp Ser Asp Glu Pro Phe Val Ala Val Ser Phe Asn Tyr Arg Ile Gly
180 185 190
Ala Leu Gly Phe Leu Pro Ser Thr Leu Thr Ala Lys Glu Gly Ile Leu
195 200 205
Asn Leu Gly Leu His Asp Gln Ile Leu Leu Leu Gln Trp Val Gln Glu
210 215 220
Asn Ile Ala His Phe Asn Gly Asp Pro Thr Gln Val Thr Leu Ile Gly
225 230 235 240
Leu Ser Ala Gly Ala His Ser Ile Ala His His Ile Met Asn Tyr Asn
245 250 255
Pro Pro Asn Thr Pro Leu Phe His Arg Ala Ile Ile Glu Ser Gly Ala
260 265 270
Ala Thr Ser Arg Ala Val His Pro Tyr Asn Ala Ser Leu His Glu Ser
275 280 285
Gln Phe Thr Asp Phe Leu Thr Glu Thr Gly Cys Thr Asn Leu Pro Asp
290 295 300
Thr Ala Ile Leu Pro Cys Leu Arg Ala Leu Pro Ser Ser Ala Ile Thr
305 310 315 320
Thr Ala Ser Ile Ser Val Phe Asp Lys Tyr Asn Pro Ser Ile Arg Trp
325 330 335
Ala Phe Gln Pro Val Ile Asp His Glu Ile Ile His Arg Arg Pro Ile
340 345 350
Asp Ala Trp Arg Ser Gly Lys Trp Asn Arg Met Pro Ile Leu Thr Gly
355 360 365
Phe Asn Ser Asn Glu Gly Thr Tyr Tyr Val Pro Arg Asn Leu Ser Leu
370 375 380
Ser Glu Asp Phe Thr Ser Phe Phe Arg Thr Leu Leu Pro Ala Tyr Pro
385 390 395 400
Glu Ser Asp Ile Gln Thr Ile Asp Glu Ile Tyr Pro Asp Pro Asn Val
405 410 415
Tyr Ala Thr Ala Ser Pro Tyr Leu Glu Thr Arg Pro Ile Pro Ser Leu
420 425 430
Gly Arg Gln Phe Lys Arg Leu Glu Ala Ala Tyr Gly His Tyr Ala Tyr

435 440 445
Ala Cys Pro Val Arg Gln Thr Ala Gly Phe Val Ala Asn Asp Asp Gly
450 455 460
Cys Gly Glu Pro Val Phe Leu Tyr Arg Trp Ala Leu Asn Lys Thr Val
465 470 475 480
Ile Gly Gly Ala Asn His Gly Asp Gln Met Glu Tyr Glu Thr Phe Asn
485 490 495
Pro Ala Val Arg Asp Ile Ser Glu Ala Gln Arg Glu Val Ala Gly Leu
500 505 510
Phe His Ala Tyr Val Thr Ser Phe Val Val His Gly Asp Pro Asn Val
515 520 525
Leu Gly Gly Arg Tyr Glu Gly Arg Glu Val Trp Glu Arg Tyr Ser Gly
530 535 540
Glu Gly Gly Glu Val Met Val Phe Gly Glu Gly Asn Asp Glu Arg Ala
545 550 555 560
Gly Gly Asp Gly Val Gly Val Ala Ala Arg Leu Lys Arg Asp Glu Trp
565 570 575
Gly Val Lys Glu Cys Gly Phe Trp Ser Gly Arg Ser Gly Ile Ser Glu
580 585 590

<210> 25
<211> 3932
<212> DNA
<213> Aspergillus niger

<400> 25
cagataacgt tttgagtttg gggatcttga ttatctcggc tccaaacaga ctcgcctatc 60
cgagagatca agtacataat gcaactagct attagtcaaa tataacgccg gcagaagtct 120
attttgtcct tttctctttc tttcctcgaa gaaaacccgt ggattaactt gagccggtcg 180
gcctcaaagt cggctcaacc ggcgcgttgc caactttaaa tgcagacaac catcgtttcc 240
ggccgttgtg ggggcgatgt agatcagatc caaattccca aaacatccat ggggtaaatc 300
aagaattgag gttacatcga ccgatagggc tcttaatcca accctcttca cggggaaaac 360
cttctatatg atacatggtt tactcctctg tttctcttcc tccccggagg tgccaaatcc 420
gggcgcatcg tgtctattct tagcaaccag cgaatttgac aaattgatcc aatcccatag 480
aatcagagta actctacaac ccaatcagtc gcctaatacg cacagcaaaa gaagatgcat 540
tcggacagcc aacgcaagaa aagagattaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 600
aaaaggcctc ccctcatcac ctcaccaaag tcgcaatcaa tcagcgacca ctagctacat 660
cgcgactgaa cgatagcatt ccgcatggtg ttaaagttca agacagttgc tatgcttgcc 720
cgaaccttta cacattcttg ccctttccgt agaattccaa gctcatcgga cagagagtag 780
tgtttctgtg aatgtggtgg tttaccaccg ttacctctgc tgtctatcac ttgctcctac 840
ccctgagcac aggcaccata gttacaacac ccccacgggg ccattgtctg ttttcagctt 900
cagcttcgtc gacaatggac tgtcatatcc cctcatctca aaagaatgtc ggaaacactg 960
tatggcatgg cgtgtgggaa ccgatcaatt tgtataatat cttaggccca cctcttcccc 1020
tccgagaggt ttgacatcag ggggtttcag agatagtccg tcgatattta tggcttcctc 1080

tgtcttcttg ccgctacttg cggcctcatt actgcccaca ctcgcttcta cacagaatgc 1140
cgatacaccg acatccgctc ctactgtgca agtccgcaat ggcacatacg agggtctcta 1200
taatcccacg tacaatcagg acttgttcct cggcataccg tatgcgcagc ctccggttgg 1260
tgagctacga ttccgtccac cacaaccgct caacacgacg tggactggca ctcgaaatgc 1320
aacagcctat tacaatgaat gtatcggtta tggtagcgac gactggtatt ggaccgacgt 1380
agtctccgaa gattgtctcg ctctcagtgt gattcgacct cacggcatcg actcaagcgc 1440
gaagctgccc gtcgtcttct ggatgcatgg tggagaattc gcagaaggag gcactcgcga 1500
ctcccgttac aacctctcct acatcgtcca acaatcccag gagatgcaat ctcccatcat 1560
tggcgtgact gtcaactacc gcctttcggg atggggattc ctctatagcc aggaagtcgc 1620
cgacgaaggc tccgccaact taggactccg cgaccaacgg cacgctctgt actggctcca 1680
agagaatatc gcttccttcg gcggcgaccc gtcgcggctc accatctggg gccaaagtgc 1740
cggtgccaac agcgtcggtc tccatttagt ggcatacgac ggccagaatg atggcatctt 1800
ccgtgccggg atcgccgaga gcggctccgt accctccctc gcagcataca tgagcgccga 1860
agatgcacaa ccatactatg atgccgtcgt caacgcaacc aactgcaccg gctcttccaa 1920
cacccttact tgtctccgtg aagttcccac cgacgtcctc agctccatct tcaacagctc 1980
cctcgtcgct ggggcaggat atcatcccgt cattgacggc gatttcctca gagcctcggg 2040
gatagttaat ctccagactg gccaattcgc caaaaccccg cttcttatcg gcaccaactt 2100
cgacgaaggg accaagtatg cccctcatgg ctataatacc accgaccaat ttgtctccct 2160
cgtccaagcc aacggaacca attataccag cgctctcacc attgcatccc tgtacccaga 2220
tgacccagcc gttggtattc cgggaaccct tcaaggtcgt cccccaccgt catacggtta 2280
ccagtggaag cgcgtggctg ccttcctcgg cgatctgctc atgcacgcgc ctcgccgcgt 2340
gacaacccag tggctggcac actggaatgt acctgcctac gtgtatcact ggaacgtgat 2400
gacactaggg ccattagatg gagccgcgca tggctatgaa gtcccccttca gtttccataa 2460
ttatgatggt ttgggcgatg aacggggaaa cgacagcgtg acctggccac aactatcgac 2520
tatgatgtca cggatgtggg tgagctttat taatcatttg gatccgaatt atagtaatag 2580
tgagtgattt gccccaccta cctctggaca ctgctttagg agcttgaggg taaggaagga 2640
tgctgacacg ctgctctgct agtgacggat atccactggc ctgtctacac aacagaaacc 2700
ccgcaaaata tggtctttga tgtcaatgtg actggactgg cttatgttga accagatacc 2760
tatagagcgg agggaattgc gtatatcact agcattctgc agagtgcctt taatcggtag 2820
ggtagactag aggcttcaat atcaatagat atcacacata caggagagca gcccatgttt 2880
ccctccagat caagagctat tccgttaaaa ggtagtgcat ccccgcaccg gggggaaggc 2940
cggggagtgc ttacctctgt gtgaaactag aattccagca acgatggttt tagaaaggcc 3000
agatctgttg actcattgtt tgatcctccg atgttgcatc cgagaaagct tctgcttggt 3060
cgtgccaagg atgttaacag ctgctgttga ggcaactcta gaaaccccat agacctttac 3120
tatctcgctg actagagggt acagtaggtc ctactttgaa ttccttggcg gttgggattt 3180
cgcggaaggt tgtctcaacc ctcaatgctt gtcacgacag acggcttggc aatgagacga 3240
gaccacgggc gattgacatg tgtcaagcag tagctatcgg gaatctgaaa aagcatggct 3300
gtcatggact ttgcaggcaa aggctgtctg ttctagacca tcggctagag cgcggtgagc 3360
atactaggcg agctgaaaag cctagaagcg gttgccggtt atccgctttg tttgtgccct 3420
ttccgtttcc gggcgtaggc aatcacattt aggcaatgcc gtgtgggcct tggagatctc 3480
acctaacctt attgcatttt acctcacggt gatacaacct gagtgactat cagggaaact 3540
gagcctattg atcatcacat attagcacca cacaaagctg ccaaggaaca atagtaatgt 3600
gagcgccaag gagatatctt tgaactttgt ctccagatct tgtactacat acccagccag 3660
acaggggttc gtatcgatgg ctccacagcg ggatatcatg aatcttcatg tcgtcacgac 3720

21078WO.ST25.txt

tcatacctcg agcgataggg ccgggtatta ctccatctgg aaattgtcat gactgtagag 3780
ctcagctgtc cgggatacga gcattatccg tcagtttata aattccaggg ccatcctgct 3840
caatctcaac atgtgggctc ttacgctgtc atcatattag ttagggtcca agagaatcac 3900
agaatcattg gcattgttct tcatcgttcc aa 3932

<210> 26
<211> 1518
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1518)

<400> 26
atg gct tcc tct gtc ttc ttg ccg cta ctt gcg gcc tca tta ctg ccc 48
Met Ala Ser Ser Val Phe Leu Pro Leu Leu Ala Ala Ser Leu Leu Pro
1 5 10 15
aca ctc gct tct aca cag aat gcc gat aca ccg aca tcc gct cct act 96
Thr Leu Ala Ser Thr Gln Asn Ala Asp Thr Pro Thr Ser Ala Pro Thr
20 25 30
gtg caa gtc cgc aat ggc aca tac gag ggt ctc tat aat ccc acg tac 144
Val Gln Val Arg Asn Gly Thr Tyr Glu Gly Leu Tyr Asn Pro Thr Tyr
35 40 45
aat cag gac ttg ttc ctc ggc ata ccg tat gcg cag cct ccg gtt ggt 192
Asn Gln Asp Leu Phe Leu Gly Ile Pro Tyr Ala Gln Pro Pro Val Gly
50 55 60
gag cta cga ttc cgt cca cca caa ccg ctc aac acg acg tgg act ggc 240
Glu Leu Arg Phe Arg Pro Pro Gln Pro Leu Asn Thr Thr Trp Thr Gly
65 70 75 80
act cga aat gca aca gcc tat tac aat gaa tgt atc ggt tat ggt agc 288
Thr Arg Asn Ala Thr Ala Tyr Tyr Asn Glu Cys Ile Gly Tyr Gly Ser
85 90 95
gac gac tgg tat tgg acc gac gta gtc tcc gaa gat tgt ctc gct ctc 336
Asp Asp Trp Tyr Trp Thr Asp Val Val Ser Glu Asp Cys Leu Ala Leu
100 105 110
agt gtg att cga cct cac ggc atc gac tca agc gcg aag ctg ccc gtc 384
Ser Val Ile Arg Pro His Gly Ile Asp Ser Ser Ala Lys Leu Pro Val
115 120 125
gtc ttc tgg atg cat ggt gga gaa ttc gca gaa gga ggc act cgc gac 432
Val Phe Trp Met His Gly Gly Glu Phe Ala Glu Gly Gly Thr Arg Asp
130 135 140
tcc cgt tac aac ctc tcc tac atc gtc caa caa tcc cag gag atg caa 480

```
Ser Arg Tyr Asn Leu Ser Tyr Ile Val Gln Gln Ser Gln Glu Met Gln
145                 150                 155                 160

tct ccc atc att ggc gtg act gtc aac tac cgc ctt tcg gga tgg gga      528
Ser Pro Ile Ile Gly Val Thr Val Asn Tyr Arg Leu Ser Gly Trp Gly
                165                 170                 175

ttc ctc tat agc cag gaa gtc gcc gac gaa ggc tcc gcc aac tta gga      576
Phe Leu Tyr Ser Gln Glu Val Ala Asp Glu Gly Ser Ala Asn Leu Gly
            180                 185                 190

ctc cgc gac caa cgg cac gct ctg tac tgg ctc caa gag aat atc gct      624
Leu Arg Asp Gln Arg His Ala Leu Tyr Trp Leu Gln Glu Asn Ile Ala
        195                 200                 205

tcc ttc ggc ggc gac ccg tcg cgg ctc acc atc tgg ggc caa agt gcc      672
Ser Phe Gly Gly Asp Pro Ser Arg Leu Thr Ile Trp Gly Gln Ser Ala
    210                 215                 220

ggt gcc aac agc gtc ggt ctc cat tta gtg gca tac gac ggc cag aat      720
Gly Ala Asn Ser Val Gly Leu His Leu Val Ala Tyr Asp Gly Gln Asn
225                 230                 235                 240

gat ggc atc ttc cgt gcc ggg atc gcc gag agc ggc tcc gta ccc tcc      768
Asp Gly Ile Phe Arg Ala Gly Ile Ala Glu Ser Gly Ser Val Pro Ser
                245                 250                 255

ctc gca gca tac atg agc gcc gaa gat gca caa cca tac tat gat gcc      816
Leu Ala Ala Tyr Met Ser Ala Glu Asp Ala Gln Pro Tyr Tyr Asp Ala
            260                 265                 270

gtc gtc aac gca acc aac tgc acc ggc tct tcc aac acc ctt act tgt      864
Val Val Asn Ala Thr Asn Cys Thr Gly Ser Ser Asn Thr Leu Thr Cys
        275                 280                 285

ctc cgt gaa gtt ccc acc gac gtc ctc agc tcc atc ttc aac agc tcc      912
Leu Arg Glu Val Pro Thr Asp Val Leu Ser Ser Ile Phe Asn Ser Ser
    290                 295                 300

ctc gtc gct ggg gca gga tat cat ccc gtc att gac ggc gat ttc ctc      960
Leu Val Ala Gly Ala Gly Tyr His Pro Val Ile Asp Gly Asp Phe Leu
305                 310                 315                 320

aga gcc tcg ggg ata gtt aat ctc cag act ggc caa ttc gcc aaa acc     1008
Arg Ala Ser Gly Ile Val Asn Leu Gln Thr Gly Gln Phe Ala Lys Thr
                325                 330                 335

ccg ctt ctt atc ggc acc aac ttc gac gaa ggg acc aag tat gcc cct     1056
Pro Leu Leu Ile Gly Thr Asn Phe Asp Glu Gly Thr Lys Tyr Ala Pro
            340                 345                 350

cat ggc tat aat acc acc gac caa ttt gtc tcc ctc gtc caa gcc aac     1104
His Gly Tyr Asn Thr Thr Asp Gln Phe Val Ser Leu Val Gln Ala Asn
        355                 360                 365

gga acc aat tat acc agc gct ctc acc att gca tcc ctg tac cca gat     1152
Gly Thr Asn Tyr Thr Ser Ala Leu Thr Ile Ala Ser Leu Tyr Pro Asp
    370                 375                 380
```

```
gac cca gcc gtt ggt att ccg gga acc ctt caa ggt cgt ccc cca ccg      1200
Asp Pro Ala Val Gly Ile Pro Gly Thr Leu Gln Gly Arg Pro Pro Pro
385                 390                 395                 400
tca tac ggt tac cag tgg aag cgc gtg gct gcc ttc ctc ggc gat ctg      1248
Ser Tyr Gly Tyr Gln Trp Lys Arg Val Ala Ala Phe Leu Gly Asp Leu
                405                 410                 415
ctc atg cac gcg cct cgc cgc gtg aca acc cag tgg ctg gca cac tgg      1296
Leu Met His Ala Pro Arg Arg Val Thr Thr Gln Trp Leu Ala His Trp
            420                 425                 430
aat gta cct gcc tac gtg tat cac tgg aac gtg atg aca cta ggg cca      1344
Asn Val Pro Ala Tyr Val Tyr His Trp Asn Val Met Thr Leu Gly Pro
        435                 440                 445
tta gat gga gcc gcg cat ggc tat gaa gtc ccc ttc agt ttc cat aat      1392
Leu Asp Gly Ala Ala His Gly Tyr Glu Val Pro Phe Ser Phe His Asn
    450                 455                 460
tat gat ggt ttg ggc gat gaa cgg gga aac gac agc gtg acc tgg cca      1440
Tyr Asp Gly Leu Gly Asp Glu Arg Gly Asn Asp Ser Val Thr Trp Pro
465                 470                 475                 480
caa cta tcg act atg atg tca cgg atg tgg gtg agc ttt att aat cat      1488
Gln Leu Ser Thr Met Met Ser Arg Met Trp Val Ser Phe Ile Asn His
                485                 490                 495
ttg gat ccg aat tat agt aat agt gag tga                              1518
Leu Asp Pro Asn Tyr Ser Asn Ser Glu
            500                 505
```

<210> 27
<211> 505
<212> PRT
<213> Aspergillus niger

<400> 27

```
Met Ala Ser Ser Val Phe Leu Pro Leu Leu Ala Ala Ser Leu Leu Pro
1               5                  10                  15
Thr Leu Ala Ser Thr Gln Asn Ala Asp Thr Pro Thr Ser Ala Pro Thr
            20                  25                  30
Val Gln Val Arg Asn Gly Thr Tyr Glu Gly Leu Tyr Asn Pro Thr Tyr
        35                  40                  45
Asn Gln Asp Leu Phe Leu Gly Ile Pro Tyr Ala Gln Pro Pro Val Gly
    50                  55                  60
Glu Leu Arg Phe Arg Pro Pro Gln Pro Leu Asn Thr Thr Trp Thr Gly
65                  70                  75                  80
Thr Arg Asn Ala Thr Ala Tyr Tyr Asn Glu Cys Ile Gly Tyr Gly Ser
                85                  90                  95
```

```
Asp Asp Trp Tyr Trp Thr Asp Val Val Ser Glu Asp Cys Leu Ala Leu
            100                 105                 110
Ser Val Ile Arg Pro His Gly Ile Asp Ser Ser Ala Lys Leu Pro Val
        115                 120                 125
Val Phe Trp Met His Gly Gly Glu Phe Ala Glu Gly Gly Thr Arg Asp
    130                 135                 140
Ser Arg Tyr Asn Leu Ser Tyr Ile Val Gln Gln Ser Gln Glu Met Gln
145                 150                 155                 160
Ser Pro Ile Ile Gly Val Thr Val Asn Tyr Arg Leu Ser Gly Trp Gly
                165                 170                 175
Phe Leu Tyr Ser Gln Glu Val Ala Asp Glu Gly Ser Ala Asn Leu Gly
            180                 185                 190
Leu Arg Asp Gln Arg His Ala Leu Tyr Trp Leu Gln Glu Asn Ile Ala
        195                 200                 205
Ser Phe Gly Gly Asp Pro Ser Arg Leu Thr Ile Trp Gly Gln Ser Ala
    210                 215                 220
Gly Ala Asn Ser Val Gly Leu His Leu Val Ala Tyr Asp Gly Gln Asn
225                 230                 235                 240
Asp Gly Ile Phe Arg Ala Gly Ile Ala Glu Ser Gly Ser Val Pro Ser
                245                 250                 255
Leu Ala Ala Tyr Met Ser Ala Glu Asp Ala Gln Pro Tyr Tyr Asp Ala
            260                 265                 270
Val Val Asn Ala Thr Asn Cys Thr Gly Ser Ser Asn Thr Leu Thr Cys
        275                 280                 285
Leu Arg Glu Val Pro Thr Asp Val Leu Ser Ser Ile Phe Asn Ser Ser
    290                 295                 300
Leu Val Ala Gly Ala Gly Tyr His Pro Val Ile Asp Gly Asp Phe Leu
305                 310                 315                 320
Arg Ala Ser Gly Ile Val Asn Leu Gln Thr Gly Gln Phe Ala Lys Thr
                325                 330                 335
Pro Leu Leu Ile Gly Thr Asn Phe Asp Glu Gly Thr Lys Tyr Ala Pro
            340                 345                 350
His Gly Tyr Asn Thr Thr Asp Gln Phe Val Ser Leu Val Gln Ala Asn
        355                 360                 365
Gly Thr Asn Tyr Thr Ser Ala Leu Thr Ile Ala Ser Leu Tyr Pro Asp
    370                 375                 380
Asp Pro Ala Val Gly Ile Pro Gly Thr Leu Gln Gly Arg Pro Pro Pro
385                 390                 395                 400
Ser Tyr Gly Tyr Gln Trp Lys Arg Val Ala Ala Phe Leu Gly Asp Leu
                405                 410                 415
Leu Met His Ala Pro Arg Arg Val Thr Thr Gln Trp Leu Ala His Trp
            420                 425                 430
Asn Val Pro Ala Tyr Val Tyr His Trp Asn Val Met Thr Leu Gly Pro
        435                 440                 445
```

Leu Asp Gly Ala Ala His Gly Tyr Glu Val Pro Phe Ser Phe His Asn
450 455 460
Tyr Asp Gly Leu Gly Asp Glu Arg Gly Asn Asp Ser Val Thr Trp Pro
465 470 475 480
Gln Leu Ser Thr Met Met Ser Arg Met Trp Val Ser Phe Ile Asn His
485 490 495
Leu Asp Pro Asn Tyr Ser Asn Ser Glu
500 505

<210> 28
<211> 3091
<212> DNA
<213> Aspergillus niger

<400> 28
ggcgaacggg cctgagcgtg cgtcggaggc agaagtagag ccgggactat ggatattggc 60
gaggaatata ttatagtaga ttatagggag tcgaatgcag ctcggattgg gttgttactt 120
tgagtcagat ggacattgtt ggaaaagatg aacgcgacgg gaaaaaaaca tgaggatttg 180
cggggatttc gtcacatgcg gaggcgcgga ttttcccctc cggatttact tcctcaactc 240
tcctttctct ttcatttcca tccgatttga gtccaactca tctcactcga agaatctcat 300
taatttcagg gtcctgctca gcccagtcaa ggttccttag tttcgatcct tcagttggcc 360
cgtcatgtcc attgaccagg aatggagcaa gccccgatga ggatcggcca gcggagacaa 420
ctgccaatcc ttggtatcca taccccttaac agcgcaatgg caccagctct ctgccgattc 480
acgtcatctg cacagcctag ctgccgatta ggcttgaccc cttctcactt gcggcatcag 540
tgccgctgat actagccccc acagagtgtt tctcccttcg actgtggctc ggaacgtggg 600
ggcgggttcc aagttcttat gcccagagtt ggttggctag ccttgctcat ctgggtggcc 660
agcacacctc ccatacaata ggatccgtgg tgttggcagg attcttgtca tttcgccatg 720
tcgaatcacc gcatgcggaa ggaggacgcc ttgccttgca atgttttctc cacatctgcg 780
accctattgt tcagaccctg gagccgattc cgcgagatgt attcctgccg ggccactgaa 840
agtgctttat aacgtctggg gtgtcctttt attgatgaga gcatgatctt tcgcgttaca 900
gttctcacaa tcggttaaag cattcgtggc cccgaggctc gttgcacaac acaatatgat 960
tttctttcat ctggcaccgt tcttctttct ctttggtcta gtagtatctt ctcagaaccc 1020
tacggtggac cttggctaca caagatataa aggcaaatct ctgcccaatg gtatcagtca 1080
gtggctgggg atacgctacg cggctgcacc taccgggtct ctgcggttct ctgcgccaca 1140
ggatcctgac acggtagatg gcgttcaaga agcattcaag gtatggtttt ttctacaata 1200
aataaaaaga tatattgcga gtctgtgctt tgctaatacc cagggcacag catggtcccc 1260
ggtgtgttcc caccagccaa tatcccactc ccgcaggcac gtccgaggat tgtctcttcc 1320
tcgatgtata cgctcccagc tcggtggaag ctactacgag gctgcccgtt ttcgtttgga 1380
ttcaaggagg cggcttcaat gccaactcca gccccaacta caatggaaca ggattgatcg 1440
aagcggccaa tatgtccatg gtggtggtca ccttcaacta cagggtcggt ccgtacgggt 1500
tcctctctgg atccgaggtg ctggagggag gaagcgtgaa caatggcctg aaggaccaaa 1560
tcaaggtcct gaagtgggtg caagagcata tcagcaaggt atgcggacac tcaccaaccc 1620
acagcaaatc accgctaatt gcagccgcag tttggaggcg atcccagtca cgttgttatc 1680

```
ggcggcgaca gcgcaggcgc agcgtctatc actctccatc tttcagccca cggtggcaga      1740
gacgacgaac tattccacgc tgccgccgca gagtcccaaa gctttgctcc tatgttgacc      1800
gtcaatcaaa gccaattcgc ctataacaac ctggtcatcc gcgccggctg cgcaagcgat      1860
tcagacaccc tcgcctgctt acgccgacta aacaccacag aactgcagcg catcaacatc      1920
aacacaccct tacccaccgc ccaacaagca cctctctacc tgtacggtcc cgtcgtcgac      1980
ggctccctca tcccagacta cacataccgg cttttccagc aaggcaaatt catcaaagtc      2040
cccgtaatct tcggcgacga caccaacgaa ggaacaatct tcgtccccaa aacgacctcc      2100
accgtcggcg aagccgacac cttcatccaa gaccaattcc ccaacatcaa cttcacccac      2160
ctaaccaagc tgaacgactg gtatctcaaa gaaaaccaaa ctcgcgagtt ccccaattcc      2220
tccccctact ggcgtcccgc tagcaccgcg tacggtgaaa tcagatatat ctgtccgggg      2280
atctacatgt cctctgtgtt tgctagtgcc ggtgtcaaca gctggaacta tcattatgct      2340
gtgcaggacc ccgccgcgga agcctcaggc agaggtgtca gtcatactgt ggaagaaaat      2400
gccatttggg gcccgcagta tgtgagtggc acaccgccgg cgtcgtatct cactgagaat      2460
gcgccaattg tgccggtgat gcagggctac tggacgagtt tcattagagt gtttgatccg      2520
aatccgctga ggtatccggg gagtccggag tggaagacgt ggagtgatgg acatggggag      2580
gattatcggc ggatatttgt ccgcacgaat gagacgagga tggagacggt gtcggaggcg      2640
cagagggaaa ggtgcgaata ttggagtagt gttgggccgg acttgtcgca gtgattgcac      2700
ttattatctt tgttcggtgg taaggtatat atatagatag tataatattg taagctatag      2760
agtgatggta cgtgaattga atatatggag aaagatggtc ttgtataaat caaaacattc      2820
tttttggct  gccattccac gatcatcatt cccaatgatc aaaccaagta actataaccg      2880
aatatataca tctatatcaa cctgcttctc atcagaatta ccaaaagacg ggtccggcac      2940
acacagctag accgagcaga tacgtcgaca tgaacccagg tgatgaaaca taatgcaaca      3000
aaagaaagag aaaagaaggc aaaacaagtg agaagcacta ctgctccaca tagagcagta      3060
aacgaacgat gaatgaggga tatcatcatc a                                     3091
```

<210> 29
<211> 1617
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1617)

<400> 29

```
atg att ttc ttt cat ctg gca ccg ttc ttc ttt ctc ttt ggt cta gta      48
Met Ile Phe Phe His Leu Ala Pro Phe Phe Phe Leu Phe Gly Leu Val
1               5                   10                  15

gta tct tct cag aac cct acg gtg gac ctt ggc tac aca aga tat aaa      96
Val Ser Ser Gln Asn Pro Thr Val Asp Leu Gly Tyr Thr Arg Tyr Lys
            20                  25                  30

ggc aaa tct ctg ccc aat ggt atc agt cag tgg ctg ggg ata cgc tac      144
Gly Lys Ser Leu Pro Asn Gly Ile Ser Gln Trp Leu Gly Ile Arg Tyr
```

```
        35                  40                  45
gcg gct gca cct acc ggg tct ctg cgg ttc tct gcg cca cag gat cct      192
Ala Ala Ala Pro Thr Gly Ser Leu Arg Phe Ser Ala Pro Gln Asp Pro
    50                  55                  60
gac acg gta gat ggc gtt caa gaa gca ttc aag cat ggt ccc cgg tgt      240
Asp Thr Val Asp Gly Val Gln Glu Ala Phe Lys His Gly Pro Arg Cys
65                  70                  75                  80
gtt ccc acc agc caa tat ccc act ccc gca ggc acg tcc gag gat tgt      288
Val Pro Thr Ser Gln Tyr Pro Thr Pro Ala Gly Thr Ser Glu Asp Cys
                85                  90                  95
ctc ttc ctc gat gta tac gct ccc agc tcg gtg gaa gct act acg agg      336
Leu Phe Leu Asp Val Tyr Ala Pro Ser Ser Val Glu Ala Thr Thr Arg
            100                 105                 110
ctg ccc gtt ttc gtt tgg att caa gga ggc ggc ttc aat gcc aac tcc      384
Leu Pro Val Phe Val Trp Ile Gln Gly Gly Gly Phe Asn Ala Asn Ser
        115                 120                 125
agc ccc aac tac aat gga aca gga ttg atc gaa gcg gcc aat atg tcc      432
Ser Pro Asn Tyr Asn Gly Thr Gly Leu Ile Glu Ala Ala Asn Met Ser
    130                 135                 140
atg gtg gtg gtc acc ttc aac tac agg gtc ggt ccg tac ggg ttc ctc      480
Met Val Val Val Thr Phe Asn Tyr Arg Val Gly Pro Tyr Gly Phe Leu
145                 150                 155                 160
tct gga tcc gag gtg ctg gag gga gga agc gtg aac aat ggc ctg aag      528
Ser Gly Ser Glu Val Leu Glu Gly Gly Ser Val Asn Asn Gly Leu Lys
                165                 170                 175
gac caa atc aag gtc ctg aag tgg gtg caa gag cat atc agc aag ttt      576
Asp Gln Ile Lys Val Leu Lys Trp Val Gln Glu His Ile Ser Lys Phe
            180                 185                 190
gga ggc gat ccc agt cac gtt gtt atc ggc ggc gac agc gca ggc gca      624
Gly Gly Asp Pro Ser His Val Val Ile Gly Gly Asp Ser Ala Gly Ala
        195                 200                 205
gcg tct atc act ctc cat ctt tca gcc cac ggt ggc aga gac gac gaa      672
Ala Ser Ile Thr Leu His Leu Ser Ala His Gly Gly Arg Asp Asp Glu
    210                 215                 220
cta ttc cac gct gcc gcc gca gag tcc caa agc ttt gct cct atg ttg      720
Leu Phe His Ala Ala Ala Ala Glu Ser Gln Ser Phe Ala Pro Met Leu
225                 230                 235                 240
acc gtc aat caa agc caa ttc gcc tat aac aac ctg gtc atc cgc gcc      768
Thr Val Asn Gln Ser Gln Phe Ala Tyr Asn Asn Leu Val Ile Arg Ala
                245                 250                 255
ggc tgc gca agc gat tca gac acc ctc gcc tgc tta cgc cga cta aac.     816
Gly Cys Ala Ser Asp Ser Asp Thr Leu Ala Cys Leu Arg Arg Leu Asn
            260                 265                 270
acc aca gaa ctg cag cgc atc aac atc aac aca ccc tta ccc acc gcc      864
```

```
Thr Thr Glu Leu Gln Arg Ile Asn Ile Asn Thr Pro Leu Pro Thr Ala
        275                 280                 285
caa caa gca cct ctc tac ctg tac ggt ccc gtc gtc gac ggc tcc ctc      912
Gln Gln Ala Pro Leu Tyr Leu Tyr Gly Pro Val Val Asp Gly Ser Leu
    290                 295                 300
atc cca gac tac aca tac cgg ctt ttc cag caa ggc aaa ttc atc aaa      960
Ile Pro Asp Tyr Thr Tyr Arg Leu Phe Gln Gln Gly Lys Phe Ile Lys
305                 310                 315                 320
gtc ccc gta atc ttc ggc gac gac acc aac gaa gga aca atc ttc gtc     1008
Val Pro Val Ile Phe Gly Asp Asp Thr Asn Glu Gly Thr Ile Phe Val
                325                 330                 335
ccc aaa acg acc tcc acc gtc ggc gaa gcc gac acc ttc atc caa gac     1056
Pro Lys Thr Thr Ser Thr Val Gly Glu Ala Asp Thr Phe Ile Gln Asp
            340                 345                 350
caa ttc ccc aac atc aac ttc acc cac cta acc aag ctg aac gac tgg     1104
Gln Phe Pro Asn Ile Asn Phe Thr His Leu Thr Lys Leu Asn Asp Trp
        355                 360                 365
tat ctc aaa gaa aac caa act cgc gag ttc ccc aat tcc tcc ccc tac     1152
Tyr Leu Lys Glu Asn Gln Thr Arg Glu Phe Pro Asn Ser Ser Pro Tyr
    370                 375                 380
tgg cgt ccc gct agc acc gcg tac ggt gaa atc aga tat atc tgt ccg     1200
Trp Arg Pro Ala Ser Thr Ala Tyr Gly Glu Ile Arg Tyr Ile Cys Pro
385                 390                 395                 400
ggg atc tac atg tcc tct gtg ttt gct agt gcc ggt gtc aac agc tgg     1248
Gly Ile Tyr Met Ser Ser Val Phe Ala Ser Ala Gly Val Asn Ser Trp
                405                 410                 415
aac tat cat tat gct gtg cag gac ccc gcc gcg gaa gcc tca ggc aga     1296
Asn Tyr His Tyr Ala Val Gln Asp Pro Ala Ala Glu Ala Ser Gly Arg
            420                 425                 430
ggt gtc agt cat act gtg gaa gaa aat gcc att tgg ggc ccg cag tat     1344
Gly Val Ser His Thr Val Glu Glu Asn Ala Ile Trp Gly Pro Gln Tyr
        435                 440                 445
gtg agt ggc aca ccg ccg gcg tcg tat ctc act gag aat gcg cca att     1392
Val Ser Gly Thr Pro Pro Ala Ser Tyr Leu Thr Glu Asn Ala Pro Ile
    450                 455                 460
gtg ccg gtg atg cag ggc tac tgg acg agt ttc att aga gtg ttt gat     1440
Val Pro Val Met Gln Gly Tyr Trp Thr Ser Phe Ile Arg Val Phe Asp
465                 470                 475                 480
ccg aat ccg ctg agg tat ccg ggg agt ccg gag tgg aag acg tgg agt     1488
Pro Asn Pro Leu Arg Tyr Pro Gly Ser Pro Glu Trp Lys Thr Trp Ser
                485                 490                 495
gat gga cat ggg gag gat tat cgg cgg ata ttt gtc cgc acg aat gag     1536
Asp Gly His Gly Glu Asp Tyr Arg Arg Ile Phe Val Arg Thr Asn Glu
            500                 505                 510
```

```
acg agg atg gag acg gtg tcg gag gcg cag agg gaa agg tgc gaa tat      1584
Thr Arg Met Glu Thr Val Ser Glu Ala Gln Arg Glu Arg Cys Glu Tyr
        515                 520                 525
tgg agt agt gtt ggg ccg gac ttg tcg cag tga                          1617
Trp Ser Ser Val Gly Pro Asp Leu Ser Gln
    530                 535
```

<210> 30
<211> 538
<212> PRT
<213> Aspergillus niger

<400> 30

```
Met Ile Phe Phe His Leu Ala Pro Phe Phe Phe Leu Phe Gly Leu Val
1               5                  10                  15
Val Ser Ser Gln Asn Pro Thr Val Asp Leu Gly Tyr Thr Arg Tyr Lys
            20                  25                  30
Gly Lys Ser Leu Pro Asn Gly Ile Ser Gln Trp Leu Gly Ile Arg Tyr
        35                  40                  45
Ala Ala Ala Pro Thr Gly Ser Leu Arg Phe Ser Ala Pro Gln Asp Pro
    50                  55                  60
Asp Thr Val Asp Gly Val Gln Glu Ala Phe Lys His Gly Pro Arg Cys
65                  70                  75                  80
Val Pro Thr Ser Gln Tyr Pro Thr Pro Ala Gly Thr Ser Glu Asp Cys
                85                  90                  95
Leu Phe Leu Asp Val Tyr Ala Pro Ser Ser Val Glu Ala Thr Thr Arg
            100                 105                 110
Leu Pro Val Phe Val Trp Ile Gln Gly Gly Gly Phe Asn Ala Asn Ser
        115                 120                 125
Ser Pro Asn Tyr Asn Gly Thr Gly Leu Ile Glu Ala Ala Asn Met Ser
    130                 135                 140
Met Val Val Val Thr Phe Asn Tyr Arg Val Gly Pro Tyr Gly Phe Leu
145                 150                 155                 160
Ser Gly Ser Glu Val Leu Glu Gly Gly Ser Val Asn Asn Gly Leu Lys
                165                 170                 175
Asp Gln Ile Lys Val Leu Lys Trp Val Gln Glu His Ile Ser Lys Phe
            180                 185                 190
Gly Gly Asp Pro Ser His Val Val Ile Gly Gly Asp Ser Ala Gly Ala
        195                 200                 205
Ala Ser Ile Thr Leu His Leu Ser Ala His Gly Gly Arg Asp Asp Glu
    210                 215                 220
Leu Phe His Ala Ala Ala Ala Glu Ser Gln Ser Phe Ala Pro Met Leu
225                 230                 235                 240
```

Thr Val Asn Gln Ser Gln Phe Ala Tyr Asn Asn Leu Val Ile Arg Ala
245 250 255
Gly Cys Ala Ser Asp Ser Asp Thr Leu Ala Cys Leu Arg Arg Leu Asn
260 265 270
Thr Thr Glu Leu Gln Arg Ile Asn Ile Asn Thr Pro Leu Pro Thr Ala
275 280 285
Gln Gln Ala Pro Leu Tyr Leu Tyr Gly Pro Val Val Asp Gly Ser Leu
290 295 300
Ile Pro Asp Tyr Thr Tyr Arg Leu Phe Gln Gln Gly Lys Phe Ile Lys
305 310 315 320
Val Pro Val Ile Phe Gly Asp Asp Thr Asn Glu Gly Thr Ile Phe Val
325 330 335
Pro Lys Thr Thr Ser Thr Val Gly Glu Ala Asp Thr Phe Ile Gln Asp
340 345 350
Gln Phe Pro Asn Ile Asn Phe Thr His Leu Thr Lys Leu Asn Asp Trp
355 360 365
Tyr Leu Lys Glu Asn Gln Thr Arg Glu Phe Pro Asn Ser Ser Pro Tyr
370 375 380
Trp Arg Pro Ala Ser Thr Ala Tyr Gly Glu Ile Arg Tyr Ile Cys Pro
385 390 395 400
Gly Ile Tyr Met Ser Ser Val Phe Ala Ser Ala Gly Val Asn Ser Trp
405 410 415
Asn Tyr His Tyr Ala Val Gln Asp Pro Ala Ala Glu Ala Ser Gly Arg
420 425 430
Gly Val Ser His Thr Val Glu Glu Asn Ala Ile Trp Gly Pro Gln Tyr
435 440 445
Val Ser Gly Thr Pro Pro Ala Ser Tyr Leu Thr Glu Asn Ala Pro Ile
450 455 460
Val Pro Val Met Gln Gly Tyr Trp Thr Ser Phe Ile Arg Val Phe Asp
465 470 475 480
Pro Asn Pro Leu Arg Tyr Pro Gly Ser Pro Glu Trp Lys Thr Trp Ser
485 490 495
Asp Gly His Gly Glu Asp Tyr Arg Arg Ile Phe Val Arg Thr Asn Glu
500 505 510
Thr Arg Met Glu Thr Val Ser Glu Ala Gln Arg Glu Arg Cys Glu Tyr
515 520 525
Trp Ser Ser Val Gly Pro Asp Leu Ser Gln
530 535

<210> 31
<211> 4575
<212> DNA
<213> Aspergillus niger

<400> 31

gatgcaactt cagtgaaatt gagacgattg taactcatca tcgcatctca catggaaagg 60
ttgtacaccc aacaattaga cctcaacata tttcacggat attcctgcaa gatatataat 120
aaagccatca ctccactttg gtagatatgt tagccaaccg ggtttgagcg agtttcttga 180
atggactcat taagggtagg atcaattctg atgtccacaa ttggtcccta tttgccagat 240
gtaggcccag agaattcggt atcttgcaga tttgcgatgc tatcccggtt tccagtaaac 300
tattaggttc ggctcggtca caccagacag acacgactga cccatgcgct gccaggaatc 360
ctgataggcc tagcagtccc gcgtgcacat atcggcttgg tagaaaagga tagccgtgaa 420
tgtataatct ttcagatgac ggttaaatgc gtttctgtat ggtgagaagc tgtgtagatg 480
ggagatgagc tgtaaatggc ttcgcagtgg caacctctag gctgctgcag gccggaatac 540
tgcatggcgt gattttcgtc gtgaatcttg ttcatataca ggtgtaaaac acacgtaagg 600
aaaatcttgt tatagcaggg ttgaaaacag ttgctagaat tggcagtgac tgttgcggtt 660
gcaagggttt attttgcacc cttgaagtac actgcgcttg gtcaaaggca aatcacccca 720
tcaagtaata aatatatatc tctgttatca agtcggctcc tctagtagtg cagcctcagt 780
acagacaaca gggactaaca gcactcttgc tgttgagctt gagcgcacct caccttttctc 840
tccggcctct ttcgtatttg gcatttcaat ggcctgttat gggacttctg agcctgcttg 900
attgagtgat atggtagtgc gagcgcaaaa aaggtgattt tcaaacacca tgatgcaaag 960
tcagaggtaa gtgcgagagg gagatcagga ggaggagagc tttatataag gccgcgtagg 1020
cggcagagac ggcaagacat ctggtgaagt accagcattc agtgaatttt ataacagtat 1080
tatttgtcat cacgactctg cattgccttt aataagctcg gcgtaatttg gtagggaccc 1140
taggtttgga tagccccagg ggggcttggt gtcggttgtg gagcttgctg cccgagattc 1200
attttacacc tagtcaggga tccgggcggg ttttatacct ccctggaggc ggaatgtacc 1260
tttgttatca ctgaaaattc cggccatttt gttctatttt actggctatg gggtttgcca 1320
ctatcgctca catcctcgca aggcacctcc cgatactgca gtcaaacgtg ggagttgccg 1380
atagaaacta caagatcaaa tctcgttccc tgggttggac ggtcacattc ggtgaaagag 1440
gtttatcttc gctccaacca gcctttcatg tcgggcgctc agtgcataag atccaagcaa 1500
ttttaagcac tgtactccac tagtcacact gttttagcag tgcatgcttc tgaatcagga 1560
ctaaactccg atttttctca gtgaatactg ctaaagacaa ttatgatcct acagactatc 1620
tctgtgaaaa agcgcagtta acttctcgtc aatcatgaag ccattttgag cctttctccg 1680
tcaatcattc acccctactg ttgactatat cagccctaag ggaataaaac atttgccgta 1740
gaggtgaact ataactcaat caatgactga aagcttaacg tatctcacaa ttcatctcac 1800
cgtgaagagt catttacatt tacgatccag ccaggccgcg ctgacatcag caggcgtgag 1860
agcgcatcca tgcttgctcg gacataagcc gaatccattg catgatgcga ccttcccgaa 1920
agagtatggg tgtccgaact gaccatgtca gtggccccat atggctctca actacacgaa 1980
cacagacctt tatcagtccc ggtccccaca acttaaatcc ggagatgcgg gggtgcagga 2040
atggaacacg gatacatgtg tggaatgtag gaccaaacaa attggctgtc gtggacattc 2100
gactcgactt gacccctcaa tgcgctggcc ggaggactga gccatagggt ataagaacac 2160
cgtgatcact catgcctcgt tatcgctttt ctatcattat gtctcgatat caggaagaca 2220
tagcatgacc gtgaacacga tgaagggaat gctcccgacg cttagttggt tggcactggg 2280
catggccagc ctggcaacct gcaccaaccc agtagcccag acaaagaacg gaagttatta 2340
tggtgtctac atgcctcagt ataatgagga ttattttctt ggaattccat ttgctaagcc 2400
cccgttggca cacttgcgtt gggccaaccc cgagagtctt aatgagtctt ggtcgggatt 2460
gcgccctgct accggctatg cgatggtaag tagcctgaac agactgctaa acgaccatgt 2520

```
acttactaac agcgcgtgtg ataggaatgt ataggttacg gcagtgatca aaaaggttat      2580
ctgcaggtga ggatttgacg ccactttctt tacgctgttc tctactaacc agcaaaatag      2640
agcgaggact gtctctacct aaacgtggtc cgtcccgctg aatacgacaa tgccagtctt      2700
ccagtccttg tatggattca tggtatgtag tgaaatctac ctcaacgaca agttactccc      2760
gacgctgaat gaacaaaaca ggcggtggct tcgcacaagg cggcactccc gaccttcgat      2820
acaatcttac atttattgtt gaacactcgg tcaatatcgg ccagccaatt atcgcagtga      2880
gcgttgccta tcgtctcggt ccttggggtt tcttcaatgg ggtcgagctc gccaatgagg      2940
gatcgttaaa tctcgggctg aaggaccagc gcttggccct gcattgggtg aaagagaaca      3000
ttgcaggttt cggtggtggg tttccataaa gctattaaac gtacacagtc caaaattact      3060
aatgacagtc actcctatac aggcgaccct agtaaagtcg tgatttacgg acaaagtgcc      3120
ggctccgaaa gcgtgggata ccaaatccgc gcgtacaacg gccgagatga cgggctcttc      3180
cgcggaggca tgatggagtc cggcgcggtg ttacctggca gtgccttgaa cctcacctgg      3240
acatatgagc cttggttcca gcaaatagca gacgaggcag gatgttccca gaccacccgc      3300
aaactggact gtctacgccg cacgcccttc acagtcctaa acaacattct gaacaccacc      3360
gccaacgaca cgacgcctta caactggagg cccacagtgg acggtgactt cgtagcgcga      3420
tatcccagcg agcaactcga cacaggagac ttcgtcaaag taccaatcat aatcggctac      3480
accacggacg aaggaacaac agagtgccca gaaccagtga acaccaccgc cgaattaaaa      3540
gaatacctca gctgtacgta cctccttccc ttcctccctt atcccccat ccccatccca      3600
ataacaccaa cccagcaaca acaacctacg gctgggccct cgactcacag gtagtatcct      3660
cgctcctgga cctctacccc aacaccacct ccttcggcat cccatcatcc gaagaactcg      3720
gcggcaacgt caccttccca cagccctacg gcgccgcatt ccgccagacg gcagcatact      3780
acggcgacgc ccagttcata gccgcgacgc gctacacctg tgagctatgg gcggcacata      3840
acctgacagc atattgctac cgattcaaca ccaagacaga cgattacaac agggaagaag      3900
gcgtggcgca tttctcggac gtgatcttca tcttcaacaa ccttaatggt tatgggttca      3960
gtccgaaccc gttcaccaat gctccagaga gctatactga gcttagctac ctcatgtccg      4020
gctcgtggat cagcttcact aatagtctgg atcctaataa gtggactggt cgcggaagga      4080
acgctacgaa gacggagaat tggcccgtgt atgatctgga gaatcccttg agtatgatct      4140
gggatgcgaa tgtcacttcg tatgcggcgc cggatacttg gcgtaaggag ggtattgcgt      4200
tgattaatgc taatcggagg gcgtatcaga ggtgaatgtg gtgtagcttg cagccgttgc      4260
ctacttgttc gactttcaaa ctcaaaactt tctattgaga gagaaaattg tgcgaggaaa      4320
gtactaccgc gggcagaaca ctctgcgcac aggtccatat ctacaaactc actgaacaga      4380
gtctatagca gattaggtag attgtcaagc ttacatacag acataacccc accacaatat      4440
cgtggtaaga tagcacattt ctttaaagaa gaaaaaaaaa gatgaataca tataatcggc      4500
tacgtcaata attcaaaaca gaatatgtca gctgtgcaca catccgacca ttacactagt      4560
aaagtgagcg gcggc                                                       4575
```

<210> 32
<211> 1695
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS

<222> (1)..(1695)

<400> 32

```
atg aag gga atg ctc ccg acg ctt agt tgg ttg gca ctg ggc atg gcc      48
Met Lys Gly Met Leu Pro Thr Leu Ser Trp Leu Ala Leu Gly Met Ala
1               5                  10                  15
agc ctg gca acc tgc acc aac cca gta gcc cag aca aag aac gga agt      96
Ser Leu Ala Thr Cys Thr Asn Pro Val Ala Gln Thr Lys Asn Gly Ser
            20                  25                  30
tat tat ggt gtc tac atg cct cag tat aat gag gat tat ttt ctt gga     144
Tyr Tyr Gly Val Tyr Met Pro Gln Tyr Asn Glu Asp Tyr Phe Leu Gly
        35                  40                  45
att cca ttt gct aag ccc ccg ttg gca cac ttg cgt tgg gcc aac ccc     192
Ile Pro Phe Ala Lys Pro Pro Leu Ala His Leu Arg Trp Ala Asn Pro
    50                  55                  60
gag agt ctt aat gag tct tgg tcg gga ttg cgc cct gct acc ggc tat     240
Glu Ser Leu Asn Glu Ser Trp Ser Gly Leu Arg Pro Ala Thr Gly Tyr
65                  70                  75                  80
gcg atg gaa tgt ata ggt tac ggc agt gat caa aaa ggt tat ctg cag     288
Ala Met Glu Cys Ile Gly Tyr Gly Ser Asp Gln Lys Gly Tyr Leu Gln
                85                  90                  95
agc gag gac tgt ctc tac cta aac gtg gtc cgt ccc gct gaa tac gac     336
Ser Glu Asp Cys Leu Tyr Leu Asn Val Val Arg Pro Ala Glu Tyr Asp
            100                 105                 110
aat gcc agt ctt cca gtc ctt gta tgg att cat ggc ggt ggc ttc gca     384
Asn Ala Ser Leu Pro Val Leu Val Trp Ile His Gly Gly Gly Phe Ala
        115                 120                 125
caa ggc ggc act ccc gac ctt cga tac aat ctt aca ttt att gtt gaa     432
Gln Gly Gly Thr Pro Asp Leu Arg Tyr Asn Leu Thr Phe Ile Val Glu
    130                 135                 140
cac tcg gtc aat atc ggc cag cca att atc gca gtg agc gtt gcc tat     480
His Ser Val Asn Ile Gly Gln Pro Ile Ile Ala Val Ser Val Ala Tyr
145                 150                 155                 160
cgt ctc ggt cct tgg ggt ttc ttc aat ggg gtc gag ctc gcc aat gag     528
Arg Leu Gly Pro Trp Gly Phe Phe Asn Gly Val Glu Leu Ala Asn Glu
                165                 170                 175
gga tcg tta aat ctc ggg ctg aag gac cag cgc ttg gcc ctg cat tgg     576
Gly Ser Leu Asn Leu Gly Leu Lys Asp Gln Arg Leu Ala Leu His Trp
            180                 185                 190
gtg aaa gag aac att gca ggt ttc ggt ggc gac cct agt aaa gtc gtg     624
Val Lys Glu Asn Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Val
        195                 200                 205
att tac gga caa agt gcc ggc tcc gaa agc gtg gga tac caa atc cgc     672
Ile Tyr Gly Gln Ser Ala Gly Ser Glu Ser Val Gly Tyr Gln Ile Arg
```

```
    210                 215                 220
gcg tac aac ggc cga gat gac ggg ctc ttc cgc gga ggc atg atg gag      720
Ala Tyr Asn Gly Arg Asp Asp Gly Leu Phe Arg Gly Gly Met Met Glu
225                 230                 235                 240
tcc ggc gcg gtg tta cct ggc agt gcc ttg aac ctc acc tgg aca tat      768
Ser Gly Ala Val Leu Pro Gly Ser Ala Leu Asn Leu Thr Trp Thr Tyr
                245                 250                 255
gag cct tgg ttc cag caa ata gca gac gag gca gga tgt tcc cag acc      816
Glu Pro Trp Phe Gln Gln Ile Ala Asp Glu Ala Gly Cys Ser Gln Thr
            260                 265                 270
acc cgc aaa ctg gac tgt cta cgc cgc acg ccc ttc aca gtc cta aac      864
Thr Arg Lys Leu Asp Cys Leu Arg Arg Thr Pro Phe Thr Val Leu Asn
        275                 280                 285
aac att ctg aac acc acc gcc aac gac acg acg cct tac aac tgg agg      912
Asn Ile Leu Asn Thr Thr Ala Asn Asp Thr Thr Pro Tyr Asn Trp Arg
    290                 295                 300
ccc aca gtg gac ggt gac ttc gta gcg cga tat ccc agc gag caa ctc      960
Pro Thr Val Asp Gly Asp Phe Val Ala Arg Tyr Pro Ser Glu Gln Leu
305                 310                 315                 320
gac aca gga gac ttc gtc aaa gta cca atc ata atc ggc tac acc acg     1008
Asp Thr Gly Asp Phe Val Lys Val Pro Ile Ile Ile Gly Tyr Thr Thr
                325                 330                 335
gac gaa gga aca aca gag tgc cca gaa cca gtg aac acc acc gcc gaa     1056
Asp Glu Gly Thr Thr Glu Cys Pro Glu Pro Val Asn Thr Thr Ala Glu
            340                 345                 350
tta aaa gaa tac ctc agc tca aca aca acc tac ggc tgg gcc ctc gac     1104
Leu Lys Glu Tyr Leu Ser Ser Thr Thr Thr Tyr Gly Trp Ala Leu Asp
        355                 360                 365
tca cag gta gta tcc tcg ctc ctg gac ctc tac ccc aac acc acc tcc     1152
Ser Gln Val Val Ser Ser Leu Leu Asp Leu Tyr Pro Asn Thr Thr Ser
    370                 375                 380
ttc ggc atc cca tca tcc gaa gaa ctc ggc ggc aac gtc acc ttc cca     1200
Phe Gly Ile Pro Ser Ser Glu Glu Leu Gly Gly Asn Val Thr Phe Pro
385                 390                 395                 400
cag ccc tac ggc gcc gca ttc cgc cag acg gca gca tac tac ggc gac     1248
Gln Pro Tyr Gly Ala Ala Phe Arg Gln Thr Ala Ala Tyr Tyr Gly Asp
                405                 410                 415
gcc cag ttc ata gcc gcg acg cgc tac acc tgt gag cta tgg gcg gca     1296
Ala Gln Phe Ile Ala Ala Thr Arg Tyr Thr Cys Glu Leu Trp Ala Ala
            420                 425                 430
cat aac ctg aca gca tat tgc tac cga ttc aac acc aag aca gac gat     1344
His Asn Leu Thr Ala Tyr Cys Tyr Arg Phe Asn Thr Lys Thr Asp Asp
        435                 440                 445
tac aac agg gaa gaa ggc gtg gcg cat ttc tcg gac gtg atc ttc atc     1392
```

```
Tyr Asn Arg Glu Glu Gly Val Ala His Phe Ser Asp Val Ile Phe Ile
    450                 455                 460
ttc aac aac ctt aat ggt tat ggg ttc agt ccg aac ccg ttc acc aat      1440
Phe Asn Asn Leu Asn Gly Tyr Gly Phe Ser Pro Asn Pro Phe Thr Asn
465                 470                 475                 480
gct cca gag agc tat act gag ctt agc tac ctc atg tcc ggc tcg tgg      1488
Ala Pro Glu Ser Tyr Thr Glu Leu Ser Tyr Leu Met Ser Gly Ser Trp
                485                 490                 495
atc agc ttc act aat agt ctg gat cct aat aag tgg act ggt cgc gga      1536
Ile Ser Phe Thr Asn Ser Leu Asp Pro Asn Lys Trp Thr Gly Arg Gly
            500                 505                 510
agg aac gct acg aag acg gag aat tgg ccc gtg tat gat ctg gag aat      1584
Arg Asn Ala Thr Lys Thr Glu Asn Trp Pro Val Tyr Asp Leu Glu Asn
        515                 520                 525
ccc ttg agt atg atc tgg gat gcg aat gtc act tcg tat gcg gcg ccg      1632
Pro Leu Ser Met Ile Trp Asp Ala Asn Val Thr Ser Tyr Ala Ala Pro
    530                 535                 540
gat act tgg cgt aag gag ggt att gcg ttg att aat gct aat cgg agg      1680
Asp Thr Trp Arg Lys Glu Gly Ile Ala Leu Ile Asn Ala Asn Arg Arg
545                 550                 555                 560
gcg tat cag agg tga                                                  1695
Ala Tyr Gln Arg
```

<210> 33
<211> 564
<212> PRT
<213> Aspergillus niger

<400> 33

```
Met Lys Gly Met Leu Pro Thr Leu Ser Trp Leu Ala Leu Gly Met Ala
1               5                   10                  15
Ser Leu Ala Thr Cys Thr Asn Pro Val Ala Gln Thr Lys Asn Gly Ser
            20                  25                  30
Tyr Tyr Gly Val Tyr Met Pro Gln Tyr Asn Glu Asp Tyr Phe Leu Gly
        35                  40                  45
Ile Pro Phe Ala Lys Pro Pro Leu Ala His Leu Arg Trp Ala Asn Pro
    50                  55                  60
Glu Ser Leu Asn Glu Ser Trp Ser Gly Leu Arg Pro Ala Thr Gly Tyr
65                  70                  75                  80
Ala Met Glu Cys Ile Gly Tyr Gly Ser Asp Gln Lys Gly Tyr Leu Gln
                85                  90                  95
Ser Glu Asp Cys Leu Tyr Leu Asn Val Val Arg Pro Ala Glu Tyr Asp
            100                 105                 110
```

Asn Ala Ser Leu Pro Val Leu Val Trp Ile His Gly Gly Gly Phe Ala
115 120 125
Gln Gly Gly Thr Pro Asp Leu Arg Tyr Asn Leu Thr Phe Ile Val Glu
130 135 140
His Ser Val Asn Ile Gly Gln Pro Ile Ile Ala Val Ser Val Ala Tyr
145 150 155 160
Arg Leu Gly Pro Trp Gly Phe Phe Asn Gly Val Glu Leu Ala Asn Glu
165 170 175
Gly Ser Leu Asn Leu Gly Leu Lys Asp Gln Arg Leu Ala Leu His Trp
180 185 190
Val Lys Glu Asn Ile Ala Gly Phe Gly Gly Asp Pro Ser Lys Val Val
195 200 205
Ile Tyr Gly Gln Ser Ala Gly Ser Glu Ser Val Gly Tyr Gln Ile Arg
210 215 220
Ala Tyr Asn Gly Arg Asp Asp Gly Leu Phe Arg Gly Gly Met Met Glu
225 230 235 240
Ser Gly Ala Val Leu Pro Gly Ser Ala Leu Asn Leu Thr Trp Thr Tyr
245 250 255
Glu Pro Trp Phe Gln Gln Ile Ala Asp Glu Ala Gly Cys Ser Gln Thr
260 265 270
Thr Arg Lys Leu Asp Cys Leu Arg Arg Thr Pro Phe Thr Val Leu Asn
275 280 285
Asn Ile Leu Asn Thr Thr Ala Asn Asp Thr Thr Pro Tyr Asn Trp Arg
290 295 300
Pro Thr Val Asp Gly Asp Phe Val Ala Arg Tyr Pro Ser Glu Gln Leu
305 310 315 320
Asp Thr Gly Asp Phe Val Lys Val Pro Ile Ile Ile Gly Tyr Thr Thr
325 330 335
Asp Glu Gly Thr Thr Glu Cys Pro Glu Pro Val Asn Thr Thr Ala Glu
340 345 350
Leu Lys Glu Tyr Leu Ser Ser Thr Thr Thr Tyr Gly Trp Ala Leu Asp
355 360 365
Ser Gln Val Val Ser Ser Leu Leu Asp Leu Tyr Pro Asn Thr Thr Ser
370 375 380
Phe Gly Ile Pro Ser Ser Glu Glu Leu Gly Gly Asn Val Thr Phe Pro
385 390 395 400
Gln Pro Tyr Gly Ala Ala Phe Arg Gln Thr Ala Ala Tyr Tyr Gly Asp
405 410 415
Ala Gln Phe Ile Ala Ala Thr Arg Tyr Thr Cys Glu Leu Trp Ala Ala
420 425 430
His Asn Leu Thr Ala Tyr Cys Tyr Arg Phe Asn Thr Lys Thr Asp Asp
435 440 445
Tyr Asn Arg Glu Glu Gly Val Ala His Phe Ser Asp Val Ile Phe Ile
450 455 460

Phe Asn Asn Leu Asn Gly Tyr Gly Phe Ser Pro Asn Pro Phe Thr Asn
465 470 475 480
Ala Pro Glu Ser Tyr Thr Glu Leu Ser Tyr Leu Met Ser Gly Ser Trp
485 490 495
Ile Ser Phe Thr Asn Ser Leu Asp Pro Asn Lys Trp Thr Gly Arg Gly
500 505 510
Arg Asn Ala Thr Lys Thr Glu Asn Trp Pro Val Tyr Asp Leu Glu Asn
515 520 525
Pro Leu Ser Met Ile Trp Asp Ala Asn Val Thr Ser Tyr Ala Ala Pro
530 535 540
Asp Thr Trp Arg Lys Glu Gly Ile Ala Leu Ile Asn Ala Asn Arg Arg
545 550 555 560
Ala Tyr Gln Arg

<210> 34
<211> 2371
<212> DNA
<213> Aspergillus niger

<400> 34
gccctgacat ggacggtgtc agatagagac cgttggaagg ctgaaccaca gggcacacgg 60
cacgttgagg accctgcatg ccggtgtatc cggataatgg cagataatcc cggctaattg 120
ggggcgacgg cagctacggc tcacaaattg tgatggaata gacacggcat gatgtttcaa 180
tgaagctcca aactttacag tgctaggctg taaacgtgat tataatcacg atgtaattga 240
ttatcatcta caactcaacc cccgcaccaa gaaatgaatc ctctcgtcgg aagaaaaaga 300
cggcattcca gaagaacttt ttcctagata acaaacagta atcagtccat ccgtccctga 360
cgatcccccc atcgaacctc ggtaagacgc tcgacccaaa aaccagaccg acaagctttt 420
caacctccct aaacgaaaca acggctgtgt tgatcgtgaa cgtggttgcc tataccaata 480
cgagaaccat ataggataga aattgagttt accgtggaaa agccacccgc tacagtttaa 540
ttaaccaacc cacccacatg cccaaggcac ctgtaacagg gactactgtc cagagagtgg 600
atagtggcta gtgggcagac gtcggatgaa ctccggaaga ccctaactga tacgtagaac 660
catcgtgaac cctggtttgt cctagttcg gggcgctatt ccccagcgtag aaaagcggcc 720
gatcctctga aacagttttc ccccggggta tacttgctag ttagtcacta tcatacaaaa 780
gtagtgtagt ggacaagacc agggtctact actattagtt agttctgttt catcccgact 840
caattttgcg tcccaagacc ctgggttgtc cgggcctgtc ttgcccaaca cgagatgtat 900
ggagtaagta tggagggaga ctaacctcgg aatattcttg tctcttttta gtactatcta 960
gcccttagtg agactatagc agtagtgaac cagagagaga gagagatgtc tatataagta 1020
cagtcgtaga tccctaaaca tgaccagctt cagactcaga ctcgagcagc cagtgcagtc 1080
cagtccactc tttcattctc accccttctt tactatctta caataatttc tattcaataa 1140
gtctgcagtg cagcacccac acacattcat tctctgagag ataaaaaata acaaaatggc 1200
ccccctcaaa tccctcctcc tcggcgcctc cctggccacc ctcgcccttt ccaccccact 1260
ggcaaccgac gccgaaaacc tctacgcacg tcaattcggc acgggctcta cagccaacga 1320
actcgagcag ggaagctgca aggatgtgac tctcatcttt gcgaggggggt caactgagct 1380

tgggaatatg gtatgcttgt tgcctgcctt tacccgtact atactatccc agaacatacc 1440
aagcacaaca tcacaaaaca tgtggagcca ggagctaatc agtggtggtg atgatatgat 1500
gtagggcacc gtaatcggcc cccctctctg cgacaacctg aaatccaaac tcggatccga 1560
caaagtcgcc tgccagggtg tcggcggcca atacagcgcc ggactcgtgc agaatgccct 1620
gccccagaac accgatccgg ggagtatctc cgccgcgaag cagatgttcg aggaggcgaa 1680
ttcgaagtgt cccaatacta agattgttgc gggtggttat aggtatatat ccctttcccc 1740
tttaccttcc cccatatcaa tgctagaggc aaaggaatat catgctaatg tagatgttgg 1800
ggaaacagtc aaggaagcgc tgtgattgac aacgccgtgc aagaactcag caccaccgtg 1860
aaagaccaag tgaagggtgt cgtgctcttc gggttcacga gaaacgtgca ggatcacggg 1920
cagatcccta attaccctaa ggatgacgtg aaggtttatt gtgccgtggg cgatctggtc 1980
tgtgatgata cgttggttgt tacggcgatg catctgacgt atggcatgga tgcgggtgat 2040
gcggcgagct ttttggccga gaaggtgcag tcttccagta gttcgactac tagctccagc 2100
tcggatgccg cgagtagttc atctgctgcg gggacgtcgt cgtcggggtt gtcgggactg 2160
tcttcttttt ttggaggtct ctaaatagaa ttagatgaga tgagtggtcc gggtgggggt 2220
ttaggggatt gttgttcgtt tctcttggat gatttagttt ccgttattta cttagctggg 2280
ataagatata tggtacatag tatagatgtg ttgtgatgtt attctggcta ttttgtacac 2340
tttgacatga tctgcgatat gggagcgtct a 2371

<210> 35
<211> 789
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(789)

<400> 35
atg gcc ccc ctc aaa tcc ctc ctc ctc ggc gcc tcc ctg gcc acc ctc 48
Met Ala Pro Leu Lys Ser Leu Leu Leu Gly Ala Ser Leu Ala Thr Leu
1 5 10 15
gcc ctt tcc acc cca ctg gca acc gac gcc gaa aac ctc tac gca cgt 96
Ala Leu Ser Thr Pro Leu Ala Thr Asp Ala Glu Asn Leu Tyr Ala Arg
20 25 30
caa ttc ggc acg ggc tct aca gcc aac gaa ctc gag cag gga agc tgc 144
Gln Phe Gly Thr Gly Ser Thr Ala Asn Glu Leu Glu Gln Gly Ser Cys
35 40 45
aag gat gtg act ctc atc ttt gcg agg ggg tca act gag ctt ggg aat 192
Lys Asp Val Thr Leu Ile Phe Ala Arg Gly Ser Thr Glu Leu Gly Asn
50 55 60
atg ggc acc gta atc ggc ccc cct ctc tgc gac aac ctg aaa tcc aaa 240
Met Gly Thr Val Ile Gly Pro Pro Leu Cys Asp Asn Leu Lys Ser Lys
65 70 75 80

```
ctc gga tcc gac aaa gtc gcc tgc cag ggt gtc ggc ggc caa tac agc      288
Leu Gly Ser Asp Lys Val Ala Cys Gln Gly Val Gly Gly Gln Tyr Ser
                85                  90                  95
gcc gga ctc gtg cag aat gcc ctg ccc cag aac acc gat ccg ggg agt      336
Ala Gly Leu Val Gln Asn Ala Leu Pro Gln Asn Thr Asp Pro Gly Ser
            100                 105                 110
atc tcc gcc gcg aag cag atg ttc gag gag gcg aat tcg aag tgt ccc      384
Ile Ser Ala Ala Lys Gln Met Phe Glu Glu Ala Asn Ser Lys Cys Pro
        115                 120                 125
aat act aag att gtt gcg ggt ggt tat agt caa gga agc gct gtg att      432
Asn Thr Lys Ile Val Ala Gly Gly Tyr Ser Gln Gly Ser Ala Val Ile
    130                 135                 140
gac aac gcc gtg caa gaa ctc agc acc acc gtg aaa gac caa gtg aag      480
Asp Asn Ala Val Gln Glu Leu Ser Thr Thr Val Lys Asp Gln Val Lys
145                 150                 155                 160
ggt gtc gtg ctc ttc ggg ttc acg aga aac gtg cag gat cac ggg cag      528
Gly Val Val Leu Phe Gly Phe Thr Arg Asn Val Gln Asp His Gly Gln
                165                 170                 175
atc cct aat tac cct aag gat gac gtg aag gtt tat tgt gcc gtg ggc      576
Ile Pro Asn Tyr Pro Lys Asp Asp Val Lys Val Tyr Cys Ala Val Gly
            180                 185                 190
gat ctg gtc tgt gat gat acg ttg gtt gtt acg gcg atg cat ctg acg      624
Asp Leu Val Cys Asp Asp Thr Leu Val Val Thr Ala Met His Leu Thr
        195                 200                 205
tat ggc atg gat gcg ggt gat gcg gcg agc ttt ttg gcc gag aag gtg      672
Tyr Gly Met Asp Ala Gly Asp Ala Ala Ser Phe Leu Ala Glu Lys Val
    210                 215                 220
cag tct tcc agt agt tcg act act agc tcc agc tcg gat gcc gcg agt      720
Gln Ser Ser Ser Ser Ser Thr Thr Ser Ser Ser Ser Asp Ala Ala Ser
225                 230                 235                 240
agt tca tct gct gcg ggg acg tcg tcg tcg ggg ttg tcg gga ctg tct      768
Ser Ser Ser Ala Ala Gly Thr Ser Ser Ser Gly Leu Ser Gly Leu Ser
                245                 250                 255
tct ttt ttt gga ggt ctc taa                                          789
Ser Phe Phe Gly Gly Leu
                260
```

<210> 36
<211> 262
<212> PRT
<213> Aspergillus niger

<400> 36

Met Ala Pro Leu Lys Ser Leu Leu Leu Gly Ala Ser Leu Ala Thr Leu
1 5 10 15
Ala Leu Ser Thr Pro Leu Ala Thr Asp Ala Glu Asn Leu Tyr Ala Arg
20 25 30
Gln Phe Gly Thr Gly Ser Thr Ala Asn Glu Leu Glu Gln Gly Ser Cys
35 40 45
Lys Asp Val Thr Leu Ile Phe Ala Arg Gly Ser Thr Glu Leu Gly Asn
50 55 60
Met Gly Thr Val Ile Gly Pro Pro Leu Cys Asp Asn Leu Lys Ser Lys
65 70 75 80
Leu Gly Ser Asp Lys Val Ala Cys Gln Gly Val Gly Gly Gln Tyr Ser
85 90 95
Ala Gly Leu Val Gln Asn Ala Leu Pro Gln Asn Thr Asp Pro Gly Ser
100 105 110
Ile Ser Ala Ala Lys Gln Met Phe Glu Glu Ala Asn Ser Lys Cys Pro
115 120 125
Asn Thr Lys Ile Val Ala Gly Gly Tyr Ser Gln Gly Ser Ala Val Ile
130 135 140
Asp Asn Ala Val Gln Glu Leu Ser Thr Thr Val Lys Asp Gln Val Lys
145 150 155 160
Gly Val Val Leu Phe Gly Phe Thr Arg Asn Val Gln Asp His Gly Gln
165 170 175
Ile Pro Asn Tyr Pro Lys Asp Asp Val Lys Val Tyr Cys Ala Val Gly
180 185 190
Asp Leu Val Cys Asp Asp Thr Leu Val Val Thr Ala Met His Leu Thr
195 200 205
Tyr Gly Met Asp Ala Gly Asp Ala Ala Ser Phe Leu Ala Glu Lys Val
210 215 220
Gln Ser Ser Ser Ser Ser Thr Thr Ser Ser Ser Ser Asp Ala Ala Ser
225 230 235 240
Ser Ser Ser Ala Ala Gly Thr Ser Ser Ser Gly Leu Ser Gly Leu Ser
245 250 255
Ser Phe Phe Gly Gly Leu
260

<210> 37
<211> 2981
<212> DNA
<213> Aspergillus niger

<400> 37
tcctcatccc atgctctccc ggcagaaccc cggagacaac ccacactaat gcacccaaag 60
caaaatgaca tggattgaat tatccggggt gcatccatct tgttcccccca cacattggac 120

21078WO.ST25.txt

```
cctttcctta taatggctgc cccggcaaac ccccaattgc tgtttaggcc agcgcagata    180
gcaaatctct cgtctgatta acgatgctaa agctcgctgt tgctcttttt tcgttacttg    240
ccgtgggcaa tgcagcgcca accaaagtgg cccgttccac ggccagtcct acggccaagg    300
ttcgcaacgg tacatatgtc ggagtgacaa atgcgcatta ccagcaagat ttctttttgg    360
gaatgccgta tgcccagcag cctttaggtg acttgcgctt cacggtgcct cagtccctga    420
acgaaagctg gagtggcgag cgcgacgcga aggaatattc caatatctgt gtaggatacg    480
gtgtgagtgc gcaaatcttc ttcgagagcc aggccctact agctgcatcc tggcactatg    540
aatataatct aatgggtaga tctgttagac cgactcgatt tggtacccac agtccgaagc    600
ttgtctaacc ttgaatgtca tccgcgattc ttctgcaaat gagaactcga agctccccgt    660
gggcgtctgg atacatggag gtggcttctt tgagggatct agtgctgacc agcgctacaa    720
catgtccgcg attgttgcca actcctataa gatcggtatg tcgacgtatg cggttgtaga    780
attagactga ctcggcttgc tcgcattgta ggaaagccgt tcattgctgt cagcttaaac    840
tatcgccttt cggcatgggg cttcttgagt tccagtcaag tctggggcac tggcaatacc    900
aatctaggta tcagggatca aaggttagca ctccattgga tcaaggagaa tatcgcggca    960
ttcggaggag acccagataa gatcactatc tggggcgaat ctgccggagc gatgtccgtg   1020
ggttatcacc ttgcagcata cggcggtagg gacgatggac tcttccgtgg aggaattatg   1080
gagtcaggag ggactattgc agctagtcca gccaactata ccgggtacca agcgcactat   1140
gatgagctcg cgggtcaagt cggttgctcc gacgtagtag attcgttgca gtgcctgcgc   1200
gaagttccgt tcgagaaatt gaacgctgct ctcaacacca ccagtggtaa ctcggatttc   1260
aatttcgggc ccgtcattga tggagatata atcagggact ggggcagcct ccagctagac   1320
aagcatgaat tcgtcaaagt ccctattctt gcaggtacca ataccgacga agggacagcc   1380
tttgggccca caggtatcaa cacgacagag gagttctatg catatctcac aggtatgtgt   1440
gataatgagt taacatcctg aaagaacccc agagcagcaa aacgggctaa tctcactggc   1500
agatggcgaa tctggattcc agctaccccc cacgatcgcc caggaaatcc tgcagctcta   1560
ccctgatgat ccagcactgg gcatccccga atttctcggt gacactagag tcccgtccaa   1620
aggctaccaa tggcggcgca cctgtgcata cgcaggggac tatgtaatgc atgccaaccg   1680
tcgccgacaa tgtgaggcgt ggacagagac ctcgacgacg gcgtactgtt atcgattcaa   1740
tatgcgtgcg gccgatgtcc ccatcctgtc tggcgccacc cattttgaag aagttgcttt   1800
tgtattcaac aacattgcag gactcgggta ccattacgga aagccgttcg cagggatgcc   1860
cgagtcctac gtacagctaa gcaacttgat gaccagcatg tgggcatcct tcatccacga   1920
tttagaccct aattcgggca tcaaggactc agctgtacag tggcaaccgt acgggaagga   1980
tcagccggtt gatctagtgt ttgatgcgaa tgtcacgagc tacagctaca tggagccaga   2040
cacgtggcgg aaggaggggа tcgactatat caattccgtg gccaacgcgt actggcgata   2100
agcttcatgc tatcgaaaac acatgtgatg agcgtgagag tttttgcctt ccgcttgatg   2160
ttgcctgcga gaggaaaagg ttaaggcaaa caaggatggt aggggtgcg agcgcatcta    2220
agtcggccac ggtagttgat tgatggttcc ctcgttagaa gcaaatacag atgccatact   2280
tcctgcaaca aacccagaac ttgttgtaat caagtttttt caaacggatg gtagatcggt   2340
tccgatttgt aaaaagcaag atcctagcgt tacgagggaa ccaagacacc cacacagagg   2400
agcattacga attccaaatt accaaagcct gtataacaaa aaccagcaga gaccgcctaa   2460
ttagtcaact acagcattgg ttcaatgtac ctgcaaggac ctttacacgc gtggtcaccc   2520
atgtaccaag ccaagccaac ggccaagaca cggaaataac caagaggaaa ccactccctc   2580
caagaatcaa gaacccaggg ggtcaagaga atctggaagc gataaagggg tcttcttttt   2640
tttctttgct tacctagaga gggaggagtc ggcgttcatc gtcaatcagt agagtgttct   2700
ccgccctgag tggtgtagtc tatatccgga ccatcgggga catgattatc atacgatcca   2760
```

taaccaagtc cccgattgta ctacggctac caaaactaga atgatgaaaa tattggagta 2820
cgaaaggaac taaaccaata ctaagaaaaa aaaaaaagag taaagaaaaa agagtaaaaa 2880
accaagctcg gaaagtaaaa atttcccctg gtcttgttgt cattccccta cctattgaga 2940
accgggttca ccaatgacag cggatccccg atttgacatc g 2981

<210> 38
<211> 1686
<212> DNA
<213> Aspergillus niger

<220>
<221> CDS
<222> (1)..(1686)

<400> 38
atg cta aag ctc gct gtt gct ctt ttt tcg tta ctt gcc gtg ggc aat 48
Met Leu Lys Leu Ala Val Ala Leu Phe Ser Leu Leu Ala Val Gly Asn
1 5 10 15
gca gcg cca acc aaa gtg gcc cgt tcc acg gcc agt cct acg gcc aag 96
Ala Ala Pro Thr Lys Val Ala Arg Ser Thr Ala Ser Pro Thr Ala Lys
20 25 30
gtt cgc aac ggt aca tat gtc gga gtg aca aat gcg cat tac cag caa 144
Val Arg Asn Gly Thr Tyr Val Gly Val Thr Asn Ala His Tyr Gln Gln
35 40 45
gat ttc ttt ttg gga atg ccg tat gcc cag cag cct tta ggt gac ttg 192
Asp Phe Phe Leu Gly Met Pro Tyr Ala Gln Gln Pro Leu Gly Asp Leu
50 55 60
cgc ttc acg gtg cct cag tcc ctg aac gaa agc tgg agt ggc gag cgc 240
Arg Phe Thr Val Pro Gln Ser Leu Asn Glu Ser Trp Ser Gly Glu Arg
65 70 75 80
gac gcg aag gaa tat tcc aat atc tgt gta gga tac ggt acc gac tcg 288
Asp Ala Lys Glu Tyr Ser Asn Ile Cys Val Gly Tyr Gly Thr Asp Ser
85 90 95
att tgg tac cca cag tcc gaa gct tgt cta acc ttg aat gtc atc cgc 336
Ile Trp Tyr Pro Gln Ser Glu Ala Cys Leu Thr Leu Asn Val Ile Arg
100 105 110
gat tct tct gca aat gag aac tcg aag ctc ccc gtg ggc gtc tgg ata 384
Asp Ser Ser Ala Asn Glu Asn Ser Lys Leu Pro Val Gly Val Trp Ile
115 120 125
cat gga ggt ggc ttc ttt gag gga tct agt gct gac cag cgc tac aac 432
His Gly Gly Gly Phe Phe Glu Gly Ser Ser Ala Asp Gln Arg Tyr Asn
130 135 140
atg tcc gcg att gtt gcc aac tcc tat aag atc gga aag ccg ttc att 480

```
Met Ser Ala Ile Val Ala Asn Ser Tyr Lys Ile Gly Lys Pro Phe Ile
145                 150                 155                 160
gct gtc agc tta aac tat cgc ctt tcg gca tgg ggc ttc ttg agt tcc      528
Ala Val Ser Leu Asn Tyr Arg Leu Ser Ala Trp Gly Phe Leu Ser Ser
                165                 170                 175
agt caa gtc tgg ggc act ggc aat acc aat cta ggt atc agg gat caa      576
Ser Gln Val Trp Gly Thr Gly Asn Thr Asn Leu Gly Ile Arg Asp Gln
            180                 185                 190
agg tta gca ctc cat tgg atc aag gag aat atc gcg gca ttc gga gga      624
Arg Leu Ala Leu His Trp Ile Lys Glu Asn Ile Ala Ala Phe Gly Gly
        195                 200                 205
gac cca gat aag atc act atc tgg ggc gaa tct gcc gga gcg atg tcc      672
Asp Pro Asp Lys Ile Thr Ile Trp Gly Glu Ser Ala Gly Ala Met Ser
    210                 215                 220
gtg ggt tat cac ctt gca gca tac ggc ggt agg gac gat gga ctc ttc      720
Val Gly Tyr His Leu Ala Ala Tyr Gly Gly Arg Asp Asp Gly Leu Phe
225                 230                 235                 240
cgt gga gga att atg gag tca gga ggg act att gca gct agt cca gcc      768
Arg Gly Gly Ile Met Glu Ser Gly Gly Thr Ile Ala Ala Ser Pro Ala
                245                 250                 255
aac tat acc ggg tac caa gcg cac tat gat gag ctc gcg ggt caa gtc      816
Asn Tyr Thr Gly Tyr Gln Ala His Tyr Asp Glu Leu Ala Gly Gln Val
            260                 265                 270
ggt tgc tcc gac gta gta gat tcg ttg cag tgc ctg cgc gaa gtt ccg      864
Gly Cys Ser Asp Val Val Asp Ser Leu Gln Cys Leu Arg Glu Val Pro
        275                 280                 285
ttc gag aaa ttg aac gct gct ctc aac acc acc agt ggt aac tcg gat      912
Phe Glu Lys Leu Asn Ala Ala Leu Asn Thr Thr Ser Gly Asn Ser Asp
    290                 295                 300
ttc aat ttc ggg ccc gtc att gat gga gat ata atc agg gac tgg ggc      960
Phe Asn Phe Gly Pro Val Ile Asp Gly Asp Ile Ile Arg Asp Trp Gly
305                 310                 315                 320
agc ctc cag cta gac aag cat gaa ttc gtc aaa gtc cct att ctt gca     1008
Ser Leu Gln Leu Asp Lys His Glu Phe Val Lys Val Pro Ile Leu Ala
                325                 330                 335
ggt acc aat acc gac gaa ggg aca gcc ttt ggg ccc aca ggt atc aac     1056
Gly Thr Asn Thr Asp Glu Gly Thr Ala Phe Gly Pro Thr Gly Ile Asn
            340                 345                 350
acg aca gag gag ttc tat gca tat ctc aca gat ggc gaa tct gga ttc     1104
Thr Thr Glu Glu Phe Tyr Ala Tyr Leu Thr Asp Gly Glu Ser Gly Phe
        355                 360                 365
cag cta ccc ccc acg atc gcc cag gaa atc ctg cag ctc tac cct gat     1152
Gln Leu Pro Pro Thr Ile Ala Gln Glu Ile Leu Gln Leu Tyr Pro Asp
    370                 375                 380
```

```
gat cca gca ctg ggc atc ccc gaa ttt ctc ggt gac act aga gtc ccg      1200
Asp Pro Ala Leu Gly Ile Pro Glu Phe Leu Gly Asp Thr Arg Val Pro
385                 390                 395                 400
tcc aaa ggc tac caa tgg cgg cgc acc tgt gca tac gca ggg gac tat      1248
Ser Lys Gly Tyr Gln Trp Arg Arg Thr Cys Ala Tyr Ala Gly Asp Tyr
                    405                 410                 415
gta atg cat gcc aac cgt cgc cga caa tgt gag gcg tgg aca gag acc      1296
Val Met His Ala Asn Arg Arg Arg Gln Cys Glu Ala Trp Thr Glu Thr
            420                 425                 430
tcg acg acg gcg tac tgt tat cga ttc aat atg cgt gcg gcc gat gtc      1344
Ser Thr Thr Ala Tyr Cys Tyr Arg Phe Asn Met Arg Ala Ala Asp Val
        435                 440                 445
ccc atc ctg tct ggc gcc acc cat ttt gaa gaa gtt gct ttt gta ttc      1392
Pro Ile Leu Ser Gly Ala Thr His Phe Glu Glu Val Ala Phe Val Phe
    450                 455                 460
aac aac att gca gga ctc ggg tac cat tac gga aag ccg ttc gca ggg      1440
Asn Asn Ile Ala Gly Leu Gly Tyr His Tyr Gly Lys Pro Phe Ala Gly
465                 470                 475                 480
atg ccc gag tcc tac gta cag cta agc aac ttg atg acc agc atg tgg      1488
Met Pro Glu Ser Tyr Val Gln Leu Ser Asn Leu Met Thr Ser Met Trp
                    485                 490                 495
gca tcc ttc atc cac gat tta gac cct aat tcg ggc atc aag gac tca      1536
Ala Ser Phe Ile His Asp Leu Asp Pro Asn Ser Gly Ile Lys Asp Ser
            500                 505                 510
gct gta cag tgg caa ccg tac ggg aag gat cag ccg gtt gat cta gtg      1584
Ala Val Gln Trp Gln Pro Tyr Gly Lys Asp Gln Pro Val Asp Leu Val
        515                 520                 525
ttt gat gcg aat gtc acg agc tac agc tac atg gag cca gac acg tgg      1632
Phe Asp Ala Asn Val Thr Ser Tyr Ser Tyr Met Glu Pro Asp Thr Trp
    530                 535                 540
cgg aag gag ggg atc gac tat atc aat tcc gtg gcc aac gcg tac tgg      1680
Arg Lys Glu Gly Ile Asp Tyr Ile Asn Ser Val Ala Asn Ala Tyr Trp
545                 550                 555                 560
cga taa                                                             1686
Arg
```

<210> 39
<211> 561
<212> PRT
<213> Aspergillus niger

<400> 39
Met Leu Lys Leu Ala Val Ala Leu Phe Ser Leu Leu Ala Val Gly Asn

21078WO.ST25.txt

```
1               5                  10                  15
Ala Ala Pro Thr Lys Val Ala Arg Ser Thr Ala Ser Pro Thr Ala Lys
            20                  25                  30
Val Arg Asn Gly Thr Tyr Val Gly Val Thr Asn Ala His Tyr Gln Gln
        35                  40                  45
Asp Phe Phe Leu Gly Met Pro Tyr Ala Gln Gln Pro Leu Gly Asp Leu
    50                  55                  60
Arg Phe Thr Val Pro Gln Ser Leu Asn Glu Ser Trp Ser Gly Glu Arg
65                  70                  75                  80
Asp Ala Lys Glu Tyr Ser Asn Ile Cys Val Gly Tyr Gly Thr Asp Ser
                85                  90                  95
Ile Trp Tyr Pro Gln Ser Glu Ala Cys Leu Thr Leu Asn Val Ile Arg
            100                 105                 110
Asp Ser Ser Ala Asn Glu Asn Ser Lys Leu Pro Val Gly Val Trp Ile
        115                 120                 125
His Gly Gly Gly Phe Phe Glu Gly Ser Ser Ala Asp Gln Arg Tyr Asn
    130                 135                 140
Met Ser Ala Ile Val Ala Asn Ser Tyr Lys Ile Gly Lys Pro Phe Ile
145                 150                 155                 160
Ala Val Ser Leu Asn Tyr Arg Leu Ser Ala Trp Gly Phe Leu Ser Ser
                165                 170                 175
Ser Gln Val Trp Gly Thr Gly Asn Thr Asn Leu Gly Ile Arg Asp Gln
            180                 185                 190
Arg Leu Ala Leu His Trp Ile Lys Glu Asn Ile Ala Ala Phe Gly Gly
        195                 200                 205
Asp Pro Asp Lys Ile Thr Ile Trp Gly Glu Ser Ala Gly Ala Met Ser
    210                 215                 220
Val Gly Tyr His Leu Ala Ala Tyr Gly Gly Arg Asp Asp Gly Leu Phe
225                 230                 235                 240
Arg Gly Gly Ile Met Glu Ser Gly Gly Thr Ile Ala Ala Ser Pro Ala
                245                 250                 255
Asn Tyr Thr Gly Tyr Gln Ala His Tyr Asp Glu Leu Ala Gly Gln Val
            260                 265                 270
Gly Cys Ser Asp Val Val Asp Ser Leu Gln Cys Leu Arg Glu Val Pro
        275                 280                 285
Phe Glu Lys Leu Asn Ala Ala Leu Asn Thr Thr Ser Gly Asn Ser Asp
    290                 295                 300
Phe Asn Phe Gly Pro Val Ile Asp Gly Asp Ile Ile Arg Asp Trp Gly
305                 310                 315                 320
Ser Leu Gln Leu Asp Lys His Glu Phe Val Lys Val Pro Ile Leu Ala
                325                 330                 335
Gly Thr Asn Thr Asp Glu Gly Thr Ala Phe Gly Pro Thr Gly Ile Asn
            340                 345                 350
Thr Thr Glu Glu Phe Tyr Ala Tyr Leu Thr Asp Gly Glu Ser Gly Phe
```

355 360 365
Gln Leu Pro Pro Thr Ile Ala Gln Glu Ile Leu Gln Leu Tyr Pro Asp
370 375 380
Asp Pro Ala Leu Gly Ile Pro Glu Phe Leu Gly Asp Thr Arg Val Pro
385 390 395 400
Ser Lys Gly Tyr Gln Trp Arg Arg Thr Cys Ala Tyr Ala Gly Asp Tyr
405 410 415
Val Met His Ala Asn Arg Arg Arg Gln Cys Glu Ala Trp Thr Glu Thr
420 425 430
Ser Thr Thr Ala Tyr Cys Tyr Arg Phe Asn Met Arg Ala Ala Asp Val
435 440 445
Pro Ile Leu Ser Gly Ala Thr His Phe Glu Glu Val Ala Phe Val Phe
450 455 460
Asn Asn Ile Ala Gly Leu Gly Tyr His Tyr Gly Lys Pro Phe Ala Gly
465 470 475 480
Met Pro Glu Ser Tyr Val Gln Leu Ser Asn Leu Met Thr Ser Met Trp
485 490 495
Ala Ser Phe Ile His Asp Leu Asp Pro Asn Ser Gly Ile Lys Asp Ser
500 505 510
Ala Val Gln Trp Gln Pro Tyr Gly Lys Asp Gln Pro Val Asp Leu Val
515 520 525
Phe Asp Ala Asn Val Thr Ser Tyr Ser Tyr Met Glu Pro Asp Thr Trp
530 535 540
Arg Lys Glu Gly Ile Asp Tyr Ile Asn Ser Val Ala Asn Ala Tyr Trp
545 550 555 560
Arg